<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta name="generator" content=
"HTML Tidy for HTML5 for Mac OS X version 5.4.0" />
<title>pvotf_10k.htm</title>
<!--Document Created by EDGARMaster-->
</head>
<body spellcheck="true" style=
"text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%">
<p style="MARGIN: 0px"></p>
<table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0"
width="100%" border="0">
<tr>
<td>
<div style=
"HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px"
name="hrule"></div>
<div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000" name=
"hrule"></div>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b><font size=
"3">UNITED STATES</font></b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b><font size=
"3">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b><font size=
"3">Washington, D.C. 20549</font></b></p>
<p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b><font size=
"5">FORM 10-K</font></b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">(Mark One)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px 0px 0px 0in"><font style=
"FONT-FAMILY: Wingdings">x</font></p>
</td>
<td valign="top" colspan="2">
<p style="MARGIN: 0px 0px 0px 0in">ANNUAL REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">For the fiscal year ended
<b>January 31, 2018</b></p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px"><font style=
"FONT-FAMILY: Wingdings">o</font></p>
</td>
<td valign="top" colspan="2">
<p style="MARGIN: 0px">TRANSITION REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">For the transition period
from&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ]
to&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ]</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">Commission file number
<b>333-161157</b>&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="65%" align="center" border=
"0">
<tr height="15">
<td style="BORDER-BOTTOM: 1px solid" valign="top" width="80%">
<p style="MARGIN: 0px" align="center"><b><font size="5">PIVOT
PHARMACEUTICALS INC.</font></b></p>
</td>
</tr>
<tr height="15">
<td valign="top" width="80%">
<p style="MARGIN: 0px 0px 0px 0in" align="center">(Exact name of
registrant as specified in its charter)</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr height="15">
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="45%">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>British
Columbia</b></p>
</td>
<td valign="bottom" width="10%">
<p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="45%">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>N/A</b></p>
</td>
</tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="center">(State or other
jurisdiction of incorporation or organization)</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="center">(I.R.S. Employer
Identification No.)</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="45%">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>1275 West
6<sup>th</sup> Avenue, Vancouver, British Columbia</b></p>
</td>
<td valign="bottom" width="10%">
<p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="45%">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>V6H
1A6</b></p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="center">(Address of
principal executive offices)</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="center">(Zip Code)</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">Registrant’s telephone
number, including area code: <b>(604) 805-7783</b></p>
&nbsp;
<p style="MARGIN: 0px 0px 0px 0in" align="center">Securities
registered pursuant to Section 12(b) of the Act:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr height="15">
<td style="BORDER-BOTTOM: 1px solid" valign="top" width="45%">
<p style="MARGIN: 0px" align="center">Title of Each Class</p>
</td>
<td valign="top" width="10%">
<p align="center">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="45%">
<p style="MARGIN: 0px" align="center">Name of Each Exchange On
Which Registered</p>
</td>
</tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px" align="center"><b>N/A</b></p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center"><b>N/A</b></p>
</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="center">Securities
registered pursuant to Section 12(g) of the Act:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="center">
<u><b>N/A</b></u></p>
<p style="MARGIN: 0px 0px 0px 0in" align="center">(Title of
class)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">Indicate by check mark if the
registrant is a well-known seasoned issuer, as defined in Rule 405
the Securities Act.&nbsp;Yes <font style=
"FONT-FAMILY: Wingdings">o</font>No <font style=
"FONT-FAMILY: Wingdings">x</font></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">Indicate by check mark if the
registrant is not required to file reports pursuant to Section 13
or Section 15(d) of the Act&nbsp;Yes <font style=
"FONT-FAMILY: Wingdings">o</font>No <font style=
"FONT-FAMILY: Wingdings">x</font></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">Indicate by check mark whether
the registrant: (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the
registrant was required to file such reports) and (2) has been
subject to such filing requirements for the last 90
days.&nbsp;Yes&nbsp;<font style="FONT-FAMILY: Wingdings">x</font>
No <font style="FONT-FAMILY: Wingdings">o</font></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">Indicate by check mark whether
the registrant has submitted electronically and posted on its
corporate Website, if any, every Interactive Data File required to
be submitted and posted pursuant to Rule 405 of Regulation S-K
(§229.405 of this chapter) during the preceding 12 months (or for
such shorter period that the registrant was required to submit and
post such files).&nbsp;Yes&nbsp;<font style=
"FONT-FAMILY: Wingdings">x</font> No <font style=
"FONT-FAMILY: Wingdings">o</font></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">Indicate by check mark if
disclosure of delinquent filers pursuant to Item 405 of Regulation
S-K (§229.405 of this chapter) is not contained herein, and will
not be contained, to the best of registrant’s knowledge, in
definitive proxy or information statements incorporated by
reference in Part III of this Form 10-K or any amendment to this
Form 10-K. <font style="FONT-FAMILY: Wingdings">¨</font></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer,
a non-accelerated filer, or a smaller reporting company. See
definition of “large accelerated filer,” “accelerated filer” and 
“smaller reporting company” in Rule 12b-2 of the Exchange Act.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr height="15">
<td valign="top" width="30%">
<p style="MARGIN: 0px 0px 0px 0in">Large accelerated filer</p>
</td>
<td valign="top" width="20%">
<p style="MARGIN: 0px 0px 0px 0in"><font style=
"FONT-FAMILY: Wingdings"><font style=
"FONT-FAMILY: Wingdings">¨</font></font></p>
</td>
<td valign="top" width="30%">
<p style="MARGIN: 0px 0px 0px 0in">Accelerated filer</p>
</td>
<td valign="top" width="20%">
<p style="MARGIN: 0px 0px 0px 0in"><font style=
"FONT-FAMILY: Wingdings">o</font></p>
</td>
</tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Non-accelerated filer</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><font style=
"FONT-FAMILY: Wingdings">o</font></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Smaller reporting company</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><font style=
"FONT-FAMILY: Wingdings"><font style=
"FONT-FAMILY: Wingdings">x</font></font></p>
</td>
</tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">Emerging growth company</p>
</td>
<td>
<p style="MARGIN: 0px"><font face="Wingdings">o</font></p>
</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a)
of the Exchange Act.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">Indicate by check mark whether
the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act).&nbsp;Yes <font style=
"FONT-FAMILY: Wingdings">o</font>No <font style=
"FONT-FAMILY: Wingdings">x</font></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">The aggregate
market value of Common Stock held by non-affiliates of the
Registrant on July 31, 2017 was $3,916,395 based on a $0.09 average
bid and asked price of such common equity, as of the last business
day of the registrant’s most recently completed second fiscal
quarter.</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">Indicate the number of shares
outstanding of each of the registrant’s classes of common stock as
of the latest practicable date.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in">88,055,160 common shares as of
May 1, 2018</p>
<p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="center">DOCUMENTS
INCORPORATED BY REFERENCE</p>
<p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="center">None.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="left">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0"
width="100%" border="0">
<tr>
<td>
<div style=
"HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px"
name="hrule"></div>
<div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000" name=
"hrule"></div>
</td>
</tr>
</table>
<p style="MARGIN: 0px"></p>
<table class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px" align="center"><b><a name="TOC" id=
"TOC">TABLE OF CONTENTS</a></b></p>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15" bgcolor="#CCEEFF">
<td valign="top" width="9%">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%201.%20Business">Item 1.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%201.%20Business">Business</a></p>
</td>
<td width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="9%">
<p style="MARGIN: 0px 0px 0px 0in" align="right">3</p>
</td>
<td width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%201A.%20Risk%20Factors">Item 1A.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%201A.%20Risk%20Factors">Risk Factors</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="right">21</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%201B.%20Unresolved%20Staff%20Comments">Item 1B.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%201B.%20Unresolved%20Staff%20Comments">Unresolved Staff
Comments</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="right">28</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%202.%20Properties">Item 2.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%202.%20Properties">Properties</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="right">28</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%203.%20Legal%20Proceedings">Item 3.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%203.%20Legal%20Proceedings">Legal Proceedings</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="right">28</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%204.%20Mine%20Safety%20Disclosures">Item 4.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%204.%20Mine%20Safety%20Disclosures">Mine Safety
Disclosures</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="right">28</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%205.%20Market%20for%20Registrant%E2%80%99s%20Common%20Equity,%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities">
Item 5.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%205.%20Market%20for%20Registrant%E2%80%99s%20Common%20Equity,%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities">
Market for Registrant’s Common Equity, Related Stockholder Matters
and Issuer Purchases of Equity Securities</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="right">29</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%206.%20Selected%20Financial%20Data">Item 6.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%206.%20Selected%20Financial%20Data">Selected Financial
Data</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="right">31</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%207.%20Management%E2%80%99s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations">
Item 7.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%207.%20Management%E2%80%99s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations">
Management’s Discussion and Analysis of Financial Condition and
Results of Operations</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="right">31</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk">
Item 7A.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk">
Quantitative and Qualitative Disclosures About Market Risk</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="right">37</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%208.%20Financial%20Statements%20and%20Supplementary%20Data">Item
8.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%208.%20Financial%20Statements%20and%20Supplementary%20Data">Financial
Statements and Supplementary Data</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="right">38</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%209A.%20Controls%20and%20Procedures">Item 9.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%209A.%20Controls%20and%20Procedures">Changes in and
Disagreements With Accountants on Accounting and Financial
Disclosure</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="right">39</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%209A.%20Controls%20and%20Procedures">Item 9A.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%209A.%20Controls%20and%20Procedures">Controls and
Procedures</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="right">39</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%209B.%20Other%20Information">Item 9B.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%209B.%20Other%20Information">Other Information</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="right">40</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%2010.%20Directors,%20Executive%20Officers%20and%20Corporate%20Governance">
Item 10.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%2010.%20Directors,%20Executive%20Officers%20and%20Corporate%20Governance">
Directors, Executive Officers and Corporate Governance</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="right">41</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%2011.%20Executive%20Compensation">Item 11.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%2011.%20Executive%20Compensation">Executive
Compensation</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="right">45</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters">
Item 12.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters">
Security Ownership of Certain Beneficial Owners and Management and
Related Stockholder Matters</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="right">48</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions,%20and%20Director%20Independence">
Item 13.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions,%20and%20Director%20Independence">
Certain Relationships and Related Transactions, and Director
Independence</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="right">49</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%2014.%20Principal%20Accounting%20Fees%20and%20Services">Item
14.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%2014.%20Principal%20Accounting%20Fees%20and%20Services">Principal
Accounting Fees and Services</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="right">50</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%2015.%20Exhibits%20and%20Financial%20Statement%20Schedules">Item
15.</a></p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in"><a href=
"#Item%2015.%20Exhibits%20and%20Financial%20Statement%20Schedules">Exhibits
and Financial Statement Schedules</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in" align="right">51</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreak0ff29308-cae0-44a1-a461-b179acf4f8af" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
2</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b><a name=
"PART I">PART I</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><a name="Item 1. Business">Item 1.
Business</a></b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">This annual
report of Pivot Pharmaceuticals Inc. for the year ended January 31,
2018 contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, which are
intended to be covered by the safe harbors created thereby. To the
extent that such statements are not recitations of historical fact,
such statements constitute forward looking statements which, by
definition involve risks and uncertainties. In particular,
statements under the Sections; Description of Business, Management’
s Discussion and Analysis of Financial Condition and Results of
Operations contain forward looking statements. Where in any forward
looking statements, the Company expresses an expectation or belief
as to future results or events, such expectation or belief is
expressed in good faith and believed to have a reasonable basis,
but there can be no assurance that the statement of expectation or
belief will result or be achieved or accomplished.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">The following
are factors that could cause actual results or events to differ
materially from those anticipated, and include but are not limited
to: general economic, financial and business conditions; changes in
and compliance with governmental regulations; changes in tax laws;
and the cost and effects of legal proceedings.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">You should not
rely on forward looking statements in this annual report. This
annual report contains forward looking statements that involve
risks and uncertainties. We use words such as “anticipates,” 
“believes,” “plans,” “expects,” “future,” “intends,” and similar
expressions to identify these forward-looking statements.
Prospective investors should not place undue reliance on these
forward looking statements, which apply only as of the date of this
annual report. Our actual results could differ materially from
those anticipated in these forward-looking statements.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Although we
believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements. Except as required
by applicable law, including the securities laws of the United
States, we do not intend to update any of the forward-looking
statements to conform these statements to actual results.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Our financial
statements are stated in U.S. Dollars (US$) and are prepared in
accordance with United States Generally Accepted Accounting
Principles.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">In this annual
report, unless otherwise specified, all dollar amounts are
expressed in US dollars and all references to “common shares” refer
to the common shares in our capital stock.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">As used in this
annual report, the terms “we”, “us”, “our” and “our company” mean
Pivot Pharmaceuticals Inc., unless otherwise indicated.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"><b><u>General
Overview</u></b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We are a development stage
pharmaceutical and nutraceutical company. We were incorporated in
the Province of British Columbia, Canada under the name “649186
B.C. Ltd.”, on June 10, 2002. On September 9, 2003, we changed our
name to “Xerxes Health Corp.” and on June 26, 2007, we changed our
name to “Neurokine Pharmaceuticals Inc.”.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Effective June 4, 2014, we
filed with the British Columbia Registrar of Companies a Form 11,
Notice of Alteration, wherein we increased our authorized share
capital from 500,000,000 common shares without par value to an
unlimited number of common shares without par value. The increase
of authorized capital was approved by our stockholders at the
annual and special meeting held on June 3, 2014.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On September 26, 2014, our
company held a special meeting of stockholders to approve the
removal of our company's Pre-Existing Company Provisions, the
cancellation of our current Articles and the adoption of new
Articles and to approve a reverse stock split on the basis of up to
one new common stock for every 100 old common stock.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak94393eb5-0f75-4822-898b-dbd9d9b9fc8f" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
3</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Effective October 8, 2014,
we filed with the British Columbia Registrar of Companies a Form
11, Notice of Alteration, wherein we removed our Pre-Existing
Company Provisions.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Effective April 7, 2015, we
filed with the British Columbia Registrar of Companies a Form 11,
Notice of Alteration, wherein we changed our name to "Pivot
Pharmaceuticals Inc.".</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Effective at the opening of
trading on April 20, 2015, as approved by FINRA, our company
effected a reverse stock split of our issued and outstanding common
shares on the basis of 10 old common stock for 1 new common
stock.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On November 20, 2015, we
completed the acquisition of IndUS Pharmaceuticals, Inc. (“IndUS”),
a Delaware corporation, pursuant to an Agreement and Plan of Merger
and Acquisition Agreement dated as of November 4, 2015 among our
company, Pivot Pharma U.S. Inc., our wholly owned subsidiary, IndUS
and Sindu Research Laboratories Pvt Ltd. As consideration for the
purchase, we issued 4,512,500 shares of common stock on November
23, 2015 and 237,500 shares of common stock on December 4, 2015 and
granted 41,833 stock options pursuant to the Agreement and Plan of
Merger. As part of the acquisition, we appointed Dr. Pravin
Chaturvedi as our new Chief Executive Officer and Director. On
September 11, 2017, we completed an exchange agreement whereby we
exchanged with Dr. Chaturvedi 100% of its shares of common stock of
IndUS and IndUS net liabilities for 3,800,000 shares of common
stock of Pivot, upon which Dr. Chaturvedi resigned as Chief
Executive Officer and Director.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On September 12, 2017, we
entered into a licensing agreement with Altum Pharmaceuticals Inc.
(“Altum”) whereby we were granted worldwide rights to BiPhasix
Transdermal Drug Delivery Technology (“BiPhasix Technology”) for
the delivery and commercialization of cannabinoids, cannabidiol (
“CBD”), and tetrahydrocannabinol (“THC”) based products. Financial
consideration included:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Issuance of 2,500,000 shares of common stock on
effective date of agreement</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Issuance of 2,500,000 shares of common stock of
Pivot upon Health Canada Natural Product Number (“NPN”)
approval;</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Royalties on annual gross sales; and</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">For pharmaceutical products, milestone payments
payable upon first Investigative New Drug Approval, upon positive
outcome of Phase II trial in first indication, and upon New Drug
Application approval.</td>
</tr>
</table>
&nbsp;
<p style="MARGIN: 0px" align="justify">On September 23, 2017, we
entered into a collaboration and license agreement with SolMic GmbH
(“Solmic”) whereby we will acquire worldwide rights to Solmic’s
Solubilisation Technology for the development and commercialization
of cannabinoid-containing natural extracts. Milestones include
payments upon the following developments: 1) Regulatory approval of
a natural health product; 2) First approval of an investigative new
drug application for a pharmaceutical product; 3) Positive outcome
of a Phase II clinical trial of a pharmaceutical product in the
first indication; and 4) Approval of a New Drug Application for a
pharmaceutical product by the US Food and Drug Administration.
Other consideration include a sales milestone upon aggregate net
sales of $5,000,000 and royalties on aggregate net sales.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On December 19, 2017, we
commenced trading on the Canadian Securities Exchange under the
symbol "PVOT".</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">On February 28,
2018, we completed the acquisition of ERS Holdings, LLC (“ERS”)
pursuant to an Exchange Agreement dated as of February 10, 2018
among Pivot Pharmaceuticals Inc. ("Pivot"), ERS and the members of
ERS. As consideration for the purchase, we paid $333,333 in cash on
closing and will pay an additional $333,333 six and twelve (12)
months after closing for total cash payment of $1 million. In
addition, we also issued 5,000,000 shares of our common stock and
will pay royalties on future net sales. ERS has developed a
patented technology called “RTIC” Ready-To-Infuse-Cannabis,
relating to the transformation of cannabis oil into powder for
infusion into a variety of food and beverage products such as
capsules, K-Cups, stick packs, baked mixes, liquid shots, protein
shakes, topicals, lotions, and bottled beverages.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">On March 2,
2018, we completed the acquisition of Thrudermic, LLC (“Thrudermic”
) and worldwide rights to Thrudermic’s patented Transdermal
Nanotechnology for the development and commercialization of
transdermal cannabinoids pursuant to an Exchange Agreement dated as
of March 2, 2018 among Pivot, Dr. Joseph Borovsky, Dr. Leonid Lurya
and Thrudermic. As consideration for the purchase, we paid $1 in
cash on closing and issued 500,000 shares of our common stock.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our principal executive
office is located at 1275 West 6th Avenue, Vancouver, B.C. Canada
V6H 1A6. Our telephone number is (604) 805-7783.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreakaaafc6a6-5477-40a7-911a-986f587b380c" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
4</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"><b><u>Our
Current Business</u></b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Pivot
Pharmaceuticals Inc. is a biopharmaceutical company engaged in the
development and commercialization of therapeutic pharmaceuticals
and nutraceuticals using innovative drug delivery platform
technologies.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Our company
focuses on pharmaceutical development of proprietary drug delivery
technologies for multiple indications using small molecules,
biological and botanical (e.g. cannabinoids) products to treat
unmet medical needs. During our year ended January 31, 2018, we
in-licensed a patented topical transdermal drug delivery technology
platform, BiPhasix, and an oral drug delivery technology, Solmic
Micelle, for delivery of cannabinoids. Subsequent to January 31,
2018, we have also acquired the Thrudermic Transdermal
Nanotechnology (transdermal) and the Ready-To-Infuse Cannabis
technology.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Our fully-owned
subsidiaries, Pivot Green Stream Health Solutions Inc. (“PGS”) and
Pivot Naturals, LLC (“Pivot Naturals”) (formerly, ERS), acquired
subsequent to January 31, 2018, focus on the research, development,
and commercialization of cannabinoid based nutraceuticals. PGS will
generate data to support the safety and efficacy of cannabinoids as
Natural Health Product (“NHPs”) as outlined in Health Canada
Regulations in order to make particular health claims. Health
Canada publishes the Natural Health Products Regulations (“NHPR”)
which set out the requirements governing the sale, manufacture,
packaging, labelling, importation, distribution and storage of
NHPs.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">According to
Health Canada, the objective of the NHPR is to provide reasonable
assurance that products offered for sale in Canada are safe,
efficacious and of high quality. PGS may also follow applicable and
harmonized regulations for product development and
commercialization in the US, European Union and Asia Pacific
regions. Alternatively, PGS will commercialize certain cannabinoid
products with a Licensed Producer and/or Licensed Distributor as
per the regulations concerning Access to Cannabis for Medical
Purposes Regulations (“ACMPR”) since certain active ingredients in
cannabinoids remain restricted until new legislation permits ease
of development and distribution in 2018.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Lastly, PGS may
also develop products containing cannabinoid active ingredients
obtained from industrial hemp according to the Industrial Hemp
Regulations (“IHR”) permitting such products provided they are
sourced from industrial hemp. Otherwise stated, this means that the
plants and plant parts of the genera Cannabis, the leaves and
flowering heads of which do not contain more than 0.3% THC w/w, and
includes the derivatives of such plants and plant parts.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">PGS’s pipeline
targets indications such as cancer supportive care, pain and
inflammation, women’s sexual dysfunction, dermatology and eye
disease.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Our overall
strategy includes the following:</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%">1.</td>
<td valign="top">Acquire market-ready natural health products from
third-parties for rebranding and re-sale;</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">2.</td>
<td valign="top">Acquire cannabinoid-based food additives for
medical consumer sales;</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">3.</td>
<td valign="top">Develop cannabinoid-based natural health products
using our BiPhasix topical platform technology;</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">4.</td>
<td valign="top">Develop pharmaceutical products delivered using
our BiPhasix topical platform technology;</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">5.</td>
<td valign="top">Obtain partnerships with Health Canada approved
Authorized Licensed Producers and/or Licensed Distributors, which
can provide restricted and non-restricted cannabinoids as per the
ACMPR or the IHR;</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">6.</td>
<td valign="top">Acquire novel proprietary drug delivery
technologies, for example, metered dose, intra-nasal,
suppositories;</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">7.</td>
<td valign="top">Make an application at the appropriate time to
acquire Health Canada’s Authorized Licensed Producers and Licensed
Dealers licenses as per the ACMPR;</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">8.</td>
<td valign="top">Out-license our platform technologies to Licensed
Producers or Licensed Distributors and other drug developers;</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">9.</td>
<td valign="top">Secure and develop further intellectual
property;</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">10.</td>
<td valign="top">Opportunistically acquire later stage drug
candidates that provide new treatment options to address unmet
medical needs in health care; and</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">11.</td>
<td valign="top">Establish partnerships with large and specialty
pharmaceutical companies and/or biotechnology companies to
collaboratively develop and/or commercialize our products.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreak8b932387-3624-4589-8315-572c3a1c0336" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
5</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in"><b><u>Our Research and
Development Strategies</u></b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Our management
team has implemented a business minded and cost conscious approach
to product research and development by focusing on development of
novel therapies to address unmet needs in health care. Our research
and development strategy will apply novel drug delivery options for
new and/or existing drugs or NHPs.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">For a drug to be
successful it must be both efficacious and acceptably safe. Before
a drug may be commercially marketed, it must be scrutinized and
approved by applicable health authorities (such as Health Canada
and the FDA in the United States) in each country or jurisdiction
where it is sought to be sold. In pharmaceutical research and
development, clinical trials are conducted to assess the safety and
efficacy of the drug and the data to be collected for such new
drugs. Health authorities then scrutinize the pre-clinical and
clinical data and determine, based on the results, whether a drug
may be sold to the public. Similarly, clinical trials can only take
place once satisfactory information has been gathered on the
quality of the product and its non-clinical safety, and approval to
conduct clinical trials has been granted by the appropriate health
authority in the country where the trial is scheduled to take
place.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Clinical trials
involving new drugs are commonly classified into four phases. Each
phase of the drug approval process is treated as a separate
clinical trial. The drug development process will normally proceed
through all four phases over many years. If the drug successfully
passes through Phases I, II and III, it will usually be approved by
the national regulatory authority for use in the general
population. Phase IV trials are ‘post approval’ studies. Due to the
considerable cost that may be required to complete a full series of
clinical trials, the burden of paying for all the necessary people
and services is usually borne by the sponsor, who may be the
pharmaceutical or biotechnology company that developed the drug
that is the subject of the study. Since the diversity of roles may
exceed the resources of the sponsor, clinical trials are often
managed by outsourced partners such as contract research
organizations. Furthermore, approval rates for new drugs at each
clinical trial stage are prohibitively low, which may require the
sponsor to finance additional trials or abandon the drug under
development altogether.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">We will also
develop products regulated under Canada’s Natural Health Products
Guidance and support claims with clinical based data as per current
regulations.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Pre-clinical
safety studies for pharmaceutical or NHP product development are
ongoing to advance at least two of our product candidates.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in"><b><u>Our Platform
Technologies</u></b></p>
<p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in"><b>BiPhasix Transdermal Drug
Delivery Technology (Topical Platform)</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Pivot has
acquired worldwide rights from Altum for its patented topical
transdermal drug delivery technology platform, or BiPhasix, which
we will use for the delivery and commercialization of cannabinoid,
cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”) based
products.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">The BiPhasix
technology has the potential to deliver drugs less invasively than
by injections. It also has the potential to topically deliver
therapeutic amounts of drugs with better absorption rates, where
creams, ointments or conventional liposomes have not been
effective.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"><u>Dermal
Barrier and Challenges</u></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">The skin is
often the subject of intensive dermatological therapy. However,
except for certain low molecular weight compounds, it is seldom
viewed as a route of delivery for systemically acting drugs. This
is due partly to the fact that, by design, the skin is a formidable
barrier to penetration by external agents and the traditional
arsenal of creams, ointments and gels have not proven themselves to
be effective in delivery. In order to reach their target site
within the underlying layers of the skin or beyond the skin to the
systemic circulation, topical drugs must first penetrate the
stratum corneum, the outermost layer of the skin. It is this layer
which is considered to be the rate-limiting barrier to drug
absorption.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"></p>
<table id="pagebreak9c2a9941-0488-48b9-a255-e83e447a05c0" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
6</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">For
dermatological applications where the goal is to treat the skin,
the residence time of drugs in the target tissue should be of
sufficiently long duration since rapid systemic absorption may
limit the therapeutic response and contribute to systemic side
effects. This latter case may be the fate of many small molecules
formulated in conventional vehicles. In some cases, it is desirable
and possible to achieve systemic delivery of small molecules via
the transdermal route (for example, nicotine). However, larger
molecules, whether intended for dermatological or systemic
delivery, would normally not gain entry beyond the stratum corneum.
The goal is to have a safe delivery system that does not irritate
or damage the skin barrier after repeated usage in patients.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Pivot will use
BiPhasix as the next generation of patented liposomal delivery
system where a number of features of liposomes are greatly
improved. In contrast to traditional liposomes that entrap a
single, aqueous phase, our system is a complex system where the
lipid bilayers entrap both aqueous and oil phases in the form of a
stabilized emulsion.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">BiPhasix is
constructed with multi-compartmental lipid vesicles, each
comprising of aqueous compartments and bi-layer compartments in
addition to the following unique features of this patented delivery
system: Micellar compartments and oily compartments.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">These additional
features make it possible to achieve greater formulation
versatility than previously attainable with traditional creams,
gels, ointments or conventional liposomal delivery systems. Thus,
the BiPhasix delivery system combines the advantages of liposomes
and micro-emulsions, offering a wider range of formulation options
for a variety of drug substances:</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Water soluble compounds;</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Lipid soluble compounds;</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Proteins;</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Peptides; and</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Plasmids.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"><u>Technical
Facts of BiPhasix</u></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">BiPhasix is a
dermal delivery system for macro-molecules and has the following
characteristics:</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Flexible and able to deliver both lipophilic and
hydrophilic molecules;</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Vesicles are composed of phospholipid bilayers
(formed from pro-liposomal gel) which entraps an oil-in-water
submicron emulsion; and</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Hydrophilic active pharmaceutical ingredients are
incorporated into the aqueous phase of the oil-in-water emulsion,
whereas lipophilic active pharmaceutical ingredients can be
incorporated into the oil phase of the submicron emulsion.</td>
</tr>
</table>
<p style="MARGIN: 0px"><font face="Symbol">&nbsp;</font></p>
<p style="MARGIN: 0px" align="center"><font face="Symbol"><img src=
"pvotf_10kimg1.jpg" /></font></p>
<p style="MARGIN: 0px" align="center">Structure, assembly and
properties of BiPhasix carrying an active pharmaceutical ingredient
include:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%">1.</td>
<td valign="top">Vesicles consist of concentric phospholipid
bilayers;</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">2.</td>
<td valign="top">Cationic submicron emulsion droplets;</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">3.</td>
<td valign="top">Cationic surfactant micelles; and</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">4.</td>
<td valign="top">A water phase.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreak6d166ce0-f4b8-4522-a02e-9e806cb1091b" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
7</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Additional facts regarding
the BiPhasix delivery system include:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">The amount of drug that can be incorporated
include quantities at the microgram to milligram levels;</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">The size of molecules formulated are approximately
300 daltons (“Da”) to 100 kilodaltons (“kDa”);</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Loading capacity range from 30-70%;</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Increased stability of proteins are provided;</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">No organic solvents are used in the process;</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">No specialized manufacturing equipment are
required;</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">BiPhasix products are easily scalable using
standard pharmaceutical industrial equipment; and</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">BiPhasix formulated product have been reviewed by
the U.S. Food and Drug Administration (“FDA”), the European
Medicines Agency (“EMA”) and the The German Federal Institute for
Drugs and Medical Devices (BfArM).</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Delivery
Mechanisms</u></p>
<p style="MARGIN: 0px" align="justify">The delivery of the BiPhasix
vesicles is achieved by the uptake of the vesicles and encapsulated
drug into the skin or mucosa via the lipid rich channels, followed
by release of drug from the vesicles in a formulation-controlled
manner. The result may be either a rapid cutaneous transit time to
produce primarily transdermal delivery of the drug, or depot
formation within the skin with slow release for primarily dermal
delivery of the drug. The following is a hypothetical diagram
showing penetration of the biphasic vesicles into the skin for drug
delivery:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">BiPhasix liposomes and
transportation through the skin (in light blue)</p>
<p align="center"><img src="pvotf_10kimg2.jpg" /></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><u>Key Advantages of BiPhasix</u></p>
<p style="MARGIN: 0px" align="justify">The key advantages of
BiPhasix are:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Alternative routes: BiPhasix can serve as an
alternative dosage form to injectables by providing less invasive
routes of administration, such as dermal, transdermal, nasal,
vaginal and rectal.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Controlled release: BiPhasix can be formulated to
effect varying degrees of tissue penetration and rate of release at
the target site, in accordance with a desired clinical goals.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Bioavailability studies: As shown in the tables
below, BiPhasix can significantly enhance the bioavailability of
many drugs, leading to improved clinical outcomes.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreak2133a421-c3ae-48e4-a1f1-b8f3a9fdc206" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
8</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p align="center"><img src="pvotf_10kimg3.jpg" /></p>
<p align="center"><img src="pvotf_10kimg4.jpg" /></p>
<p style="MARGIN: 0px"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Stability: As shown in the above tables, BiPhasix
has demonstrated excellent stability with most therapeutic agents
tested, especially proteins, which are characteristically unstable
in traditional vehicles. Vulnerable drugs can be shielded from
degradation in BiPhasix, thereby enhancing their clinical
usefulness and commercial viability. BiPhasix is compatible with
most plastics and other container-closure systems.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Solvent-free and no animal product: BiPhasix is
formulated with biocompatible materials. Neither organic solvents
nor ingredients of animal origin are used in its manufacture.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Manufacturing feasibility: Clinical supplies and
commercial batches can be prepared using conventional manufacturing
equipment and container closure systems. Specialized equipment and
extensive capital investment are not required.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Patented technology: The BiPhasix patent pending
technology provides market exclusivity for new NHP or prescription
drug products containing Cannabinoids, CBD and THC.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Clinical experience: As shown in the above tables,
the BiPhasix delivery system has been tested in FDA and EMA
approved trial settings delivering large molecule interferon alpha
2b to women to treat HPV induced cervical neoplasia.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreak896d1687-c461-4f75-a0f0-2d2c358bf726" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
9</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in"><b>Thrudermic Transdermal
Nanotechnology (Topical Platform)</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Pivot has
acquired, in March 2018, the worldwide rights to Thrudermic’s
patented Transdermal Nanotechnology for the development and
commercialization of transdermal cannabinoids. Developed in Israel,
the Thrudermic lipid-based nano dispersion technology for topical
cannabinoids uses FDA approved materials. The technology has the
ability to specifically formulate individual drugs to control and
prolong drug release while maintaining steady therapeutic
concentrations, The technology can handle water soluble and water
insoluble drugs with no change to the skin morphology, no
sensitivity to the digestive system, no pain from injections and no
observed adverse reactions.</p>
<p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in"><b>Solmic Solubilization Drug
Delivery Technology (Oral Platform)</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Pivot has
acquired the worldwide rights to Solmic’s Solubilisation Technology
for the development and commercialization of cannabinoid-containing
natural extracts. Solmic’s technology allows active ingredients to
become water soluble without changing their composition and nature.
Solubilized substances that are packed in micelles are protected
from degradation from light, stomach acid, and from enzymes
released in the intestinal tract. The micellisation process results
in a stable, homogenous and transparent mixture, which
significantly increases uptake of fat soluble ingredients from the
gut into the blood system of fat soluble ingredients, resulting in
greater bioavailability.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">
<b>Ready-To-Infuse Cannabis Technology</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Pivot’s patented
Ready-To-Infuse-Cannabis (“RTIC”) process technology, acquired in
February 2018, creates precise and repeatable dosing of cannabis by
transforming concentrated cannabis oil into a stable, emulsifiable,
odorless and flavorless powder form. The derived powder may then be
encapsulated and infused for use in beverages, edibles, lotions and
additional health and personal care products. The RTIC process is
conducive for manufacturing of a wide array of products,
including:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">1. Capsules/Tablets: One of
our patents is issued for use in capsules and tablets. Another of
our patents has numerous claims for adding other active ingredients
to tablets and capsules, such as Melatonin or Gingko Biloba,
allowing for specific treatment for targeted effects. Efficient
mass production of capsules, conforming to GMP standards is part of
our core competencies and manufacturing capabilities. Production of
capsules is scheduled for the third quarter of the calendar year
2018.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">2. Beverage/Additive Stick
Packs: Single-serve stick packs are convenient and functional when
used in hot beverages. Stick packs are also highly functional.
Production of stick packs is scheduled for the third quarter of the
calendar year 2018.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">3. Pet Products: Our
patented cannabis powder will also be mass produced and packaged in
bulk for both consumer pet health needs. Production of pet powders
is scheduled for the third quarter of calendar year 2018.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">4. Lotions and Topical
Creams: Our patented lotion and topical technology will be mass
produced and packaged for consumer health needs. Production of
lotions and topical creams is scheduled for the first quarter of
calendar 2019.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"></p>
<table id="pagebreak2b5e2286-18db-4268-8804-7f0b992454dd" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
10</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"><b><u>Our
Product Development Initiatives</u></b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Our product
development initiatives will address unmet medical needs in health
care.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"11%">
<p style="MARGIN: 0px" align="left"><b>PRODUCT</b></p>
</td>
<td width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"20%">
<p style="MARGIN: 0px" align="left"><b>DELIVERY</b></p>
<p style="MARGIN: 0px" align="left"><b>TECHNOLOGY</b></p>
</td>
<td width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px" align="left"><b>INDICATION</b></p>
</td>
<td width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"11%">
<p style="MARGIN: 0px" align="center"><b>GLOBAL</b></p>
<p style="MARGIN: 0px" align="center"><b>MARKET SIZE
<sup>(1)</sup></b></p>
</td>
<td width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" width=
"12%">
<p style="MARGIN: 0px" align="center"><b>ESTIMATED</b></p>
<p style="MARGIN: 0px" align="center"><b>PRODUCT</b></p>
<p style="MARGIN: 0px" align="center"><b>LAUNCH</b></p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">PGS-N001</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">Solmic Solubilisate / Oral</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Cancer supportive care
(CINV) (chemo-induced nausea and vomiting)</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&gt;$1B</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">2018</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">PGS-N002</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">Solmic Solubilisate / Oral</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Restless leg syndrome</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&gt;$2B</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">2018</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">PGS-N003</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">Solmic Solubilisate / Oral</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Pain and inflammation (for
opioid withdrawal)</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&gt;$15B</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">2018</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">PGS-N004</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">Solmic Solubilisate / Oral</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Cancer supportive care
(mucositis relief)</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&gt;$12B</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">2018</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">PGS-N005</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">BiPhasix / Topical</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Female sexual dysfunction
(HSDD) (hypoactive sexual desire disorder)</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&gt;$6B</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">2019</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">PGS-N006</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">BiPhasix / Topical</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Pain and inflammation
(joints/opioid withdrawal)</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&gt;$20B</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">2018</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">PGS-N007</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">BiPhasix / Topical</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Dermatology (skin
irritation/redness/ itching)</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&gt;$13B</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">2018</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">PGS-N008</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">BiPhasix / Topical</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Eye disease (glaucoma,
intra-ocular pressure)</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&gt;$3B</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">2019</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">PGS-N009</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">Thrudermic / Topical</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Pain and inflammation
(opioid withdrawal)</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&gt;$15B</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">2018</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">PGS-N010</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">Solmic Solubilisate / Oral</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">Migraine (nausea, vomiting,
dizziness, sensitivity to light, sounds and smells)</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">&gt;$10B</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">2019</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">_________&nbsp;</p>
<p style="MARGIN: 0px" align="justify">(1) Derived from IMS
data</p>
<p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in"><b><u>Clinical Trial Phases (for
Pharmaceuticals Products Only)</u></b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">The following
section describes the most common phases of clinical drug trials
with reference to the clinical trial requirements that we
anticipate will be required for each of our pharmaceutical products
in the future and funding permitting.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>Pre-Clinical
Trials</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Pre-clinical
trials involve <i>in vitro</i> (test tube) and <i>in vivo</i>
(animal) experiments using wide ranging doses of the study drug to
obtain preliminary efficacy, toxicity and pharmacokinetic
information. Such tests assist pharmaceutical companies in deciding
whether a drug candidate possesses scientific merit for further
development as an investigational new drug. In addition,
formulation and dosage regimen work studies will need to be
conducted.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"><u>Phase
0</u></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Phase 0 is a
recent designation for exploratory, first in human trials conducted
in accordance with the FDA’s 2006 Guidance on Exploratory
Investigational New Drug. These trials are generally used for novel
anticancer drugs.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Distinctive
features of Phase 0 trials include the administration of single
subtherapeutic doses (doses not intended to treat diseases) of the
study drug to a small number of subjects (10-15) to gather
preliminary data on the agent’s pharmacokinetics and
pharmacodynamics.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"><u>Phase
I</u></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Phase I trials
are the first stage of drug testing in human subjects. Normally, a
small group of healthy volunteers (20-50) will be selected. This
phase includes trials designed to assess the safety, tolerability
and effects of the drug in relation to the human body, including
how it is absorbed, distributed, metabolized and eliminated by the
body. These trials are often conducted in an inpatient clinic,
where the subject can be observed by full-time staff. The subject
who receives the drug is usually observed until several half-lives
of the drug have passed.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Phase I trials
also normally include dose-ranging (or dose escalation) studies so
that the appropriate dose for therapeutic use can be found. The
tested range of doses will usually be a fraction of any dose that
causes harm in animal testing.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Phase I trials
most often include healthy volunteers; however, real patients are
used in some circumstances, such as when patients have an end-stage
disease and lack other treatment options. This exception to the
rule most often occurs in oncology (cancer) and HIV drug trials.
Volunteers are paid an inconvenience fee for the time they spend in
the volunteer center. Pay ranges from a small amount of money for a
short period of residence to a larger amount of up to approximately
$6,000 depending on the length of the volunteer’s participation in
the trial.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"></p>
<table id="pagebreak54ca3633-b22c-4074-bf5a-9d479ccfe40f" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
11</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Phase II</u></p>
<p style="MARGIN: 0px" align="justify">Once the initial safety of a
study drug has been confirmed in Phase I trials, Phase II trials
are performed on larger groups (20-300) and are designed to assess
how well the drug works, as well as to continue Phase I safety
assessments using a larger group of volunteers and patients. When
the development process for a new drug fails, this usually occurs
during Phase II trials when the drug is discovered not to work as
planned or to have toxic effects.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Phase II studies are
sometimes divided into Phase IIA and Phase IIB. Phase IIA is
specifically designed to assess dosing requirements (how much of
the drug should be given), while Phase IIB is specifically designed
to study efficacy (how well the drug works at the prescribed
dose(s)).</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Some trials combine Phase I
and Phase II, and test both efficacy and toxicity.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">All of our planned
anticancer products will need to undergo Phase II clinical trials.
Completion of these trials is subject to our ability to obtain
adequate financing.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We will not establish a firm
start date until we raise sufficient financing, which there is no
guarantee that we will be able to do. The trial protocol for our
Phase II trial has been developed with input from our clinical
advisors.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Phase III</u></p>
<p style="MARGIN: 0px" align="justify">Phase III studies are
randomized controlled multi-center trials on large patient groups
(300-3,000 or more, depending upon the disease or medical condition
studied), and are intended to definitively assess the effectiveness
of the drug as compared to the current “gold standard” treatment.
Because of their size and comparatively long duration, Phase III
trials are the most expensive, time-consuming and difficult trials
to design and run, especially in therapies for chronic medical
conditions.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">It is common practice that
certain Phase III trials may continue while a regulatory submission
is pending at the appropriate regulatory agency. This allows
patients to continue to receive possibly lifesaving drugs until the
drug can be obtained commercially. Other reasons for performing
additional trials at this stage may include “label expansion” (to
show the drug is suitable for additional types of patients/diseases
beyond the original use for which the drug was approved for
marketing), obtaining additional safety data, or to support
marketing claims for the drug. Studies in this phase are
categorized by some companies as “Phase IIIB studies”.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">While not required in all
cases, it is typically expected that at least two successful Phase
III trials will be necessary to demonstrate a drug’s safety and
efficacy to obtain approval from appropriate regulatory agencies,
such as the FDA in the United States, the Therapeutic Goods
Administration in Australia or the European Medicines Agency in the
European Union, for example.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Once a drug has proved
satisfactory after Phase III trials, the trial results are usually
combined into a large document containing a comprehensive
description of the methods and results of human and animal studies,
manufacturing procedures, formulation details and shelf life. This
collection of information makes up the regulatory submission that
is provided for review to the appropriate regulatory authorities in
different countries. They review each submission, and, it is hoped,
give sponsors approval to market the drug.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Most drugs undergoing Phase
III clinical trials can be marketed under FDA norms with proper
recommendations and guidelines, but the drugs must be recalled
immediately from the market if any adverse effects are reported.
While most pharmaceutical companies refrain from this practice, it
is not abnormal to see many drugs undergoing Phase III clinical
trials in the market.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We anticipate that all of
our current planned products will require us to undertake the
conduct of Phase III clinical trials; however, we lack sufficient
information to estimate the costs or timeframe required to complete
any Phase III clinical trials at this time. Our ability to pursue
Phase III trials will be subject to our ability to obtain adequate
financing and successfully complete earlier trials phases for the
products in question.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak3488ab16-0174-4b39-939f-01c404d4d4d1" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
12</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Phase IV</u></p>
<p style="MARGIN: 0px" align="justify">A Phase IV trial is also
known as a post-marketing surveillance trial. Phase IV trials
involve safety surveillance (pharmacovigilance) and ongoing
technical support of a drug after it receives permission to be
sold. Phase IV studies may be required by regulatory authorities or
may be undertaken by a sponsoring company for competitive or other
reasons (for example, the drug may not have been tested for
interactions with other drugs, or on certain population groups such
as pregnant women, who are unlikely to subject themselves to
trials). The safety surveillance is designed to detect any rare or
long-term adverse effects over a much larger patient population and
longer time period than was possible during the Phase I through III
clinical trials. Harmful effects discovered by Phase IV trials may
result in a drug no longer being sold or being restricted to
certain uses.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We are unable to accurately
anticipate at this time whether our current planned products will
require us to undertake Phase IV clinical trials. Similarly, we are
unable to accurately anticipate at this time what the costs or
timeframe to complete those trials might be. Our ability to pursue
any Phase IV trials which may be required of us or which we may
undertake voluntarily will be subject to our ability to adequately
finance those trials and to successfully complete Phase III
trials.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><u>Other</u></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Manufacturing</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We have limited experience
in, and do not own facilities for, manufacturing any products or
product candidates. Although we intend to continue to rely on
contract manufacturers to produce our products for both clinical
and commercial supplies, we will oversee the production of those
products and do not anticipate relying on any particular contract
manufacturer exclusively.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">If we obtain FDA approval in
the United States or marketing application approval outside the
United States for any of our product candidates, we plan to rely on
contract manufacturers to produce sufficient quantities for
large-scale commercialization. These contract manufacturers will be
subject to extensive government regulations. Regulatory authorities
in the markets that we intend to serve require that drugs be
manufactured, packaged and labeled in conformity with current Good
Manufacturing Practices (“GMP”) as set by the FDA. In this regard,
we plan to engage only contract manufacturers who have the
capability to manufacture drug products in compliance with current
GMP in bulk quantities for commercialization. We also intend to
safeguard our intellectual property when working with contract
manufacturers by working only with manufacturers who in our
estimation have a strong track record of safeguarding confidential
information and who are willing to enter into agreements with us
that impose upon them strict intellectual property protection
measures.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Sales, Marketing and
Distribution</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We currently have no sales
or distribution capabilities and limited marketing capabilities. In
order to commercialize our products, we must develop sales,
marketing and distribution capabilities or make arrangements with
other parties to perform these services for us.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Competition</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">If any of our products
receive marketing approval, they may compete against, and may be
used in combination with, well-established products that are
currently used for the treatment of their respective indications.
By the time we are able to commercialize a product candidate, the
competition and potential competition may be greater and more
direct. Several companies are focusing on new compounds, most of
which are in pre-clinical or early phases of development.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We expect to compete with
others on, among other things, the safety and efficacy of our
products. Competing successfully will depend on our continued
ability to attract and retain skilled and experienced personnel; to
identify, secure the rights to and develop pharmaceutical products
and compounds; and to exploit these products and compounds
commercially before others are able to develop competing products.
In addition, our ability to compete may be affected because
insurers and other third-party payors in some cases seek to
encourage the use of generic products making branded products less
attractive to buyers from a cost perspective.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak69f99216-2dfc-4764-aa53-eb14a4717b79" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
13</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Patents and Proprietary
Rights</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our success will depend in
part on our ability to protect our products and product candidates
by obtaining and maintaining a strong proprietary position both in
the United States and in other countries. To develop and maintain
our proprietary position, we will rely on patent protection,
regulatory protection, trade secrets, know-how, continuing
technological innovations and licensing opportunities.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">It is our policy to require
our employees, consultants, contractors, or scientific and other
advisors, to execute confidentiality agreements upon the
commencement of employment or consulting relationships with us.
These agreements provide that all confidential information
developed or made known to the individual during the individual’s
relationship with us is to be kept confidential and not disclosed
to third parties except in specific circumstances. These agreements
provide that all inventions related to our business that are
conceived by the individual during our relationship shall be our
exclusive property. There can be no assurance, however, that these
agreements will provide meaningful protection or adequate remedies
for our trade secrets in the event of unauthorized use or
disclosure of such information.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>Government Regulations</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our current and future
operations and research and development activities are or will be
subject to various laws and regulations in the countries in which
we conduct or plan to conduct our business, including but not
limited to the United States, Canada, United Kingdom and
potentially certain member countries from the European Union. These
laws and regulations govern the research, development, sale and
marketing of pharmaceuticals, taxes, labor standards, occupational
health and safety, toxic substances, chemical products and
materials, waste management and other matters relating to the
pharmaceutical industry. We may require permits, registrations or
other authorizations to maintain our operations and to carry out
our future research and development activities, and these permits,
registrations or authorizations will be subject to revocation,
modification and renewal.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Governmental authorities
have the power to enforce compliance with lease conditions,
regulatory requirements and the provisions of required permits,
registrations or other authorizations, and violators may be subject
to civil and criminal penalties including fines, injunctions, or
both. The failure to obtain or maintain a required permit may also
result in the imposition of civil and criminal penalties, and third
parties may have the right to sue to enforce compliance.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We expect to be able to
comply with all applicable laws and regulations and do not believe
that such compliance will have a material adverse effect on our
competitive position. We have obtained and intend to obtain all
permits, licenses and approvals required by all applicable
regulatory agencies to maintain our current operations and to carry
out our future research and development activities. We are not
aware of any material violations of permits, licenses or approvals
issued with respect to our operations, and we believe that we will
continue to comply with all applicable laws and regulations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Pharmaceutical Regulatory
Regimes</u></p>
<p style="MARGIN: 0px" align="justify">Regulation by governmental
authorities in the United States and other countries is a
significant factor in the development, manufacture and marketing of
pharmaceuticals. All our pharmaceutical product candidates will
require regulatory approval by governmental agencies prior to
commercialization. Our drug candidates are subject to rigorous
pre-clinical testing and subsequent clinical trials and other
premarketing approval requirements of the FDA and regulatory
authorities in other countries. Various federal, state and foreign
statutes and regulations govern or affect the manufacturing,
safety, labeling, stability, record-keeping and marketing of
pharmaceutical products. The lengthy process of seeking required
approvals and the continuing need for compliance with applicable
statutes and regulations require the expenditure of substantial
resources. When we obtain regulatory approval for any of our
product candidates, the approval may be limited in scope, which may
significantly limit the indicated uses for which our product
candidates may be marketed, promoted and advertised. Further,
approved pharmaceuticals and manufacturers are subject to ongoing
review and previously unknown problems may be discovered that may
result in restrictions on the manufacture, sale or use of approved
pharmaceuticals or their withdrawal from the market.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Pre-Clinical
Studies</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Before testing any compounds
with potential therapeutic value in human subjects in the United
States, stringent governmental requirements for pre-clinical data
must be satisfied. Pre-clinical testing includes both <i>in
vitro</i> and <i>in vivo</i> laboratory evaluation and
characterization of the safety and efficacy of a drug and its
formulation. Pre-clinical testing results obtained from these
studies, including tests in several animal species, are submitted
to the FDA as part of an Investigational New Drug Application and
are reviewed by the FDA prior to the commencement of human clinical
trials. These pre-clinical data must provide an adequate basis for
evaluating both the safety and the scientific rationale for initial
trials in human volunteers.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak301526f4-fe4e-4b68-bb15-8f6aa509a1ba" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
14</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Clinical Trials</u></p>
<p style="MARGIN: 0px" align="justify">If a company wants to
conduct clinical trials in the United States to test a new drug in
humans, an Investigational New Drug (“IND”) Application must be
prepared and submitted to the FDA. The IND Application becomes
effective, if not rejected or put on clinical hold by the FDA,
within 30 days of filing the application. In addition, an
Institutional Review Board must review and approve the trial
protocol and monitor the trial on an ongoing basis. The FDA may, at
any time during the 30 day review period or at any time thereafter,
impose a clinical hold on proposed or ongoing clinical trials. If
the FDA imposes a clinical hold, clinical trials may commence or
recommence without FDA authorization, and then only under terms
authorized by the FDA. The IND Application process can result in
substantial delay and expense.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>New Drug
Application</u></p>
<p style="MARGIN: 0px" align="justify">After completion of clinical
trials, if there is substantial evidence that the drug is both safe
and effective, a New Drug Application is prepared and submitted to
the FDA for review. The New Drug Application must contain all of
the essential information on the drug gathered to that date,
including data from preclinical studies and clinical trials, and
the content and format of a New Drug Application must conform with
all FDA regulations and guidelines. Accordingly, the preparation
and submission of a New Drug Application is an expensive and major
undertaking for a sponsor.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The FDA reviews all New Drug
Applications submitted before it accepts them for filing and may
request additional information from the sponsor rather than
accepting a New Drug Application for filing. In such an event, the
New Drug Application must be submitted with the additional
information and, again, is subject to review before filing. Once
the submission is accepted for filing, the FDA begins an in depth
review of the New Drug Application. By law, the FDA has 180 days in
which to conduct the initial review the New Drug Application and
respond to the applicant. The review process is often significantly
extended by the FDA through requests for additional information and
clarification. The FDA may refer the application to an appropriate
advisory committee, typically a panel of clinicians, for review,
evaluation and a recommendation as to whether the application
should be approved and the scope of any approval. The FDA is not
bound by the recommendation, but gives great weight to it. If the
FDA evaluations of both the New Drug Application and the
manufacturing facilities are favorable, the FDA may issue either an
approval letter or an approvable letter, which usually contains a
number of conditions that must be satisfied in order to secure
final approval. If the FDA’s evaluation of the New Drug Application
submission or manufacturing facility is not favorable, the FDA may
refuse to approve the New Drug Application or issue a not
approvable letter.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Fast Track Designation
and Priority Review</u></p>
<p style="MARGIN: 0px" align="justify">The FDA’s fast track program
is intended to facilitate the development and expedite the review
of drugs that are intended for the treatment of a serious or
life-threatening condition for which there is no effective
treatment and which demonstrate the potential to address unmet
medical needs for their condition. Under the fast track program,
the sponsor of a new drug may request the FDA to designate the drug
for a specific indication as a fast track product at any time
during the clinical development of the product. The FDA must
determine if the product qualifies for fast track designation
within 60 days of receipt of the sponsor’s request.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">For a product candidate
where fast track designation is obtained, the FDA may initiate
review of sections of a New Drug Application before the application
is complete. This rolling review is available if the applicant
provides a schedule for the submission of the remaining information
and pays applicable user fees. However, the time period specified
in the <i>Prescription Drug User Fees Act</i>, which governs the
time period goals the FDA has committed to reviewing a New Drug
Application, does not begin until the complete application is
submitted. Additionally, the fast track designation may be
withdrawn by the FDA if the FDA believes that the designation is no
longer supported by data emerging in the clinical trial
process.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In some cases, the FDA may
designate a product for priority review. A product is eligible for
priority review, or review within a targeted six-month time frame
from the time of acceptance of filing a New Drug Application, if
the product provides a significant improvement compared to marketed
products in the treatment, diagnosis or prevention of a disease. A
fast track designated product generally meets the FDA’s criteria
for priority review. We cannot guarantee that any of our products
will receive a priority review designation, or if a priority
designation is received, that review or approval will be faster
than conventional FDA procedures.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreaka1b803f8-a5d9-48e2-887c-9e03a15ca842" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
15</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">When appropriate, we intend
to seek fast track designations for our products. We cannot predict
the ultimate impact, if any, of the fast track process on the
timing or likelihood of FDA approval on any of our potential
products. Importantly, fast track designation does not result in
the elimination or waiver of any pre-clinical or clinical trial
requirements.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Orphan Drug
Designation</u></p>
<p style="MARGIN: 0px" align="justify">The FDA may grant orphan
drug designation to drugs intended to treat a rare disease or
condition that affects fewer than 200,000 individuals in the United
States. Orphan drug designation must be requested before submitting
a New Drug Application. If the FDA grants orphan drug designation,
the generic identity of the therapeutic agent and its potential
orphan use are disclosed publicly by the FDA. Orphan drug
designation does not convey any advantage in, or shorten the
duration of, the regulatory review and approval process. If a
product that has orphan drug designation subsequently receives FDA
approval for the indication for which it has such designation, the
product is entitled to a longer market [orphan] exclusivity, which
means the FDA may not approve any other applications to market the
same drug for the same indication, except in very limited
circumstances, for up to seven years after receiving FDA
approval.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>The Hatch-Waxman
Act</u></p>
<p style="MARGIN: 0px" align="justify">Under the <i>Drug Price
Competition and Patent Term Restoration Act</i> of 1984, known as
the <i>Hatch-Waxman Act</i>, newly approved drugs may benefit from
a statutory period of non-patent marketing exclusivity in the
United States. The <i>Hatch-Waxman Act</i> provides five years of
marketing exclusivity to the first applicant to gain approval of a
New Drug Application under Section 505(b) of the <i>Food, Drug and
Cosmetic Act</i> for a new chemical entity. A drug qualifies as a
new chemical entity if the FDA has not previously approved any
other drug containing the same active ingredient. The
<i>Hatch-Waxman Act</i> provides data exclusivity by prohibiting
abbreviated New Drug Applications, and the submission of section
505(b)(2) applications, which are marketing applications where the
applicant does not own or have a legal right of reference to all
the data required for approval, by another company for another
version of such drug during the exclusive period. Protection under
the <i>Hatch-Waxman Act</i> will not prevent the filing or approval
of a full New Drug Application for the same active ingredient,
although the applicant would be required to conduct its own
adequate and well-controlled clinical trials to demonstrate safety
and effectiveness.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Other Regulatory
Requirements</u></p>
<p style="MARGIN: 0px" align="justify">Any products we manufacture
or distribute under FDA approvals are subject to pervasive and
continuing regulation by the FDA, including record-keeping
requirements and reporting of adverse experiences with the
products. Drug manufacturers and their subcontractors are required
to register with the FDA and, where appropriate, state agencies,
and are subject to periodic unannounced inspections by the FDA and
state agencies for compliance with current Good Manufacturing
Practices, or cGMP, regulations which impose procedural and
documentation requirements upon us and each third-party
manufacturer we utilize.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The FDA closely regulates
the marketing and promotion of drugs. A company can make only those
claims relating to safety and efficacy that are approved by the
FDA. Failure to comply with these requirements can result in
adverse publicity, warning letters, corrective advertising and
potential civil and criminal penalties. Physicians may prescribe
legally available drugs for uses that are not described in the
product’s labeling and that differ from those tested by us and
approved by the FDA. Such off-label uses are common across medical
specialties. Physicians may believe that such off-label uses are
the best treatment for many patients in varied circumstances. The
FDA does not regulate the behavior of physicians in their choice of
treatments. The FDA does, however, restrict manufacturers from
communicating on the subject of off-label use.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The FDA’s policies may
change and additional government regulations may be enacted which
could prevent or delay regulatory approval of our programs or our
future product candidates, or such approval of new indications for
our future products. We cannot predict the likelihood, nature or
extent of adverse governmental regulations that might arise from
future legislative or administrative action, either in the United
States or abroad in the European Union.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak6676ddfb-2f0f-4c9b-96c9-ce03059106c9" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
16</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Clinical Trials</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Similar to the United
States, the various phases of pre-clinical and clinical research in
the European Union are subject to significant regulatory controls.
The regulatory controls on clinical research in the European Union
are now largely harmonized following the implementation of the
Clinical Trials Directive 2001/20/EC, or CTD. Compliance with the
national implementations of the CTD has been mandatory since May 1,
2004. However, variations in member state regimes continue to
exist, particularly in the small number of member states that have
yet to implement the CTD fully.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">All member states currently
require regulatory and independent ethics committee approval of
interventional clinical trials. European regulators and ethics
committees also require the submission of adverse event reports
during a study and a copy of the final study report.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Marketing
Authorization</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In the European Union,
approval of new medicinal products can be obtained through the
mutual recognition procedure or the centralized procedure. The
mutual recognition procedure entails initial assessment by the
national authorities of a single member state and subsequent review
by national authorities in other member states based on the initial
assessment. The centralized procedure requires the submission of a
single Marketing Authorization Application (a “MAA”) to the EMA
leading to an approval that is valid in all European Union member
states. It is required for certain medicinal products, such as
biotechnology products and certain new chemical entities, and is
optional, or available at the EMA’s discretion, for other new
chemical entities or innovative medicinal products with novel
characteristics.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Under the centralized
procedure, a MAA is submitted to the EMA. Two European Union member
states are appointed to conduct an initial evaluation of each MAA.
These countries each prepare an assessment report, which are then
used as the basis of a scientific opinion of the Committee for
Medicinal Products for Human Use. If this opinion is favorable, it
is sent to the European Commission which drafts a decision. After
consulting with the member states, the European Commission adopts a
decision and grants a marketing authorization, which is valid
throughout the European Union and confers the same rights and
obligations in each of the member states as a marketing
authorization granted by that member state.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Advertising</u></p>
<p style="MARGIN: 0px" align="justify">In the European Union, the
promotion of prescription medicines is subject to intense
regulation and control, including a prohibition on
direct-to-consumer advertising. Some jurisdictions require that all
promotional materials for prescription medicines be subjected to
either prior internal or regulatory review or approval.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Data Exclusivity</u></p>
<p style="MARGIN: 0px" align="justify">For an MAA filed after
October 30, 2005, European Union regulators offer eight years of
data exclusivity during which generic drug manufacturers cannot
file abridged applications. This is followed by two years of market
exclusivity during which generic MAAs may be reviewed and approved
but during which generic drug manufacturers cannot launch products.
The manner in which these new exclusivity provisions will be
applied in practice remains far from clear and there can be no
assurance that our programs or our other current or future product
candidates will qualify for such exclusivity.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Other Regulatory
Requirements</u></p>
<p style="MARGIN: 0px" align="justify">If a marketing authorization
is granted for our products in the European Union, the holder of
the marketing authorization will be subject to ongoing regulatory
obligations. A holder of a marketing authorization for our products
is legally obliged to fulfill a number of obligations by virtue of
its status as a Marketing Authorization Holder (a “MAH”). While the
associated legal responsibility and liability cannot be delegated,
the MAH can delegate the performance of related tasks to third
parties, provided that this delegation is appropriately documented.
A MAH can therefore either ensure that it has adequate resources,
policies and procedures to fulfill its responsibilities, or can
delegate the performance of some or all of its obligations to
others, such as distributors or marketing partners.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreakd8610493-165f-4755-91cf-f3f8184e3025" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
17</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The obligations of a MAH
include:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Manufacturing and Batch Release: MAHs should
guarantee that all manufacturing operations comply with relevant
laws and regulations, applicable good manufacturing practices, the
product specifications and manufacturing conditions set out in the
marketing authorization and that each batch of product is subject
to appropriate release formalities.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Pharmacovigilance: MAHs are obliged to monitor the
safety of products post-approval and to submit to the regulators
safety reports on an expedited and periodic basis. There is an
obligation to notify regulators of any other information that may
affect the risk benefit ratio for the product.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Advertising and Promotion: MAHs remain responsible
for all advertising and promotion of their products in the relevant
jurisdiction, including promotional activities by other companies
or individuals on their behalf. Some jurisdictions require that a
MAH subject all promotional materials to either prior internal or
regulatory review and approval.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Medical Affairs/Scientific Service: MAHs are
required to have a function responsible for disseminating
scientific and medical information on their medicinal products,
predominantly to healthcare professionals, but also to regulators
and patients.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Legal Representation and Distributor Issues: MAHs
are responsible for regulatory actions or inactions of their
distributors and agents, including the failure of distributors to
provide a MAH with safety data within a timeframe that allows the
MAH to fulfill its reporting obligations.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">Preparation, Filing and Maintenance of the
Application and Subsequent Marketing Authorization: MAHs have
general obligations to maintain appropriate records, to comply with
the marketing authorization’s terms and conditions, to submit
renewal applications and to pay all appropriate fees to the
authorities. There are also general reporting obligations, such as
an obligation to inform regulators of any information that may lead
to the modification of the marketing authorization dossier or
product labeling, and of any action to suspend, revoke or withdraw
an approval or to prohibit or suspend the marketing of a
product.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We may hold marketing
authorizations for our products in our own name, or appoint an
affiliate or a collaboration partner to hold the marketing
authorization on our behalf. Any failure by a MAH to comply with
these obligations may result in regulatory action against the MAH
and its approvals and ultimately threaten our ability to
commercialize our products.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Approvals Outside of the
United States and the European Union</u></p>
<p style="MARGIN: 0px" align="justify">We will also be subject to a
wide variety of foreign regulations governing the development,
manufacture and marketing of our products. Whether or not FDA
approval or European marketing authorization has been obtained,
approval of a product by the comparable regulatory authorities of
other foreign countries must still be obtained prior to
manufacturing or marketing the product in those countries. The
approval process varies from country to country and the time needed
to secure approval may be longer or shorter than that required for
FDA approval or a European marketing authorization. We cannot
assure you that clinical trials conducted in one country will be
accepted by other countries or that approval in one country will
result in approval in any other country.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Third-Party Reimbursement
and Pricing Controls</u></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>General:</i></p>
<p style="MARGIN: 0px" align="justify">In the United States and
elsewhere, patients’ access to pharmaceutical products depends in
significant part on the coverage and reimbursement of a product or
service by third-party payors, such as government programs, private
insurance plans and employers. Third-party payors increasingly are
challenging the prices charged for medical products and services.
It will be time consuming and expensive for us to go through the
process of seeking reimbursement from Medicare, Medicaid and
private payors. We may be unable to achieve reimbursement from some
payors because they may not consider our products to be “reasonable
and necessary” or cost-effective. Furthermore, it is possible that
even if payors are willing to reimburse patients for our products,
the reimbursement levels may not be sufficient to allow us to sell
our products on a competitive and profitable basis.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In many foreign markets,
including the countries in the European Union, the pricing of
pharmaceutical products is subject to direct governmental control
and to drug reimbursement programs with varying price control
mechanisms. In the European Union, governments influence the price
of pharmaceutical products through their pricing and reimbursement
rules and the control of national health care systems that fund a
large part of the cost of such products to consumers. The approach
taken varies from member state to member state: some jurisdictions
operate positive and/or negative list systems under which products
may only be marketed once a reimbursement price has been agreed,
and other member states allow companies to fix their own prices for
medicines, but monitor and control company profits. The downward
pressure on health care costs in general, particularly prescription
drugs, has become very intense. As a result, increasingly high
barriers are being erected to the entry of new products, as
exemplified by the National Institute for Clinical Excellence in
the United Kingdom which evaluates the data supporting new
medicines and passes reimbursement recommendations to the
government. In addition, in some countries cross-border imports
from low-priced markets (parallel imports) exert a commercial
pressure on pricing within a country.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak32e8590f-df03-4ebe-8346-188de971a376" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
18</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In the United States, there
have been, and we expect that there will continue to be, a number
of federal and state proposals to implement means by which the
government can negotiate lower drug prices for Medicare and
Medicaid beneficiaries. While we cannot predict whether such
legislative bills will become law, their enactment could have a
material adverse effect on our business, financial condition and
results of operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Medicare:</i></p>
<p style="MARGIN: 0px" align="justify">In the following section,
all references to “CMS” refer to the Center for Medicare and
Medicaid Services.</p>
<p style="MARGIN: 0px" align="justify">We expect that in the United
States, some or possibly a majority of the patients who are treated
with our products will be Medicare beneficiaries. The CMS is the
agency within the Department of Health and Human Services that
administers both Medicare and Medicaid. Two aspects of Medicare
reimbursement will be relevant to our products: the availability of
reimbursement for physician services for administration of our
products and the availability of reimbursement for our products
themselves.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The CMS has asserted the
authority of Medicare not to cover particular products or services
if it determines that they are not “reasonable and necessary” for
Medicare beneficiaries. The CMS may create a national coverage
determination (a “NCD”) for a product, which establishes on a
nationwide basis the indications that will be covered and the
frequency limits for administration of the product. However, for
most new drugs that are eligible for payment, the CMS does not
create a NCD. We do not know whether we will seek or obtain a NCD
for any of our current or potential products or whether any NCD we
obtain will contain favorable coverage terms. As mentioned above,
if Medicare coverage for our products is available, the CMS may
decide to provide reimbursement through one of two avenues: Part B
coverage for physician-administered drugs, or Part D coverage for
outpatient prescription drugs. Under Part B coverage, Medicare
reimburses purchasers of drugs that meet three statutory
requirements:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">the product is reasonable and necessary;</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">the product is not usually self-administered and
as such is incidental to a physician’s service in the office
setting; and</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">the administering physician bills Medicare
directly for the product.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">If there is not a national
coverage decision, the local Medicare contractors that are
responsible for administering the Part B program on a regional
basis may have the discretion to decline coverage and reimbursement
for a drug or to issue a local coverage decision (an “LCD”). These
policies can include both coverage criteria for the drug and
frequency limits for the administration of the drug. The local
contractors in different areas of the country may determine that
our products should be treated like most topical patches and may
deny coverage under Part B or, even if they allow coverage, may
establish varying coverage criteria and frequency limits for any
product. Furthermore, obtaining LCDs in the various regions can be
a time-consuming and expensive process.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Medicare payment for
physician services related to the administration of any of our
products, if any, will most likely be determined according to a
prospectively set payment rate, determined by a procedure code
established by the American Medical Association. These codes,
called Current Procedural Terminology (“CPT”) codes, describe the
procedure performed and can be specific or more general in nature.
We believe that although there are existing CPT codes that could be
used, although a specific code for the administration of each of
our products would be preferable. If applicable, we plan to apply
for a specific CPT code. If, at launch, a specific CPT code is not
available, local Medicare contractors will advise which existing
CPT code should be used for services related to the administration
of our products.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The CMS has been considering
changes to Medicare reimbursement that could result in lower
payments for physician-administered drugs, and Congress may also
consider legislation that would mandate lower reimbursement levels.
A reduction in reimbursement levels could materially and adversely
affect our revenue.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreakeeccf1fd-752d-458d-9b3c-eda79d594c4c" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
19</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The CMS may determine that
some of our products do not qualify for Part B coverage and should
instead be covered under the Part D outpatient prescription drug
benefit. Because, unlike Part B, Part D coverage reimburses
patients only for the drug itself and does not provide
reimbursement for the physician’s administration services (though a
physician can bill for service under Part B and it is possible that
the CMS will provide such coverage for the administration of any of
our products, even if the product in question is covered under Part
D), physicians may not consider our products as attractive a
treatment option if they are reimbursed under Part D instead of
Part B. In addition, under Part D, there are multiple types of
plans and numerous plan sponsors, each with its own formulary and
product access requirements. While the CMS evaluates Part D plans’
proposed formularies for potentially discriminatory practices, the
plans have considerable discretion in establishing formularies,
establishing tiered co-pay structures and placing prior
authorization and other restrictions on the use of specific
products. Moreover, Part D plan sponsors are permitted and
encouraged to negotiate rebates with manufacturers. Revenue for our
products will be substantially affected by their respective
formulary status on Part D plans and the rebates that Part D plan
sponsors are able to negotiate.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Medicaid:</i></p>
<p style="MARGIN: 0px" align="justify">Most State Medicaid programs
have established preferred drug lists, and the process, criteria
and timeframe for obtaining placement on the preferred drug list
vary from state to state. A federal law establishes minimum rebates
that a manufacturer must pay for Medicaid utilization of a product,
and many states have established supplemental rebate programs as a
condition for including a drug product on a preferred drug list.
Submitting a preferred drug list application to each state will be
a time-consuming and expensive process, and it is not clear how
many or which state programs will accept the applications. Review
times for these applications can vary from weeks to 14 months or
more.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Private Insurance
Reimbursement:</i></p>
<p style="MARGIN: 0px" align="justify">Commercial insurers usually
offer two types of benefits: medical benefits and pharmacy
benefits. In most private insurance plans, physician-administered
drugs are provided under the medical benefit. If private insurers
decide to cover any of our products, they will reimburse for the
drug(s) and its administration in a variety of ways, depending on
the insurance plan’s revenue targets, employer and benefit manager
input and the contract negotiated with their physicians. Like
Medicare and Medicaid, commercial insurers have the authority to
place coverage and utilization limits on physician-administered
drugs. Many private insurers tend to adopt reimbursement
methodologies for a product similar to those adopted by Medicare.
Revenue for our products may be materially and adversely affected
if private payors make unfavorable reimbursement decisions or delay
making favorable reimbursement decisions.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Subsidiaries</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">We own 100% of the outstanding common stock
of Pivot Green Stream Health Solutions Inc., Pivot Naturals, LLC
and Thrudermic, LLC.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Employees and
Consultants</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As of May 1, 2018, we have
employment contracts with our chief business officer, chief
financial officer as well as our president, director and vice
president of our wholly-owned subsidiaries. We currently engage
independent contractors in the areas of legal and auditing
services. We plan to engage independent contractors in the areas of
preclinical toxicity studies and clinical trial execution and data
management.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>REPORTS TO SECURITY
HOLDERS</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We are required to file
annual, quarterly and current reports, proxy statements and other
information with the Securities and Exchange Commission and our
filings are available to the public over the internet at the
Securities and Exchange Commission’s website at http://www.sec.gov.
The public may read and copy any materials filed by us with the
Securities and Exchange Commission at the Securities and Exchange
Commission’s Public Reference Room at 100 F Street N.E. Washington
D.C. 20549. The public may obtain information on the operation of
the Public Reference Room by calling the Securities and Exchange
Commission at 1-800-732-0330. The SEC also maintains an Internet
site that contains reports, proxy and formation statements, and
other information regarding issuers that file electronically with
the SEC, at http://www.sec.gov.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreakac8514c6-ad81-4ce9-bead-8d3009f24a3b" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
20</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><a name="Item 1A. Risk Factors">Item 1A.
Risk Factors</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>There is substantial
doubt as to whether we will continue operations. If we discontinue
operations, you could lose your investment.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Our financial
statements have been prepared on the going concern basis, which
assumes that we will be able to realize our assets and discharge
our liabilities in the normal course of business. However, as at
January&nbsp;31, 2018, we have not earned any revenues and had an
accumulated deficit of $20,718,935. We anticipate that we will
incur increased expenses without realizing sufficient revenues (if
any) to offset those expenses and we therefore expect to incur
significant losses for the foreseeable future. Our ability to
continue our operations is dependent on obtaining additional
financing and generating future revenues, and no assurance can be
given that we will successfully be able to do so. Accordingly, our
financial statements contain disclosure of management’s
determination that these factors raise substantial doubt about our
ability to continue as a going concern. Importantly, the inclusion
in our financial statements of a going concern opinion may
negatively impact our ability to raise future financing and achieve
future revenue. The threat of our ability to continue as a going
concern will be removed only when, in the opinion of our auditor,
our revenues have reached a level that is able to sustain our
business operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">If we are unable to obtain
additional financing from outside sources and eventually generate
enough revenues, we may be forced to sell a portion or all of our
assets, or curtail or discontinue our operations. If any of these
happens, you could lose all or part of your investment. Our
financial statements do not include any adjustments to our recorded
assets or liabilities that might be necessary if we become unable
to continue as a going concern.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>We have incurred
operating losses in each year since our inception and expect to
continue to incur substantial and increasing losses for the
foreseeable future. We also have negative capital cash flows from
operating activities. If we cannot generate sufficient revenues to
operate profitably or with positive cash flow from operating
activities, we may suspend or cease our operations.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We have not generated any
revenue since our inception on June 10, 2002 and we have incurred
operating and net losses in each year of our existence. We
experienced a net loss of $121,182 for the year ended January 31,
2018, compared to a net loss of $6,278,207 for the year ended
January 31, 2017. We expect to incur substantial and increasing
losses for the foreseeable future as we develop, seek regulatory
approval for and commercialize our product candidates and pursue
our other research and development activities. If our products are
not successful in research and development or in clinical trials,
does not gain regulatory approval or does not achieve market
acceptance, we may never generate any revenue. We also cannot
assure you that we will be profitable even if we successfully
commercialize our products. If we fail to generate sufficient
revenues to operate profitability, or if we are unable to fund our
continuing losses, you could lose all or part of your
investment.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>We will require
substantial additional funds to complete our research and
development activities and proposed acquisition, and if such funds
are not available we may need to significantly curtail or cease our
operations.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We will require substantial
funds to research, develop, test and protect our product
candidates, and to manufacture and market any such candidates that
may be approved for commercial sale. Based on our planned research
and development and commercialization activities, we anticipate
that we will require funds of approximately $24.45 million to
proceed with completing the development and commercialization of
our products. If we do not raise sufficient funds, our plan of
operation will be delayed until such time as we raise sufficient
funds, provided we are able to do so. Further, the cost of carrying
out our operating activities and research and development
activities is not fixed, and our cash levels may at any time prove
to be insufficient to finance them. Our financing needs may change
substantially because a number of factors which are difficult to
predict or which may be outside of our control. These include
increased competition, the costs of licensing existing drugs and
protecting rights to our proprietary technology, the resources
required to complete pre-clinical and clinical studies, and the
length and results of the regulatory approval process.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We may not succeed in
raising the additional funds that we require because such funds may
not be available to us on acceptable terms, if at all. We intend to
seek additional funding through strategic alliances or through
public or private sales of our equity securities, and we may also
obtain equipment leases and pursue opportunities to obtain debt
financing in the future. If we are unable to obtain sufficient
funding on a timely basis, we may be forced to significantly
curtail or cease our operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak6fdd5ad4-3aee-480e-935c-75af2dd57bc1" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
21</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Our inability to complete
our research and development projects in a timely manner could have
a material adverse effect of our results of operations, financial
condition and cash flows.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">If our R&amp;D projects are
not completed in a timely fashion, our Company could
experience:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">substantial additional cost for the conduct of IND
supporting R&amp;D activities;</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">additional competition in the pharmaceutical and
nutraceutical indications in our pipeline;</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">additional delay in obtaining requisite regulatory
approvals; and</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">delay in obtaining future inflow of cash from
financial or partnership activities, any of which could have a
material adverse effect of our results of operations, financial
condition and cash flows.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Any products that we may
develop will be required to undergo a time-consuming, costly and
burdensome pre-market approval process, and if we are unable to
obtain regulatory approval for our products we may never become
profitable.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Any products that we may
develop will be subject to extensive governmental regulations
relating to development activities, conduct of clinical trials,
manufacturing and commercialization. In the United States, for
example, the prospective therapeutic products that we intend to
develop and market are regulated by the FDA under its new drug
development and review process. Before such therapeutic products
can be marketed, we must obtain clearance from the FDA by
submitting an investigational new drug application, then by
successfully completing human testing under three phases of
clinical trials, and finally by submitting a new drug
application.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The time required to obtain
approvals for our prospective therapeutic products from the FDA and
other agencies in foreign locales with similar processes is
unpredictable. We expect to be able to accelerate the approval
process and to increase the chances of approval by using existing
and approved drugs as the basis for our own technology. However, we
cannot guarantee that our expectations will be realized, and there
is no assurance that we will ever receive regulatory approval to
use our proprietary substances, methods and processes. If we do not
obtain such regulatory approval, we may never become
profitable.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>We may not commence
clinical testing for any of our prospective therapeutic products
and the commercial value of any clinical study that we may conduct
will depend significantly upon our choice of indication and our
patient population selection. If we are unable to commence clinical
testing or if we make a poor choice in terms of clinical strategy,
we may never achieve revenues.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In order to commence
clinical testing, we must successfully complete and obtain positive
scientific results from pre-clinical studies and, in the case of an
existing drug that we are re-profiling for a new indication, adopt
existing pre-clinical or early stage clinical studies to our own
research. If we successfully complete any clinical study of our
own, the commercial value of any such study will significantly
depend upon our choice of indication and our patient population
selection for that indication.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Our clinical trials for
each drug may fail to adequately demonstrate the safety and
efficacy of that candidate, which could force us to abandon our
product development plans for that drug candidate.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Before obtaining regulatory
approval for the commercial sale of any of our product candidates,
we must demonstrate through lengthy, complex and expensive
pre-clinical testing and clinical trials that each product is both
safe and effective for use in each target indication. Clinical
trial results are inherently difficult to predict, and the results
we have obtained or may obtain from third-party trials or from our
own trials may not be indicative of results from future trials. We
may also suffer significant setbacks in advanced clinical trials
even after obtaining promising results in earlier studies.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Although we intend to modify
any of our protocols in ongoing studies to address any setbacks,
there can be no assurance that these modifications will be adequate
or that these or other factors will not have a negative effect on
the results of our clinical trials. This could significantly
disrupt our efforts to obtain regulatory approvals and
commercialize our product candidates. Furthermore, we may
voluntarily suspend or terminate our clinical trials if at any time
we believe that they present an unacceptable safety risk to
patients, either in the form of undesirable side effects or
otherwise. If we cannot show that our product candidates are both
safe and effective in clinical trials, we may be forced to abandon
our business plan.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak9705be3c-1b0d-4bcf-b1a6-4fe9152d6137" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
22</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>We will rely on third
parties to conduct our formulation development, chemistry
activities, as well as pre-clinical and clinical trials. If these
third parties do not perform as contractually required or otherwise
expected we may not be able to obtain regulatory approval for our
product candidates, which may prevent us from becoming
profitable.</i></p>
<p style="MARGIN: 0px" align="justify"><i>If we are unable to
establish a sales, marketing and distribution infrastructure or
enter into collaborations with partners to perform these functions,
we may not be successful in commercializing our product
candidates.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In order to successfully
commercialize any of our product candidates, we must either develop
a satisfactory sales, marketing and distribution infrastructure or
enter into collaborations with partners to perform these services
for us. We will require substantial resources to create such an
infrastructure, and we may never possess the resources to do so.
For example, we may be unable to recruit and retain an adequate
number of effective sales and marketing personnel or we may incur
unforeseen costs and expenses in connection with developing the
necessary infrastructure.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Although we plan to develop
our own sales and marketing organizations in some markets, we
intend to enter into partnering, co-promotion and other
distribution arrangements to commercialize our products in most
markets. We may not be able to enter into collaborations on
acceptable terms, if at all, and we may face competition in our
search for partners with whom we may collaborate. If we are not
able to build a satisfactory sales, marketing and distribution
infrastructure or collaborate with one or more partners to perform
these functions, we may not be able to successfully commercialize
our product candidates, which could cause us to cease our
operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Our product candidates
may never gain market acceptance even if we obtain the necessary
regulatory approvals, which could prevent us from generating
revenues.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Even if we receive the
necessary regulatory approvals to commercially sell our product
candidates, the success of these candidates will depend on their
acceptance by physicians and patients, among other things. Market
acceptance of, and demand for, any product that we develop and
commercialize will depend on many factors, including:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">our ability to provide acceptable evidence of
safety and efficacy;</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">our ability to obtain sufficient third-party
insurance coverage or reimbursement;</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">the availability, relative cost and relative
efficacy of alternative and competing treatments;</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">the effectiveness of our or our collaborators’
sales, marketing and distribution strategy; and</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">publicity concerning our products or competing
products and treatments.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">If our product candidates
fail to gain market acceptance, we may be unable to generate
sufficient revenue to continue our business.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>We will depend on other
parties to manufacture our product candidates. If these parties
fail to meet our manufacturing requirements and applicable
regulatory requirements, our product development and
commercialization efforts could suffer and we may never realize a
profit.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">If we obtain the necessary
regulatory approvals to market our products, we will rely on
contract manufacturers as single source suppliers for our product
candidates.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Because of our planned
reliance on contract manufacturers, we may also be exposed to
additional risks, including those related to intellectual property
and the failure of such manufacturers to comply with
strictly-enforced regulatory requirements, manufacture components
to our specifications, or deliver sufficient component quantities
to us in a timely manner. For example, a contract manufacturer
working on our behalf may violate the intellectual property rights
of a third party in manufacturing a component of one of our
products, and if such a violation occurs without our knowledge, we
may be held vicariously liable for the acts of our contractor,
incur related costs and court mandated damages, or become enjoined
from selling products which violate those third-party intellectual
property rights. Similarly, if a contract manufacturer working on
our behalf is found to be in violation of FDA or other national
regulatory standards regarding the manufacture, packaging or
labeling of any of our products, we could face any number of
adverse consequences including costly regulatory investigations and
fines, interruptions in the flow of our products or materials,
product recalls, or liability to consumers regarding any of our
products that do not meet such regulatory requirements. If any of
these events occurs, if our relationship with any of our potential
contract manufacturers terminates, or if any such manufacturer is
unable fulfill its obligations to us for any reason, our product
development and commercialization efforts could suffer and we may
never realize a profit.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak6e5a778d-9b41-4e13-a68e-ad58aad66b88" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
23</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>We face potential product
liability exposure, and any claim brought against us may cause us
to divert resources from our normal operations or terminate
selling, distributing and marketing any product for which we have
received regulatory approval. This may cause us to cease our
operations as it relates to that product.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The use of our product
candidates in clinical trials and the sale of any products for
which we obtain regulatory approval may expose us to product
liability claims from consumers, health care providers,
pharmaceutical companies or other entities. Although we plan to
obtain product liability insurance coverage for our clinical trials
with limits that we hope will be customary and adequate to provide
us with coverage for foreseeable risks associated with our product
development efforts, our insurance coverage may be insufficient to
reimburse us for the actual expenses or losses we may suffer.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">If we obtain sufficient
financing to proceed with our planned clinical trials, we intend to
purchase insurance in amounts customary for trials comparable to
our own. To that effect, we intend to consult with industry
professionals to determine the optimal amount of coverage. In order
to obtain insurance, we must subject our clinical trial protocol to
a full review by our eventual insurance provider. The process of
binding an insurance policy for a clinical trial can take as long
as three months.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We also plan to expand our
insurance to cover the commercial sale of products if we obtain the
necessary regulatory approval to do so; however, the same product
liability risks apply in those circumstances as in clinical trials.
Further, even if we are able to successfully defend ourselves
against any potential claims, we will likely incur substantial
costs in the form of unanticipated expenses and negative publicity.
This could result in decreased demand for our product candidates,
the withdrawal of clinical trial participants, an impaired business
reputation, revenue loss or an inability to commercialize our
product candidates. Any of these consequences could cause us to
cease our operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>We face substantial
competition in the therapeutic pharmaceutical research and
development industry, which could harm our business and our ability
to operate profitably.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our industry is highly
competitive, and many of our potential competitors, either alone or
together with their partners, have substantially greater financial
resources, research and development programs, clinical trial and
regulatory experience, expertise in the protection of intellectual
property rights, and manufacturing, distribution and sales and
marketing capabilities than us. As a result, they may be able
to:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">develop product candidates and market products
that are faster to market and thus less expensive, potentially
safer, and/or more effective or involve more convenient treatment
procedures than our future products;</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">commercialize competing products before we can
launch any of our product candidates;</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">initiate or withstand substantial price
competition more successfully than us;</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">enjoy greater success in recruiting skilled
scientific workers from a limited pool of available talent;
and</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">more effectively negotiate third-party licenses
and strategic alliances.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>All of our product
candidates and product development processes will be subject to
ongoing regulatory requirements, and may therefore be the subject
of regulatory or enforcement action. The associated costs could
prevent us from achieving our goals or becoming profitable.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our product candidates,
clinical data, third-party manufacturing facilities and processes
and advertising and promotional activities for any product that
receives regulatory approval will be subject to significant review
and ongoing and changing regulation by various regulatory agencies.
Our failure to comply with any regulatory requirements may subject
us to administrative and judicial sanctions, which may include
warning letters, civil and criminal penalties, injunctions, product
seizures or detention, product recalls, total or partial suspension
of production, or the denial of pending product marketing
applications.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreakce733ffa-8754-4d65-b00c-3dc2279b9f58" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
24</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">Even if we receive regulatory approval to
market a particular product candidate, such approval could be
conditional upon our conducting costly post-approval studies or
could limit the indicated uses that we are able to include on our
product labels. In addition, regulatory or enforcement actions
could adversely affect our ability to develop, market and sell our
prospective products successfully and harm our reputation, which
could lead to reduced market demand for such products.
Consequently, the costs associated with any such action could cause
our business to suffer and prevent us from achieving our goals or
becoming profitable.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Since our directors are
located outside of Canada, you may be limited in your ability to
enforce Canadian civil actions against them for damages to the
value of your investment.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>We plan to indemnify our
directors and officers against liability to us and our security
holders, and such indemnification could increase our operating
costs.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our Articles allow us to
indemnify our directors and officers against claims associated with
carrying out the duties of their offices. Our Articles also allow
us to reimburse them for the costs of certain legal defenses.
Insofar as indemnification for liabilities arising under relevant
securities legislation may be permitted to our directors, officers
or control persons, certain securities regulations may deem that
such indemnification is against public policy and is therefore
unenforceable in that jurisdiction.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Since our officers and
directors are aware that they may be indemnified for carrying out
the duties of their offices, they may be less motivated to meet the
standards required by law to properly carry out such duties, which
could increase our operating costs. Further, if our officers and
directors file a claim against us for indemnification, the
associated expenses could also increase our operating costs.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Not all jurisdictions
allow for the medicinal use of cannabis and those jurisdictions
which allow it could reverse their position.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Certain jurisdictions
currently allow the medicinal use of cannabis. Many other
jurisdictions do not. There can be no assurance that additional
jurisdictions will allow the medicinal use of cannabis or that
those jurisdictions which currently allow it will continue to do
so. If either of these events occur, then not only will our growth
prospects in this field be materially impacted, we may experience a
declining market for our products.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Risks Related to Our
Intellectual Property</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>If we are unable to
maintain and enforce our proprietary intellectual property rights,
we may not be able to operate profitably.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our commercial success will
depend, in part, on obtaining and maintaining patent protection,
trade secret protection and regulatory protection of our
technologies and product candidates as well as successfully
defending third-party challenges to such technologies and
candidates. We will be able to protect our technologies and product
candidates from use by third parties only to the extent that valid
and enforceable patents, trade secrets or regulatory protection
cover them and we have exclusive rights to use them. The ability of
our licensors, collaborators and suppliers to maintain their patent
rights against third-party challenges to their validity, scope or
enforceability will also play an important role in determining our
future.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In addition, our commercial
success will depend, in part, on maintaining patent rights we have
licensed and plan to license in the future, related to products we
may market in the future. Since we will not fully control the
patent prosecution of any licensed patent applications, it is
possible that our licensors will not devote the same resources or
attention to the prosecution of the licensed patent applications as
we would if we controlled the prosecution of the applications
ourselves. Consequently, the resulting patent protection, if any,
may not be as strong or comprehensive as it would be had we done
so.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The patent positions of
biopharmaceutical companies can be highly uncertain and involve
complex legal and factual questions that include unresolved
principles and issues. No consistent policy regarding the breadth
of claims allowed regarding such companies’ patents has emerged to
date in the United States, and the patent situation outside the
United States is even more uncertain. Changes in either the patent
laws or in interpretations of patent laws in the United States or
other countries may diminish the value of our intellectual
property. Accordingly, we cannot predict with any certainty the
range of claims that may be allowed or enforced concerning our
patents or third-party patents.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreakce6bcced-fbca-470d-8e7f-6eb5c9abbb08" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
25</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We also rely on trade
secrets to protect our technologies, especially where we do not
believe patent protection is appropriate or obtainable. However,
trade secrets are difficult to protect. While we seek to protect
confidential information, in part, through confidentiality
agreements with our consultants and scientific and other advisors,
they may unintentionally or willfully disclose our information to
competitors. Enforcing a claim against a third party related to the
illegal acquisition and use of trade secrets can be expensive and
time consuming, and the outcome is often unpredictable. If we are
not able to maintain patent or trade secret protection on our
technologies and product candidates, then we may not be able to
exclude competitors from developing or marketing competing
products, and we may not be able to operate profitability.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>If we are the subject of
an intellectual property infringement claim, the cost of
participating in any litigation could cause us to go out of
business.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">There has been, and we
believe that there will continue to be, significant litigation and
demands for licenses in our industry regarding patent and other
intellectual property rights. Although we anticipate having a valid
defense to any allegation that our current product candidates,
production methods and other activities infringe the valid and
enforceable intellectual property rights of any third parties, we
cannot be certain that a third party will not challenge our
position in the future. Other parties may own patent rights that we
might infringe with our products or other activities, and our
competitors or other patent holders may assert that our products
and the methods we employ are covered by their patents. These
parties could bring claims against us that would cause us to incur
substantial litigation expenses and, if successful, may require us
to pay substantial damages. Some of our potential competitors may
be better able to sustain the costs of complex patent litigation,
and depending on the circumstances, we could be forced to stop or
delay our research, development, manufacturing or sales activities.
Any of these costs could cause us to go out of business.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>We may in the future be
required to license patent rights from third-party owners in order
to develop our products candidates. If we cannot obtain those
licenses or if third-party owners do not properly maintain or
enforce the patents underlying such licenses, we may not be able to
market or sell our planned products.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We have licensed
patent-protected technologies with Altum Pharmaceuticals Inc. and
we may also license other intellectual property from other third
parties, if we believe it is necessary or useful to use additional
third-party intellectual property to develop our products.
Typically, we would seek to negotiate and obtain any required third
party licenses immediately following the completion of preliminary
research to establish a concept and plan of development for a new
product candidate. However, depending on the ongoing results and
requirements of pre-clinical or clinical trials, which may
unexpectedly vary from our anticipated plan of development, we may
be required to seek additional third-party licenses at later stages
of product development. We will also be required to pay license
fees, certain milestones or royalties or both to obtain such
licenses, and there is no guarantee that such licenses will be
available on acceptable terms, if at all. Even if we are able to
successfully obtain a license, certain rights may be non- or
co-exclusive, and this would give our competitors access to some of
the intellectual property as us, which could ultimately prevent us
from commercializing a product.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Upon obtaining a license,
our business prospects will depend, in part, on the ability of our
licensors to obtain, maintain and enforce patent protection on our
licensed intellectual property. Our licensors may terminate our
license, may not pursue and successfully prosecute any potential
patent infringement claim, may fail to maintain their patent
applications, or may pursue any litigation less aggressively than
we would. Without protection for the intellectual property that we
license, other companies may be able to offer substantially similar
products for sale, and we may not be able to market or sell our
planned products or generate any revenues.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>If the FDA grants one of
our competitors an orphan drug designation for a drug and
indication combination that is similar to the drug and indication
combination used and targeted by one of our products, we will face
significant competition in marketing our product during the seven
year exclusivity period.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The FDA grants an orphan
drug designation to a drug intended to treat a rare disease or
condition that affects fewer than 200,000 individuals in the United
States. An orphan drug designation must be requested before a
sponsor submits a New Drug Application to the FDA, and if the FDA
grants such a designation the generic identity of the therapeutic
agent and its potential orphan use are disclosed publicly by the
FDA. An orphan drug designation does not convey any advantage in,
or shorten the duration of, the regulatory review and approval
process that a drug must undergo; however, if a product that is the
subject of an orphan drug designation subsequently receives FDA
approval for the indication for which it has such a designation,
the product is entitled to orphan exclusivity for up to seven years
after receiving FDA approval. This means that the FDA may not
approve any other applications to market the same drug for the same
indication, except in very limited circumstances.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak5c024a02-8ab4-4010-a1ac-b928839cfdfd" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
26</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Therefore, if one of our
competitors obtains an orphan drug designation for a drug and
indication combination that is identical to the drug and indication
combination of one of our products (i.e. the same underlying drug
applied to the same indication), our product may not be approved
for the same indication for up to seven subsequent years.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Risks Associated with Our
Securities</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Trading on the OTC
Bulletin Board and the Canadian Securities Exchange (the “CSE”) may
be volatile and sporadic, which could depress the market price of
our common stock and make it difficult for our stockholders to
resell their shares.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our common stock is quoted
on the OTCQB service of the Financial Industry Regulatory Authority
and is traded on the CSE. Trading in stock quoted on the OTC
Bulletin Board or listed on the CSE is often thin and characterized
by wide fluctuations in trading prices, due to many factors that
may have little to do with our operations or business prospects.
This volatility could depress the market price of our common stock
for reasons unrelated to operating performance. Moreover, the OTC
Bulletin Board is not a stock exchange, and trading of securities
on the OTC Bulletin Board is often more sporadic than the trading
of securities listed on a quotation system like NASDAQ or a stock
exchange like Amex. Accordingly, shareholders may have difficulty
reselling any of their shares.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Our stock is a penny
stock. Trading of our stock may be restricted by the SEC’s penny
stock regulations and FINRA’s sales practice requirements, which
may limit a stockholder’s ability to buy and sell our
stock.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our stock is a penny stock.
The Securities and Exchange Commission in the United States (the 
“SEC”) has adopted Rule 15g-9 which generally defines “penny stock”
to be any equity security that has a market price (as defined) less
than $5.00 per share or an exercise price of less than $5.00 per
share, subject to certain exceptions. Our securities are covered by
the penny stock rules, which impose additional sales practice
requirements on broker-dealers who sell to persons other than
established customers and “accredited investors”. The term 
“accredited investor” refers generally to institutions with assets
in excess of $5,000,000 or individuals with a net worth in excess
of $1,000,000 or annual income exceeding $200,000 or $300,000
jointly with their spouse. The penny stock rules require a
broker-dealer, prior to a transaction in a penny stock not
otherwise exempt from the rules, to deliver a standardized risk
disclosure document in a form prepared by the SEC which provides
information about penny stocks and the nature and level of risks in
the penny stock market. The broker-dealer also must provide the
customer with current bid and offer quotations for the penny stock,
the compensation of the broker-dealer and its salesperson in the
transaction and monthly account statements showing the market value
of each penny stock held in the customer’s account. The bid and
offer quotations, and the broker-dealer and salesperson
compensation information, must be given to the customer orally or
in writing prior to effecting the transaction and must be given to
the customer in writing before or with the customer’s confirmation.
In addition, the penny stock rules require that prior to a
transaction in a penny stock not otherwise exempt from these rules,
the broker-dealer must make a special written determination that
the penny stock is a suitable investment for the purchaser and
receive the purchaser’s written agreement to the transaction. These
disclosure requirements may have the effect of reducing the level
of trading activity in the secondary market for the stock that is
subject to these penny stock rules. Consequently, these penny stock
rules may affect the ability of broker-dealers to trade our
securities. We believe that the penny stock rules discourage
investor interest in, and limit the marketability of, our common
stock.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In addition to the “penny
stock” rules promulgated by the Securities and Exchange Commission,
the Financial Industry Regulatory Authority has adopted rules that
require that in recommending an investment to a customer, a
broker-dealer must have reasonable grounds for believing that the
investment is suitable for that customer. Prior to recommending
speculative low priced securities to their non-institutional
customers, broker-dealers must make reasonable efforts to obtain
information about the customer’s financial status, tax status,
investment objectives and other information. Under interpretations
of these rules, the Financial Industry Regulatory Authority
believes that there is a high probability that speculative
low-priced securities will not be suitable for at least some
customers. The Financial Industry Regulatory Authority requirements
make it more difficult for broker-dealers to recommend that their
customers buy our common stock, which may limit your ability to buy
and sell our stock.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak44afc57b-e477-4816-9fd3-ba97eee01c90" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
27</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>You will experience
dilution or subordinated stockholder rights, privileges and
preferences as a result of our financing efforts.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We must raise additional
capital from external sources to carry out our business plan over
the next two years. To do so, we may issue debt securities, equity
securities or a combination of these securities; however, we may
not be able to sell these securities, particularly under current
market conditions. Even if we are successful in finding buyers for
our securities, such buyers could demand high interest rates or
require us to agree to onerous operating covenants, which could in
turn harm our ability to operate our business by reducing our cash
flow and restricting our operating activities. If we choose to sell
shares of our common stock, this will result in dilution to our
existing stockholders. In addition, any shares of common stock we
may issue may have rights, privileges and preferences superior to
those of our current stockholders.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>We do not intend to pay
dividends and there will thus be fewer ways in which you are able
to make a gain on your investment, if at all.</i></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We have never paid dividends
and do not intend to pay any dividends for the foreseeable future.
To the extent that we may require additional funding currently not
provided for in our financing plan, our funding sources may
prohibit the declaration of dividends. Because we do not intend to
pay dividends, any gain on your investment will need to result from
an appreciation in the price of our common stock. There will
therefore be fewer ways in which you are able to make a gain on
your investment, if at all. There is also no guarantee that your
investment will appreciate.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Other Risks</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Because one of our directors
is located in jurisdictions other than Canada, you may have no
effective recourse against the director not located in Canada for
misconduct and may not be able to enforce judgment and civil
liabilities against this director.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">One of our directors is a
national and/or resident of a country other than Canada,
specifically the Germany. As a result, it may be difficult for
investors to enforce within Canada any judgments obtained against
our director, including judgments predicated upon the civil
liability provisions of the securities laws of Canada.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Trends, Risks and
Uncertainties</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We have sought to identify
what we believe to be the most significant risks to our business,
but we cannot predict whether, or to what extent, any of such risks
may be realized nor can we guarantee that we have identified all
possible risks that might arise. Investors should carefully
consider all of such risk factors before making an investment
decision with respect to our common stock.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><a name=
"Item 1B. Unresolved Staff Comments">Item 1B. Unresolved Staff
Comments</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As a “smaller reporting
company”, we are not required to provide the information required
by this Item.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><a name="Item 2. Properties">Item 2.
Properties</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We maintain a dedicated
mailing address and telephone reception service located at 1275
West 6th Avenue, Vancouver, British Columbia, Canada V6H 1A6. We
also have access to office and meeting space for a nominal fee, on
an as-used basis.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><a name="Item 3. Legal Proceedings">Item
3. Legal Proceedings</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We know of no material,
existing or pending legal proceedings against our company, nor are
we involved as a plaintiff in any material proceeding or pending
litigation. There are no proceedings in which any of our directors,
officers or affiliates, or any registered or beneficial
stockholder, is an adverse party or has a material interest adverse
to our interest.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><a name=
"Item 4. Mine Safety Disclosures">Item 4. Mine Safety
Disclosures</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Not applicable.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreakee8fa8e4-d4e6-4953-8cb0-1b3b0f145c3b" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
28</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><a name="PART II">PART
II</a></b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px"><b><a name=
"Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities">
Item 5. Market for Registrant’s Common Equity, Related Stockholder
Matters and Issuer Purchases of Equity Securities</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our common stock quoted on
the OTCQB under the Symbol "PVOTF". Our common stock was listed for
quotation on April 13, 2010.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The following table reflects
the high and low bid information for our common stock obtained from
Stockwatch and reflects inter-dealer prices, without retail
mark-up, markdown or commission, and may not necessarily represent
actual transactions.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The high and low bid prices
of our common stock for the periods indicated below are as
follows:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" colspan=
"9">
<p style="MARGIN: 0px" align="center"><b style="MARGIN: 0px">OTC
Bulletin Board<sup>(1)</sup></b></p>
</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px" align="left"><b>Quarter Ended</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>High</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Low</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">January 31, 2018</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">2.46</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.355</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">October 31, 2017</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.52</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.047</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">July 31, 2017</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.125</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.054</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">April 30, 2017</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.145</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.054</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">January 31, 2017</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.145</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.02</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">October 31, 2016</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.16</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.04</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">July 31, 2016</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.375</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.073</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">April 30, 2016</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.90</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.20</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">January 31, 2016</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">1.10</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.80</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">__________</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="3%">(1)</td>
<td valign="top">Over-the-counter market quotations reflect
inter-dealer prices without retail mark-up, mark-down or
commission, and may not represent actual transactions.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As of May 1, 2018, there
were approximately 81 holders of record of our common stock. As of
such date, 88,055,160 common shares were issued and
outstanding.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our common shares are issued
in registered form. National Issuer Services Ltd., 760 – 777 Hornby
Street, Vancouver, BC Canada V6Z 1S4, telephone number
(604)559-8880, is the registrar and transfer agent for our common
shares.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Dividend Policy</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We have not paid any cash
dividends on our common stock and have no present intention of
paying any dividends on the shares of our common stock. Our current
policy is to retain earnings, if any, for use in our operations and
in the development of our business. Our future dividend policy will
be determined from time to time by our board of directors.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak915d8552-57a2-4ac2-aa39-005831457c39" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
29</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Recent Sales of
Unregistered Securities; Use of Proceeds from Registered
Securities</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Other than as set out below,
we did not sell any equity securities which were not registered
under the Securities Act during the year ended January 31, 2018
that were not otherwise disclosed on our quarterly reports on Form
10-Q or our current reports on Form 8-K filed during the year ended
January 31, 2018.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On June 20, 2017, we issued
200,000 shares of our common stock to a third party for services
rendered. We relied on Regulation D and/or Section 4(2) of the
Securities Act of 1933.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On September 28, 2017, we
issued 2,500,000 shares of our common stock to acquire worldwide
rights to BiPhasix™ transdermal drug delivery technology for the
development and commercialization of Cannabinoids, Cannabidiol and
Tetrahydrocannabinol products. On September 29, 2017, we issued
4,623,825 shares of our common stock upon conversion of outstanding
principal and accrued interest on convertible debentures. We relied
on Regulation D and/or Section 4(2) of the Securities Act of
1933.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Effective October 17, 2017,
we closed a private placement for an aggregate of 2,230,000 shares
of our common stock at price of $0.10 per share, for gross proceeds
of $223,000. Finder’s fee consisted of issuance of 200,000 common
shares. On October 30 and November 2, 2017, we issued the
securities to six (6) non U.S. persons (at that term as defined in
Regulation S of the Securities Act of 1933), relying on Regulation
S and/or Section 4(2) of the Securities Act of 1933 and one (1)
U.S. person (as that term is defined in Regulation S of the
Securities Act of 1933) relying upon Rule 506 of Regulation D of
the Securities Act of 1933.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On October 26, 2017, we
issued 100,000 shares of our common stock pursuant to a promissory
note dated September 27, 2017. On November 2, 2017, we issued
92,384 shares of our common stock for settlement of accounts
payable. On November 7, 2017, we issued 50,000 shares of our common
stock to a third party for services rendered. We relied on
Regulation D and/or Section 4(2) of the Securities Act of 1933.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Effective December 15, 2017,
we closed a private placement for an aggregate of 505,000 units,
consisting of one common share and one half of one share purchase
warrant, at price of $0.20 per unit for gross proceeds of
US$101,000. On November 21, 2017, we issued 380,000 common shares
and 190,000 share purchase warrants to seven (7) non U.S. persons
(at that term as defined in Regulation S of the Securities Act of
1933), relying on Regulation S and/or Section 4(2) of the
Securities Act of 1933. On December 18, 2017, we issued 125,000
common shares and 62,500 share purchase warrants to four (4) non
U.S. persons (at that term as defined in Regulation S of the
Securities Act of 1933), relying on Regulation S and/or Section
4(2) of the Securities Act of 1933. Finder’s fee consisted of a
cash payment of $5,050 and issuance of 25,250 units, consisting of
one common share and one half of one share purchase warrant. On
December 18, 2017, we issued 25,250 common shares and 12,625 share
purchase warrants, related to finder’s fee, to one (1) non U.S.
persons (at that term as defined in Regulation S of the Securities
Act of 1933), relying on Regulation S and/or Section 4(2) of the
Securities Act of 1933.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Effective February 28, 2018,
we issued a private placement offering of senior secured
convertible debentures ("Convertible Debentures") with a conversion
price of $1.74 per common share for aggregate gross proceeds of
CDN$5,000,000 (the "Offering"). The Convertible Debentures will
bear interest at the rate of 10% per annum, payable quarterly, and
will mature 12 months following the date of their issuance.
Beginning on the date that is four months and one day following the
issuance of the Convertible Debentures, we may force the conversion
of the principal amount of the then outstanding Convertible
Debentures at the Conversion Price on not less than 30 days’ notice
should the daily volume weighted average trading price of the
Common Shares be greater than $2.50 for any 20 consecutive trading
days on the Canadian Stock Exchange, or such other exchange our
common shares are principally traded. We relied on Regulation S of
the Securities Act of 1933.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On February 28, 2018, we
completed the acquisition of ERS pursuant to which we issued
5,000,000 shares of our common stock. On March 2, 2018, we
completed the acquisition of Thrudermic, and worldwide rights to
Thrudermic’s patented Transdermal Nanotechnology pursuant to which
we issued 500,000 shares of our common stock.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On March 12, 2018, we issued
75,000 shares of common stock to a third party for services
provided. On March 31, 2018, we issued 44,087 shares of our common
stock pursuant to employment agreements. On April 4, 2018, we
issued 62,500 shares of our common stock to a third party for
services provided. We relied on Regulation D and/or Section 4(2) of
the Securities Act of 1933.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak9f798e7b-4ec5-403b-b81c-680f936c9c78" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
30</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Equity Compensation Plan
Information</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Except as disclosed below,
we do not have a stock option plan in favor of any director,
officer, consultant or employee of our company.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Convertible
Securities</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As of May 1, 2018, we had
13,620,833 outstanding options to purchase shares of our common
stock at exercise prices ranging from $0.05 to $1.31 and
exercisable until March 11, 2023. As of May 1, 2018, we had
outstanding warrants to purchase 265,125 shares of our common stock
at exercise price of $0.35 and exercisable until June 14, 2019.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Purchase of Equity
Securities by the Issuer and Affiliated Purchasers</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We did not purchase any of
our shares of common stock or other securities during our fourth
quarter of our fiscal year ended January 31, 2018.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><a name=
"Item 6. Selected Financial Data">Item 6. Selected Financial
Data</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As a “smaller reporting
company”, we are not required to provide the information required
by this Item.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><a name=
"Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations">
Item 7. Management’s Discussion and Analysis of Financial Condition
and Results of Operations</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">The following
discussion should be read in conjunction with our audited financial
statements and the related notes for the years ended January 31,
2018 and January 31, 2017 that appear elsewhere in this annual
report. The following discussion contains forward-looking
statements that reflect our plans, estimates and beliefs. Our
actual results could differ materially from those discussed in the
forward looking statements. Factors that could cause or contribute
to such differences include, but are not limited to those discussed
below and elsewhere in this annual report, particularly in the
section entitled "Risk Factors" of this annual report.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our audited financial
statements are stated in United States Dollars and are prepared in
accordance with United States Generally Accepted Accounting
Principles.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Purchase of Significant
Equipment</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We do not intend to purchase
any significant equipment over the next twelve months.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Personnel Plan</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We do not expect any
material changes in the number of employees over the next 12 month
period (although we may enter into employment or consulting
agreements with our officers or directors). We do and will continue
to outsource contract employment as needed.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak347c9de5-9694-430a-b9dc-eb3a82cb822a" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
31</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Results of
Operations</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>For the Years Ending
January 31, 2018 and 2017</i></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" colspan="6" align="center">
<p style="MARGIN: 0px" align="center"><b>Year Ended January
31,</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2017</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Revenue</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">Nil</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">Nil</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Operating expenses</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
1,049,255</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
6,023,652</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Accretion of discounts on convertible
debentures</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
105,392</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
69,784</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">(Gain) loss on change in fair value
derivative</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(204,711</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
173,110</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Gain on disposal of asset</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(609,311</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>$</td>
<td>
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Gain on settlements of
debentures</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(246,828</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>$</td>
<td>
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Interest expense</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">27,385</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">11,661</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Net loss</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">121,182</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
$</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">6,278,207</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">During the year
ended January 31, 2018, we disposed of our shares of common stock
of IndUS and IndUS net liabilities for 3,800,000 shares of common
stock of Pivot, which resulted in a gain on disposal of asset of
$609,311. In addition, we recorded a gain on settlement of
debentures related to conversion of debentures into our common
stock, settlement of accounts payable into common stock and
conversion of accrued management fees into a promissory note upon
the disposal of our shares of IndUS common stock.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Expenses</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our operating expenses for
our years ended January 31, 2018 and 2017 are outlined in the table
below:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" colspan="6" align="center">
<p style="MARGIN: 0px" align="center"><b>Year Ended January
31,</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2017</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Depreciation and amortization</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
25,075</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">Nil</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Due diligence costs</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">8,750</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">Nil</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Foreign exchange loss</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
101,466</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
194,566</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">General and administrative</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
344,868</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
1,597,990</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Management fees</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
303,421</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
4,119,231</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Professional fees</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
195,371</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
111,865</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Research and development</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
70,304</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">Nil</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Operating expenses for year
ended January 31, 2018 decreased by $4,974,397 as compared to the
comparative period in 2017. In 2017, $1,304,738 of stock-based
compensation was included in general and administrative expense as
a result of 700,000 common stock issued for services and grants of
6,320,833 options to purchase our common stock. In 2018, $148,909
of stock-based compensation was included in general and
administrative to recognize 350,000 shares of our common stock
issued to third party service providers and 100,000 stock options
granted to members of our advisory board. Management fees decreased
by $3,815,810 from the year ended January 31, 2017 to the year
ended January 31, 2018. In 2017, 5,000,000 options to purchase our
common stock granted to management. In 2018, no options were
granted.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Revenue</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We have not earned any
revenues since our inception and we do not anticipate earning
revenues in the upcoming quarter.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Equity
Compensation</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our company has a stock
option plan which was adopted and approved by our shareholders on
December 30, 2015.</p>
<p style="MARGIN: 0px" align="justify">During our fiscal year ended
January 31, 2017:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">7,250,000 stock options with exercise price of
$0.70 and maturity on February 22, 2021 were granted to directors,
officers and consultants,</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">29,000 stock options with exercise price of $0.34,
maturity on May 2, 2021 and vesting on May 3, 2016 (26,000 stock
options), November 2, 2016 (1,000 stock options), May 2, 2017
(1,000 stock options) and November 2, 2017 (1,000 stock options)
were granted to a consultant, and</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">41,833 stock options with exercise price of $0.05
and maturity on January 23, 2022 were granted to related parties
pursuant to the Agreement and Plan of Merger and Acquisition
Agreement dated as of November 4, 2015 between our company and
IndUS.</td>
</tr>
</table>
<p style="MARGIN: 0px"><font face="Symbol">&nbsp;</font></p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak6c77b681-20fb-4a8a-8c2e-9b340e84de28" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
32</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">During our fiscal year ended
January 31, 2018, 100,000 stock options with exercise price of
$0.39 and maturity on November 14, 2022 were granted.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We currently do not have any
other equity compensation plans or arrangements.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b>Liquidity and Financial Condition</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Working Capital</u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="2" align="center"><b>At</b>
<p style="MARGIN: 0px"><b>January 31,</b></p>
<b>2018</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="2" align="center"><b>At</b>
<p style="MARGIN: 0px"><b>January 31,</b></p>
<b>2017</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Current Assets</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="10%" align="right">
149,253</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="10%" align="right">
129,758</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Current Liabilities</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">$</td>
<td id="ffcell" valign="bottom" align="right">429,200</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">$</td>
<td id="ffcell" valign="bottom" align="right">1,606,979</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Working Capital (Deficit)</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">$</td>
<td id="ffcell" valign="bottom" align="right">(279,947</td>
<td valign="bottom">)</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">$</td>
<td id="ffcell" valign="bottom" align="right">(1,477,221</td>
<td valign="bottom">)</td>
</tr>
</table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><u>Cash Flows</u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="2" align="center"><b>Year Ended</b>
<p style="MARGIN: 0px"><b>January 31,</b></p>
<b>2018</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="2" align="center"><b>Year Ended</b>
<p style="MARGIN: 0px"><b>January 31,</b></p>
<b>2017</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Net Cash used in Operating Activities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="10%" align="right">
(395,602</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="10%" align="right">
(377,783</td>
<td valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Net Cash used in Investing Activities</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">$</td>
<td id="ffcell" valign="bottom" align="right">Nil</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">$</td>
<td id="ffcell" valign="bottom" align="right">Nil</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Net Cash Provided by Financing
Activities</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">$</td>
<td id="ffcell" valign="bottom" align="right">360,500</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">$</td>
<td id="ffcell" valign="bottom" align="right">398,052</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Effects of exchange rate changes on cash</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">(12,808</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">)</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">20,513</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px"><b>(Decrease) Increase in Cash During the
Period</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom"><b>$</b></td>
<td id="ffcell" valign="bottom" align="right"><b>(47,910</b></td>
<td valign="bottom"><b>)</b></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom"><b>$</b></td>
<td id="ffcell" valign="bottom" align="right"><b>40,782</b></td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We will require additional
funds to fund our budgeted expenses over the next 12 months. These
funds may be raised through equity financing, debt financing, or
other sources, which may result in further dilution in the equity
ownership of our shares. There is still no assurance that we will
be able to maintain operations at a level sufficient for an
investor to obtain a return on his investment in our common stock.
Further, we may continue to be unprofitable. We need to raise
additional funds in the immediate future in order to proceed with
our budgeted expenses.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">Specifically, we estimate our expenses and
working capital requirements for the next 12 months to be as
follows:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style=
"WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px"><b>Product Development</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Estimated</b></p>
<p style="MARGIN: 0px" align="center"><b>Expenses</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Development of BiPhasix Topical Cream
(20g)</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
1,430,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Development of Thrudermic Topical Tube
(20g)</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
1,590,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Development of Solmic Oral Dropper Bottle
(30ml)</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
1,040,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Development of Ready-to-infuse Powderized
Products</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
2,310,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Product Registration and Regulatory</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
1,590,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Data Generation to Claim Indications</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
3,180,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Manufacturing and Supply</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
7,150,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px"><b>Sales and Marketing Costs</b></p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<b>3,970,000</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px"><b>General and Administrative</b></p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<b>1,990,000</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px"><b>Total:</b></p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%"><b>$</b></td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right"><b>24,250,000</b></td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreakadcf2539-0479-45f8-a665-063bfa17fea5" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
33</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Based on our planned
expenditures, we will require additional funds of approximately
$24.25 million to proceed with our business plan over the next 12
months and the commencement of commercialization of our product
initiatives. If we secure less than the full amount of financing
that we require, we will not be able to carry out our complete
business plan and we will be forced to proceed with a scaled back
business plan based on our available financial resources.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Funds raised will be used
towards the recruitment of appropriate management and research and
development (“R&amp;D”) personnel, as well as towards product
development expenditures. Specifically, the funds will be used to
cover R&amp;D expenses associated with 1) manufacturing scale-up of
our products at a GMP-certified, high potency drug manufacturing
facility; 2) development and manufacture of formulation of our
products at a GMP-certified product manufacturing facility for
administration of the drug candidates in animals (for safety
evaluation) and subsequently to humans 3) submission to appropriate
regulatory authorities for NHP registration.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We anticipate that we will
incur substantial losses for the foreseeable future. We have
negative cash flows from current operating activities and may
continue to be unprofitable. Even if we carry out our expanded
research and development activities on our products, there is no
guarantee that we will be able to market them or derive any
revenues from their sale.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Although we are anticipating
commercialization to commence on some of our product initiatives
over the next 12 months, anticipated revenues will not be
sufficient to finance our business plan. We intend to raise capital
through equity and, if necessary, debt financing. We anticipate
that the bulk of any additional funding we receive will be in the
form of equity financing from the sale of our common stock.
However, we do not have any financing arranged and we cannot
provide any assurance that we will be able to raise sufficient
funds from the sale of our common stock to fund our operations or
planned research and development activities. In the absence of such
financing, we will not be able to carry out our planned research
and development activities. Even if we are successful in obtaining
equity financing to fund our operations and research and
development activities, there is no assurance that we will obtain
the funding necessary to pursue any advanced research and
development following the completion of our planned clinical
trials. If we do not continue to obtain additional financing, we
may be forced to abandon our business plan. There is no assurance
that we will be able to maintain operations at a level sufficient
for an investor to obtain a return on his investment in our common
stock.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Any modifications to our
plans will be based on many factors, including the results of our
R&amp;D and the amount of available capital. Further, the extent to
which we carry out our development of planned products is dependent
upon the amount of financing available to us.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Future Financings</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We will require additional
financing in order to enable us to proceed with our plan of
operations, as discussed above, including approximately $24.25
million over the next 12 months to pay for product development,
sales and marketing and general and administrative expenses. These
cash requirements are in excess of our current cash and working
capital resources. Accordingly, we will require additional
financing in order to continue operations and to repay our
liabilities. There is no assurance that any party will advance
additional funds to us in order to enable us to sustain our plan of
operations or to repay our liabilities.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We anticipate continuing to
rely on equity sales of our common stock in order to continue to
fund our business operations. Issuances of additional shares will
result in dilution to our existing stockholders. There is no
assurance that we will achieve any additional sales of our equity
securities or arrange for debt or other financing to fund our
planned business activities.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We presently do not have any
arrangements for additional financing for the expansion of our
operations, and no potential lines of credit or sources of
financing are currently available for the purpose of proceeding
with our plan of operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Contractual
Obligations</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As a “smaller reporting
company”, we are not required to provide tabular disclosure
obligations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak0cc1cce5-f38e-4470-8106-5dcfd4fb9165" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
34</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Going Concern</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We have not generated any
revenues and are dependent upon obtaining outside financing to
carry out our operations and pursue our pharmaceutical research and
development activities. If we are unable to generate future cash
flows, raise equity or secure alternative financing, we may not be
able to continue our operations and our business plan may fail. You
may lose your entire investment.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">If our operations and cash
flow improve, management believes that we can continue to operate.
However, no assurance can be given that management’s actions will
result in profitable operations or an improvement in our liquidity
situation. The threat of our ability to continue as a going concern
will cease to exist only when our revenues have reached a level
able to sustain our business operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Off-Balance Sheet
Arrangements</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We have no off-balance sheet
arrangements that have or are reasonably likely to have a current
or future effect on our financial condition, changes in financial
condition, revenues or expenses, results of operations, liquidity,
capital expenditures or capital resources that is material to
stockholders.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Critical Accounting
Policies</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The discussion and analysis
of our financial condition and results of operations are based upon
our financial statements, which have been prepared in accordance
with the accounting principles generally accepted in the United
States of America. Preparing financial statements requires
management to make estimates and assumptions that affect the
reported amounts of assets, liabilities, revenue, and expenses.
These estimates and assumptions are affected by management’s
application of accounting policies. We believe that understanding
the basis and nature of the estimates and assumptions involved with
the following aspects of our financial statements is critical to an
understanding of our financial statements.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Use of Estimates</i></p>
<p style="MARGIN: 0px" align="justify">The preparation of these
financial statements in conformity with generally accepted
accounting principles in the United States requires management to
make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting
period. Our company regularly evaluates estimates and assumptions
related to the recoverability of long-lived assets, valuation of
convertible debentures, assumptions used to determine the fair
value of stock-based compensation and derivative liabilities, and
deferred income tax asset valuation allowances. Our company bases
its estimates and assumptions on current facts, historical
experience and various other factors that it believes to be
reasonable under the circumstances, the results of which form the
basis for making judgments about the carrying values of assets and
liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced
by our company may differ materially and adversely from our company’
s estimates. To the extent there are material differences between
the estimates and the actual results, future results of operations
will be affected.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Long-lived Assets</i></p>
<p style="MARGIN: 0px" align="justify">In accordance with ASC 360, 
“Property, Plant and Equipment”, our company tests long-lived
assets or asset groups for recoverability when events or changes in
circumstances indicate that their carrying amount may not be
recoverable. Circumstances which could trigger a review include,
but are not limited to: significant decreases in the market price
of the asset; significant adverse changes in the business climate
or legal factors; accumulation of costs significantly in excess of
the amount originally expected for the acquisition or construction
of the asset; current period cash flow or operating losses combined
with a history of losses or a forecast of continuing losses
associated with the use of the asset; and current expectation that
the asset will more likely than not be sold or disposed
significantly before the end of its estimated useful life.
Recoverability is assessed based on the carrying amount of the
asset and its fair value, which is generally determined based on
the sum of the undiscounted cash flows expected to result from the
use and the eventual disposal of the asset, as well as specific
appraisal in certain instances. An impairment loss is recognized
when the carrying amount is not recoverable and exceeds fair
value.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreakec4a806b-8006-4a54-bcb3-d977ed4ba9c9" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
35</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Stock-Based
Compensation</i></p>
<p style="MARGIN: 0px" align="justify">Our company records
stock-based compensation in accordance with ASC 718,
<i>Compensation – Stock-Based Compensation</i>, using the fair
value method. All transactions in which goods or services are the
consideration received for the issuance of equity instruments are
accounted for based on the fair value of the consideration received
or the fair value of the equity instrument issued, whichever is
more reliably measurable.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Derivative Financial
Instruments</i></p>
<p style="MARGIN: 0px" align="justify">Derivative financial
instruments that are not classified as equity and are not used in
hedging relationships are measured at fair value. Subsequent
changes to fair value are recorded in the statement of
operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Income Taxes</i></p>
<p style="MARGIN: 0px" align="justify">Our company accounts for
income taxes using the asset and liability method in accordance
with ASC 740, “Income Taxes”. The asset and liability method
provides that deferred tax assets and liabilities are recognized
for the expected future tax consequences of temporary differences
between the financial reporting and tax bases of assets and
liabilities, and for operating loss and tax credit carryforwards.
Deferred tax assets and liabilities are measured using the
currently enacted tax rates and laws that will be in effect when
the differences are expected to reverse. Our company records a
valuation allowance to reduce deferred tax assets to the amount
that is believed more likely than not to be realized. As of January
31, 2018 and 2017, our company did not have any amounts recorded
pertaining to uncertain tax positions.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our company files federal
and provincial income tax returns in Canada. Our company recognizes
interest and penalties related to uncertain tax positions in tax
expense. During the years ended January 31, 2018 and 2017, there
were no charges for interest or penalties.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Financial Instruments and
Fair Value Measures</i></p>
<p style="MARGIN: 0px" align="justify">ASC 820, <i>Fair Value
Measurements</i>, requires an entity to maximize the use of
observable inputs and minimize the use of unobservable inputs when
measuring fair value. ASC 820 establishes a fair value hierarchy
based on the level of independent, objective evidence surrounding
the inputs used to measure fair value. A financial instrument’s
categorization within the fair value hierarchy is based upon the
lowest level of input that is significant to the fair value
measurement. ASC 820 prioritizes the inputs into three levels that
may be used to measure fair value:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Level 1 -</i> Level 1
applies to assets or liabilities for which there are quoted prices
in active markets for identical assets or liabilities.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Level 2 -</i> Level 2
applies to assets or liabilities for which there are inputs other
than quoted prices that are observable for the asset or liability
such as quoted prices for similar assets or liabilities in active
markets; quoted prices for identical assets or liabilities in
markets with insufficient volume or infrequent transactions (less
active markets); or model-derived valuations in which significant
inputs are observable or can be derived principally from, or
corroborated by, observable market data.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Level 3 -</i> Level 3
applies to assets or liabilities for which there are unobservable
inputs to the valuation methodology that are significant to the
measurement of the fair value of the assets or liabilities.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our company’s financial
instruments consist principally of cash, amounts receivable,
accounts payable, and accrued liabilities, due to related parties
and convertible debenture. Pursuant to ASC 820, the fair value of
our cash is determined based on “Level 1” inputs, which consist of
quoted prices in active markets for identical assets. We believe
that the recorded values of all of our other financial instruments
approximate their current fair values because of their nature and
respective maturity dates or durations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak015ad024-6b20-4f56-a1fe-672f5536a68e" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
36</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><i>Foreign Currency
Translation</i></p>
<p style="MARGIN: 0px" align="justify">The functional currency of
our parent entity, Pivot Pharmaceuticals Inc., and our wholly-owned
subsidiary, Pivot Green Stream Health Solutions Inc., is the
Canadian dollar. Our company’s presentation currency is the US
dollar.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Monetary assets and
liabilities are translated using the exchange rate prevailing at
the balance sheet date. Non-monetary assets and liabilities
denominated in foreign currencies are translated at rates of
exchange in effect at the date of the transaction. Expenses are
translated at average rates for the period. Gains and losses
arising on translation or settlement of foreign currency
denominated transactions or balances are included in the
determination of income.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Results of operations are
translated into our company’s presentation currency, US dollars, at
an appropriate average rate of exchange during the year. Net assets
and liabilities are translated to US dollars for presentation
purposes at rates of exchange in effect at the end of the period.
Gains or losses arising on translation are recognized in other
comprehensive income (loss) as foreign currency translation
adjustments.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Recent Accounting
Pronouncements</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our company has implemented
all new accounting pronouncements that are in effect and that may
impact its financial statements and does not believe that there are
any other new accounting pronouncements that have been issued that
might have a material impact on its financial position or results
of operations.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><a name=
"Item 7A. Quantitative and Qualitative Disclosures About Market Risk">
Item 7A. Quantitative and Qualitative Disclosures About Market
Risk</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As a “smaller reporting
company”, we are not required to provide the information required
by this Item.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreaka3b3ecfc-0d08-41fb-8b04-6a52c1b7bd3b" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
37</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><a name=
"Item 8. Financial Statements and Supplementary Data">Item 8.
Financial Statements and Supplementary Data</a></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>PIVOT PHARMACEUTICALS
INC.</b></p>
<p style="MARGIN: 0px" align="center">Consolidated Financial
Statements</p>
<p style="MARGIN: 0px" align="center">Years ended January 31, 2018
and 2017</p>
<p style="MARGIN: 0px" align="center">(Expressed in U.S.
dollars)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak13f61e9d-7a79-4e2c-8cb7-299fc64d59b0" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
38</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p><img src="pvotf_10kimg6.jpg" /></p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><u>REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM</u></b></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px">To the Board of Directors and Shareholders
of Pivot Pharmaceuticals Inc.:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><u>Opinion on the Financial
Statements</u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">We have audited the accompanying
consolidated balance sheets of Pivot Pharmaceuticals Inc. (“the
Company”) as of January 31, 2018 and 2017, the related consolidated
statements of operations and comprehensive income (loss),
stockholders’ deficit, and cash flows for each of the years in the
two-year period ended January 31, 2018 and the related notes
(collectively referred to as the “financial statements”). In our
opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of the Company as
of January 31, 2018 and 2017, and the results of its operations and
its cash flows for each of the years in the two-year period ended
January 31, 2018, in conformity with accounting principles
generally accepted in the United States of America.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><u>Explanatory Paragraph Regarding Going
Concern</u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">The accompanying financial statements have
been prepared assuming that the Company will continue as a going
concern. As discussed in Note 1 to the financial statements, the
Company has suffered recurring losses from operations and has a net
capital deficiency which raise substantial doubt about its ability
to continue as a going concern. Management's plans in regard to
these matters are also described in Note 1. The financial
statements do not include any adjustments that might result from
the outcome of this uncertainty.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><u>Basis for Opinion</u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">These financial statements are the
responsibility of the Company’s management. Our responsibility is
to express an opinion on the Company’s financial statements based
on our audits. We are a public accounting firm registered with the
Public Company Accounting Oversight Board (United States) (“PCAOB”)
and are required to be independent with respect to the Company in
accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and
the PCAOB.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">We conducted our audits in accordance with
the standards of the PCAOB. Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether
the financial statements are free of material misstatement, whether
due to error or fraud. The Company is not required to have, nor
were we engaged to perform, an audit of its internal control over
financial reporting. As part of our audits, we are required to
obtain an understanding of internal control over financial
reporting, but not for the purpose of expressing an opinion on the
effectiveness of the Company’s internal control over financial
reporting. Accordingly, we express no such opinion.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">Our audits included performing procedures to
assess the risks of material misstatement of the financial
statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included
examining on a test basis, evidence regarding the amounts and
disclosures in the financial statements. Our audits also included
evaluating the accounting principles used and significant estimates
made by management, as well as evaluating the overall presentation
of the financial statements. We believe that our audits provide a
reasonable basis for our opinion.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><i>/s/ Sadler, Gibb &amp; Associates,
LLC</i></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">We have served as the Company’s auditor
since 2014.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">Salt Lake City, UT</p>
<p style="MARGIN: 0px">May 1, 2018</p>
<p style="MARGIN: 0px 0px 0px 0in">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in"><img src=
"pvotf_10kimg5.jpg" /></p>
<p style="MARGIN: 0px"></p>
<table id="pagebreak7f896240-508f-4922-ad28-5eb08e508c0c" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
F-1</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>PIVOT PHARMACEUTICALS
INC.</b></p>
<p style="MARGIN: 0px" align="justify">Consolidated Balance
Sheets</p>
<p style="MARGIN: 0px" align="justify">(Expressed in U.S.
dollars)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style=
"WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>January 31,</b></p>
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>January 31,</b></p>
<p style="MARGIN: 0px" align="center"><b>2017</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px"><b>Assets</b></p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">Current assets</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Cash</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
64,511</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
112,421</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Prepaids and other current
assets</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">84,742</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">17,337</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Total current assets</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
149,253</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
129,758</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Security deposit</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">2,900</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Intangible asset, net (Note 5)</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">234,564</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Total assets</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">383,817</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">132,658</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px"><b>Liabilities and Stockholders’
Deficit</b></p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Current liabilities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accounts payable and accrued
liabilities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
217,921</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
996,853</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Due to related parties (Note
13)</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
10,104</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
22,574</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Convertible debenture, net
(Note 6)</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
275,011</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Derivative liabilities (Note
7)</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
312,541</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Promissory note (Note 8)</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">201,175</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Total liabilities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">429,200</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">1,606,979</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Stockholders’ Deficit</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px" align="left">Common stock:
Unlimited shares authorized, without par value, 82,373,559 and
75,647,114 shares issued and outstanding, respectively (Note 9)</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
8,263,767</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
7,327,588</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Additional paid-in capital</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
11,816,057</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
11,211,031</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accumulated other comprehensive
income</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
593,728</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
584,813</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accumulated deficit</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(20,718,935</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(20,597,753</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Total stockholders’ deficit</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(45,383</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(1,474,321</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Total liabilities and stockholders’
deficit</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">383,817</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">132,658</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">Nature of operations and continuance of
business (Note 1)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">(The accompanying notes are
an integral part of these consolidated financial statements)</p>
<p style="MARGIN: 0px" align="left">&nbsp;</p>
<p style="MARGIN: 0px" align="left"></p>
<table id="pagebreak99893aaf-3871-4ce8-8fa1-449642b63502" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
F-2</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>PIVOT PHARMACEUTICALS INC.</b></p>
<p style="MARGIN: 0px" align="justify">Consolidated Statements of
Operations and Comprehensive Income (Loss)</p>
<p style="MARGIN: 0px" align="justify">(Expressed in U.S.
dollars)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style=
"WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Year Ended</b></p>
<p style="MARGIN: 0px" align="center"><b>January 31,</b></p>
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Year Ended</b></p>
<p style="MARGIN: 0px" align="center"><b>January 31,</b></p>
<p style="MARGIN: 0px" align="center"><b>2017</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Revenue</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Expenses</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Amortization</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
25,075</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Due diligence costs</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">8,750</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Foreign exchange loss</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
101,466</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
194,566</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">General and administrative</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
344,868</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
1,597,990</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Management fees</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
303,421</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
4,119,231</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Professional fees</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
195,371</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
111,865</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Research and development</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">70,304</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Total expenses</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">1,049,255</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">6,023,652</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Loss from operations</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(1,049,255</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(6,023,652</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Other (expenses) income</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Amortization of discount on
convertible debentures</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(105,392</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(69,784</td>
<td valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Gain (loss) on change in fair
value of derivative liabilities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
204,711</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(173,110</td>
<td valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Gain on disposal of asset (Note
3)</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
609,311</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Gain on settlement of debts</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
246,828</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Interest expense</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(27,385</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(11,661</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Total other income (expenses)</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">928,073</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(254,555</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Net loss</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(121,182</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(6,278,207</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Other comprehensive income (loss)</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Foreign currency translation
adjustment</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">8,915</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(160,438</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Net comprehensive loss</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(112,267</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(6,438,645</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Net loss per share, basic and diluted</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(0.00</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(0.08</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Weighted average shares outstanding – basic
and diluted</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">79,898,541</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" width="9%" align="right">75,315,288</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="center">(The accompanying notes are
an integral part of these consolidated financial statements)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreakf344ed65-14c9-4a20-bfcb-2f85b8f49762" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
F-3</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>PIVOT PHARMACEUTICALS
INC.</b></p>
<p style="MARGIN: 0px" align="justify">Consolidated Statements of
Stockholders’ Deficit</p>
<p style="MARGIN: 0px">(Expressed in U.S. dollars)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style=
"WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" colspan="6" align="center">
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Common
Stock</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Common</b></p>
<p style="MARGIN: 0px" align="center"><b>Stock</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Additional</b></p>
<p style="MARGIN: 0px" align="center"><b>Paid-In</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Foreign<br />
Currency</b></p>
<p style="MARGIN: 0px" align="center"><b>Translation</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" valign="bottom" colspan="2" align="center"></td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" valign="bottom" colspan="2" align="center"></td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Shares</b></p>
<p style="MARGIN: 0px" align="center"><b>#</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Amount</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Issuable</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Capital</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Adjustment</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Deficit</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Total</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Balance – January 31, 2016</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
74,722,100</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
7,054,499</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
16,206</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
6,174,601</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
745,251</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
(14,319,546</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
(328,989</td>
<td valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Common stock issued for
services</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
925,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
273,089</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
(16,206</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
256,883</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Warrants issued with convertible
debenture</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
20,113</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
20,113</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Stock-based compensation</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
5,016,317</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
5,016,317</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Net loss</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">(160,438</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">(6,278,207</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">(6,438,645</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Balance – January 31, 2017</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
75,647,100</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
7,327,588</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
11,211,031</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
584,813</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
(20,597,753</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
(1,474,321</td>
<td valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Common stock issued for
services</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
350,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
98,479</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
98,479</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Common stock issued for
settlement of accounts payable and accrued liabilities to related
parties</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
92,384</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
35,153</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
35,153</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Capital contribution by officers
in forgiveness of liabilities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
552,888</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
552,888</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Common stock issued for
conversion of debenture</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
4,623,825</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
601,097</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
601,097</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Common stock issued for
acquisition of license</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
2,500,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
262,500</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
262,500</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Common stock and warrants issued for
cash</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
2,735,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
324,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
324,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Common stock issued for finder’s
fee</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
225,250</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
(5,050</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
(5,050</td>
<td valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Cancellation of common stock
pursuant to disposal of asset</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
(3,800,000</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
(380,000</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
(380,000</td>
<td valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Stock-based compensation</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
52,138</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
52,138</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Net loss</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">(8,915</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">(121,182</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">(112,267</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="7%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 0in">Balance – January 31, 2018</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">82,373,559</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">8,263,767</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">11,816,057</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">593,728</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">(20,718,935</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="7%" align="right">(45,383</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
</table>
&nbsp;&nbsp;
<p style="MARGIN: 0px" align="center">(The accompanying notes are
an integral part of these consolidated financial statements)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreak59f5628c-cacb-40cc-8022-e691e451d2cd" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
F-4</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>PIVOT PHARMACEUTICALS INC.</b></p>
<p style="MARGIN: 0px" align="justify">Consolidated Statements of
Cash Flows</p>
<p style="MARGIN: 0px" align="justify">(Expressed in U.S.
dollars)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style=
"WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Year Ended</b></p>
<p style="MARGIN: 0px" align="center"><b>January 31,</b></p>
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Year Ended</b></p>
<p style="MARGIN: 0px" align="center"><b>January 31,</b></p>
<p style="MARGIN: 0px" align="center"><b>2017</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">Operating activities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Net loss</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(121,182</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(6,278,207</td>
<td valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Adjustments to reconcile net loss to net
cash used in operating activities:</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Amortization</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
25,075</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Amortization of discount on
convertible debenture</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
105,392</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
69,784</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Common stock issued for
services</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
98,479</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
256,867</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Fair value of stock options
vested</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
49,608</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
4,820,100</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">(Gain) loss on change in fair
value of derivative liabilities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(204,711</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
173,110</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Gain on disposal of assets</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(609,311</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Gain on settlement of debts</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(246,828</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Changes in operating assets and
liabilities:</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Prepaids and other current
assets</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(72,747</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">8,018</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Due to related parties</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">9,616</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
18,334</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Accounts payable and accrued
liabilities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
534,384</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
572,545</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Other liabilities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">36,623</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Net cash used in operating activities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(395,602</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(359,449</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Financing activities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Proceeds from issuance of
common stock and warrants</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
324,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Proceeds from debenture</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
36,500</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Proceeds from issuance of
convertible debenture</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">379,718</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Net cash provided by financing
activities</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">360,500</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">379,718</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Effects of exchange rate changes on cash</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(12,808</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">20,513</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Net change in cash</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(47,910</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
40,782</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Cash – beginning of period</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">112,421</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">71,639</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Cash – end of period</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">64,511</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">112,421</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">Supplemental cash flow disclosures (Note
13)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">(The accompanying notes are
an integral part of these consolidated financial statements)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreakdc90fe82-812c-40ed-977d-cf0d13dcabad" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
F-5</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>PIVOT
PHARMACEUTICALS INC.</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Notes to the
Consolidated Financial Statements</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Year ended
January 31, 2017</p>
<p style="MARGIN: 0px">(Expressed in U.S. dollars)</p>
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
<b>1. Nature of Operations and Continuance of Business</b>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">Pivot
Pharmaceuticals Inc. (the “Company”) was incorporated in British
Columbia under the Business Corporations Act on June 10, 2002. On
April 7, 2015, the Company changed its name from Neurokine
Pharmaceuticals Inc. to Pivot Pharmaceuticals Inc. The Company is
in the business of developing and commercializing therapeutic
pharmaceuticals and nutraceuticals, as well as drug delivery
platform technologies.</p>
<p style="MARGIN: 0px 0px 0px 45px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">These
consolidated financial statements have been prepared on the going
concern basis, which assumes that the Company will be able to
realize its assets and discharge its liabilities in the normal
course of business. As at January 31, 2018, the Company has not
earned any revenue, has a working capital deficit of $279,947 and
an accumulated deficit of $20,718,935. The continued operations of
the Company are dependent on its ability to generate future cash
flows or obtain additional financing. These factors raise
substantial doubt about the Company’s ability to continue as a
going concern for a period of one year from the issuance of these
financial statements. These consolidated financial statements do
not include any adjustments to the recorded assets or liabilities
that might be necessary should the Company be unable to continue as
a going concern.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>2. Significant Accounting
Policies</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%">(a)</td>
<td valign="top">Basis of Presentation</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td valign="top">The consolidated financial statements and the
related notes of the Company are prepared in accordance with
generally accepted accounting principles in the United States and
are expressed in U.S. dollars. The Company’s fiscal year-end is
January 31.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(b)</td>
<td valign="top">Use of Estimates</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td valign="top">The preparation of these consolidated financial
statements in conformity with generally accepted accounting
principles in the United States requires management to make
estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and
liabilities at the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the
reporting period. The Company regularly evaluates estimates and
assumptions related to the useful life and recoverability of
long-lived assets, assumptions used to determine the fair values of
stock-based compensation and derivative liabilities and deferred
income tax asset valuation allowances. The Company bases its
estimates and assumptions on current facts, historical experience
and various other factors that it believes to be reasonable under
the circumstances, the results of which form the basis for making
judgments about the carrying values of assets and liabilities and
the accrual of costs and expenses that are not readily apparent
from other sources. The actual results experienced by the Company
may differ materially and adversely from the Company’s estimates.
To the extent there are material differences between the estimates
and the actual results, future results of operations will be
affected.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(c)</td>
<td valign="top">Basis of Consolidation</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td valign="top">The consolidated financial statements incorporate
the financial statements of the Company and entities controlled by
the Company. Control is achieved where the Company has the power to
govern the financial and operating policies of an entity so as to
obtain benefits from its activities. The consolidating entities
include:</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>% of</b></p>
<p style="MARGIN: 0px" align="center"><b>ownership</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" align="center">
<p style="MARGIN: 0px" align="center"><b>Jurisdiction</b></p>
</td>
<td>&nbsp;</td>
</tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" valign="bottom" align="center"></td>
<td>&nbsp;</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="bottom">
<p style="MARGIN: 0px">Pivot Pharmaceuticals Inc.</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" valign="bottom" width="9%" colspan="2" align=
"center">
<p style="MARGIN: 0px" align="center">Parent</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" valign="bottom" width="9%" align="center">
<p style="MARGIN: 0px" align="center">Canada</p>
</td>
<td>&nbsp;</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Pivot Green Stream Health Solutions Inc.</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">100</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="center">Canada</p>
</td>
<td width="1%">&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreak49dbde77-5704-4c7a-8122-9d3192c3c6a6" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
F-6</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>PIVOT
PHARMACEUTICALS INC.</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Notes to the
Consolidated Financial Statements</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Year ended
January 31, 2017</p>
<p style="MARGIN: 0px">(Expressed in U.S. dollars)</p>
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
<b>2. Significant Accounting Policies</b> (continued)
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%">(d)</td>
<td valign="top">Cash and Cash Equivalents</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td valign="top">The Company considers all highly liquid
instruments with a maturity of three months or less at the time of
issuance to be cash equivalents. As at January 31, 2018 and 2017,
the Company had no cash equivalents.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(e)</td>
<td valign="top">Intangible Asset</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td valign="top">Intangible assets consists of costs incurred to
acquire a license. Intangible assets are considered finite live
assets and recorded at cost less accumulated amortization and
accumulated impairment. Subsequent expenditures are capitalized
only when they increase the future economic benefits embodied in
the asset. Amortization is recorded using the straight-line method
and is intended to amortize the license over its estimated useful
life of four years.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(f)</td>
<td valign="top">Stock-Based Compensation</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td valign="top">The Company records stock-based compensation in
accordance with ASC 718, Compensation – Stock-Based Compensation,
using the fair value method. All transactions in which goods or
services are the consideration received for the issuance of equity
instruments are accounted for based on the fair value of the
consideration received or the fair value of the equity instrument
issued, whichever is more reliably measurable.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(g)</td>
<td valign="top">Derivative Financial Instruments</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td valign="top">Derivative financial instruments that are not
classified as equity and are not used in hedging relationships are
measured at fair value. Subsequent changes to fair value are
recorded in the statement of operations and comprehensive
income.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(h)</td>
<td valign="top">Loss Per Share</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">The Company computes net
loss per share in accordance with ASC 260, Earnings Per Share. ASC
260 requires presentation of both basic and diluted earnings per
share (“EPS”) on the face of the consolidated statement of
operations. Basic EPS is computed by dividing net income (loss)
available to common shareholders (numerator) by the weighted
average number of shares outstanding (denominator) during the
period. Diluted EPS gives effect to all dilutive potential common
shares outstanding during the period using the treasury stock
method and convertible preferred stock using the if-converted
method. In computing diluted EPS, the average stock price for the
period is used in determining the number of shares assumed to be
purchased from the exercise of stock options or warrants. Diluted
EPS excludes all dilutive potential shares if their effect is
anti-dilutive. As at January 31, 2018, the Company has excluded
6,153,764 (2017 – 6,840,834) potential dilutive shares.</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(i)</td>
<td valign="top">Comprehensive Income (Loss)</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td valign="top">
<p style="MARGIN: 0px"><em>ASC 220,</em> <em>Comprehensive
Income</em>, establishes standards for the reporting and display of
comprehensive loss and its components in the consolidated financial
statements. As at January 31, 2018 and 2017, the Company’s
comprehensive income included foreign currency translation
adjustments.</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(j)</td>
<td valign="top">Research and Development Costs</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td valign="top">Research costs are expensed in the period that
they are incurred.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreak9df894ac-44e9-462f-984e-0885435608bf" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
F-7</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>PIVOT
PHARMACEUTICALS INC.</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Notes to the
Consolidated Financial Statements</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Year ended
January 31, 2017</p>
<p style="MARGIN: 0px">(Expressed in U.S. dollars)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>2. Significant Accounting
Policies</b> (continued)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%">(k)</td>
<td valign="top">Income Taxes</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td valign="top">The Company accounts for income taxes using the
asset and liability method in accordance with ASC 740, “Income
Taxes”. The asset and liability method provides that deferred tax
assets and liabilities are recognized for the expected future tax
consequences of temporary differences between the financial
reporting and tax bases of assets and liabilities, and for
operating loss and tax credit carry-forwards. Deferred tax assets
and liabilities are measured using the currently enacted tax rates
and laws that will be in effect when the differences are expected
to reverse. The Company records a valuation allowance to reduce
deferred tax assets to the amount that is believed more likely than
not to be realized. As of January 31, 2018 and 2017, the Company
did not have any amounts recorded pertaining to uncertain tax
positions.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td valign="top">The Company files federal and provincial income
tax returns in Canada. The Company recognizes interest and
penalties related to uncertain tax positions in tax expense. During
the years ended January 31, 2018 and 2017, there were no charges
for interest or penalties.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(l)</td>
<td valign="top">Financial Instruments and Fair Value Measures</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td valign="top">
<p style="MARGIN: 0px">ASC 820, Fair Value Measurements, requires
an entity to maximize the use of observable inputs and minimize the
use of unobservable inputs when measuring fair value. ASC 820
establishes a fair value hierarchy based on the level of
independent, objective evidence surrounding the inputs used to
measure fair value. A financial instrument’s categorization within
the fair value hierarchy is based upon the lowest level of input
that is significant to the fair value measurement. ASC 820
prioritizes the inputs into three levels that may be used to
measure fair value:</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 135px" align="justify"><i>Level
1</i></p>
<p style="MARGIN: 0px 0px 0px 135px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 135px" align="justify">Level 1
applies to assets or liabilities for which there are quoted prices
in active markets for identical assets or liabilities.</p>
<p style="MARGIN: 0px 0px 0px 135px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 135px" align="justify"><i>Level
2</i></p>
<p style="MARGIN: 0px 0px 0px 135px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 135px" align="justify">Level 2
applies to assets or liabilities for which there are inputs other
than quoted prices that are observable for the asset or liability
such as quoted prices for similar assets or liabilities in active
markets; quoted prices for identical assets or liabilities in
markets with insufficient volume or infrequent transactions (less
active markets); or model-derived valuations in which significant
inputs are observable or can be derived principally from, or
corroborated by, observable market data.</p>
<p style="MARGIN: 0px 0px 0px 135px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 135px" align="justify"><i>Level
3</i></p>
<p style="MARGIN: 0px 0px 0px 135px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 135px" align="justify">Level 3
applies to assets or liabilities for which there are unobservable
inputs to the valuation methodology that are significant to the
measurement of the fair value of the assets or liabilities.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 90px" align="justify">The Company’s
financial instruments consist principally of cash,&nbsp;accounts
payable, and accrued liabilities, due to related parties and
promissory note. Pursuant to ASC 820, the fair value of our cash is
determined based on “Level 1” inputs, which consist of quoted
prices in active markets for identical assets, and the fair value
of derivative liabilities is determined based on “Level 3” inputs.
The recorded values of all other financial instruments approximate
their current fair values because of their nature and respective
maturity dates or durations.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreakaf333517-fc89-43bc-81f2-9b9f4c73bcac" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
F-8</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>PIVOT
PHARMACEUTICALS INC.</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Notes to the
Consolidated Financial Statements</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Year ended
January 31, 2017</p>
<p style="MARGIN: 0px">(Expressed in U.S. dollars)</p>
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
<b>2. Significant Accounting Policies</b> (continued)
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%">(m)</td>
<td valign="top">Foreign Currency Translation</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td valign="top">The functional currency of the parent entity,
Pivot Pharmaceuticals Inc., and the wholly-owned subsidiary, Pivot
Green Stream Health Solutions Inc., is the Canadian dollar. The
Company’s presentation currency is the US dollar.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td valign="top">Monetary assets and liabilities are translated
using the exchange rate prevailing at the consolidated balance
sheet date. Non-monetary assets and liabilities denominated in
foreign currencies are translated at rates of exchange in effect at
the date of the transaction. Expenses are translated at average
rates for the period. Gains and losses arising on translation or
settlement of foreign currency denominated transactions or balances
are included in the determination of income.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td valign="top">Results of operations are translated into the
Company’s presentation currency, US dollars, at an appropriate
average rate of exchange during the year. Net assets and
liabilities are translated to US dollars for presentation purposes
at rates of exchange in effect at the end of the period. Gains or
losses arising on translation are recognized in other comprehensive
income (loss) as foreign currency translation adjustments.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(n)</td>
<td valign="top">Reclassifications</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td valign="top">We have made reclassifications to certain numbers
reported in the prior year to conform to the presentation of the
current year.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(o)</td>
<td valign="top">Recent Accounting Pronouncements</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td valign="top">The Company has implemented all new accounting
pronouncements that are in effect and that may impact its
consolidated financial statements and does not believe that there
are any other new accounting pronouncements that have been issued
that might have a material impact on its consolidated financial
position or results of operations.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>3. Disposal of
Asset</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">On September
11, 2017, the Company completed an exchange agreement whereby the
Company exchanged with its past Chief Executive Officer 100% of its
shares of common stock of its wholly-owned subsidiary, IndUS
Pharmaceuticals, Inc. (“IndUS”), for 3,800,000 shares of common
stock of the Company (Note 9(b)). Pursuant to the exchange
agreement, the Company has provided its former Chief Executive
Officer a promissory note (Note 8(a)) in the amount of $200,000 in
discharge of all obligations with respect to Dr. Chaturvedi’s
accrued salary totaling $267,267 through September 11, 2017 for
which a gain of $102,259 has been included in gain on settlement of
debts in the statement of operations.</p>
<p style="MARGIN: 0px 0px 0px 45px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">The disposal of
IndUS resulted in a gain as follows:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">3,800,000 shares of common stock acquired
and cancelled</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
380,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Net liabilities exchanged</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">229,311</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Gain on disposal of asset</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">$</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">609,311</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">The disposal of
IndUS did not meet the definition of discontinued operations as it
did not represent a strategic shift that has a major effect on the
Company’s operations and financial results.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreakf9b98d79-c514-4138-8c22-134e53f975e0" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
F-9</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>PIVOT
PHARMACEUTICALS INC.</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Notes to the
Consolidated Financial Statements</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Year ended
January 31, 2017</p>
<p style="MARGIN: 0px">(Expressed in U.S. dollars)</p>
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
<b>4. Asset Acquisitions</b>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">(a)</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px">BiPhasix License</p>
</td>
</tr>
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="justify">On September 12, 2017, the
Company entered into a licensing agreement with Altum
Pharmaceuticals Inc. (“Altum”), a party related by way of common
director and officers, whereby the Company acquired worldwide
rights to the BiPhasix™ transdermal drug delivery technology for
the development and commercialization of Cannabinoids, Cannabidiol
and Tetrahydrocannabinol products. Consideration included:</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">1)</td>
<td valign="top">
<p style="MARGIN: 0px">Issuance of 2,500,000 shares of common stock
on September 12, 2017 valued at $247,556 (Notes 5 and 9(c));</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">2)</td>
<td valign="top">
<p style="MARGIN: 0px">Issuance of 2,500,000 shares of common stock
of Pivot upon Health Canada Natural Product Number approval (not
yet issued as of the date of this report);</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">3)</td>
<td valign="top">Royalties on annual gross sales; and</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">4)</td>
<td valign="top">
<p style="MARGIN: 0px">For pharmaceutical products, milestone
payments payable upon first Investigative New Drug Approval, upon
positive outcome of Phase II trial in first indication, and upon
New Drug Application approval. As of January 31, 2018 and the date
of this report, no milestones have been achieved.</p>
</td>
</tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">(b)</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px">SolMic Solubilization License</p>
</td>
</tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px">On September 23, 2017, the Company entered
into a collaboration and license agreement with SolMic GmbH (
“Solmic”) whereby the Company will acquire worldwide rights to
Solmic’s Solubilization Technology for the development and
commercialization of cannabinoid-containing natural extracts.
Milestones include payments upon the following developments: 1)
Regulatory approval of a natural health product; 2) First approval
of an investigative new drug application for a pharmaceutical
product; 3) Positive outcome of a Phase II clinical trial of a
pharmaceutical product in the first indication; and 4) Approval of
a New Drug Application for a pharmaceutical product by the US Food
and Drug Administration. Other consideration include a sales
milestone upon aggregate net sales of $5,000,000 and royalties on
aggregate net sales, which have not been achieved as at January 31,
2018 and as of the date of this report.</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>5. Intangible
Asset</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px"><b>Cost</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>BiPhasix</b></p>
<p style="MARGIN: 0px" align="center"><b>License</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Balance, January 31, 2017</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">License agreement (Note 4(a))</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
247,556</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Effect of foreign exchange rate changes</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
12,083</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Balance, January 31, 2018</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
259,639</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="top">
<p style="MARGIN: 0px"><b>Accumulated Amortization</b></p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Balance, January 31, 2017</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Amortization</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">25,075</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Balance, January 31, 2018</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">25,075</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Net book value, January 31, 2018</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">234,564</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Net book value, January 31, 2017</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px">Weighted average life remaining
on intangible asset is 3.6 years. Future amortization for the next
four years is:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreak1840da3e-5fae-4631-99e7-f4bf9d964636" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
F-10</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>PIVOT
PHARMACEUTICALS INC.</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Notes to the
Consolidated Financial Statements</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Year ended
January 31, 2017</p>
<p style="MARGIN: 0px">(Expressed in U.S. dollars)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>5. Intangible Asset
(continued)</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px" align="left"><b>Expiry Date</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">2019</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
79,793</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">2020</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
79,793</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">2021</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
79,793</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">2022</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
48,969</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>6. Convertible
Debenture</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">On September
30, 2016, the Company issued a convertible debenture with a
non-related party for $500,000 Canadian Dollars ($380,411 US
Dollars at September 30, 2016) (“Initial Advance”). The debenture
is secured under a General Security Agreement, bears interest at 8%
per annum and matures on the earlier of:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">The date the lender demands repayment of principal
and interest following an event of default,</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">The date of a dissolution event,</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">The date of a liquidity event, and</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">March 30, 2017.</td>
</tr>
</table>
<font face="Symbol">&nbsp;</font>&nbsp;
<p style="MARGIN: 0px 0px 0px 45px" align="justify">The Company may
request one or more additional advances of up to an aggregate
amount of $1,000,000 Canadian Dollars (“Additional Advances”)
provided that the aggregate amount under the convertible debenture
does not exceed $1,500,000 Canadian Dollars.</p>
<p style="MARGIN: 0px 0px 0px 45px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">The note,
including the Initial Advance and any Additional Advances, is
convertible into common shares at a conversion price equal to the
average closing market price of the Company’s common stock during
the five day period leading up to the conversion date. The Company
recorded the conversion feature of the convertible debenture as a
derivative liability at an estimated fair value of $134,892 with a
corresponding discount to the convertible debenture (Note 7).</p>
<p style="MARGIN: 0px 0px 0px 45px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">Pursuant to the
convertible loan agreement, the Company issued 434,622 share
purchase warrants to which the lender may acquire an interest in
the Company equal to 12% of the maximum principal amount
outstanding at any time at a price of $0.10 per share, which
equates to the ten day average trading price of the Company’s
common stock determined as at September 30, 2016. The Company
calculated the 434,622 share purchase warrants based on the maximum
outstanding principal balance on the convertible loan as of
September 30, 2016. The Company recorded the share purchase warrant
at an estimated fair value of $20,154 with a corresponding discount
to the convertible debenture (Note 11).</p>
<p style="MARGIN: 0px 0px 0px 45px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">On September
18, 2017, the lender converted the outstanding principal and
accrued interest of the convertible debenture into 4,623,825 shares
of common stock (Note 9(d)) of the Company at a conversion price of
$0.10. A loss on conversion of debenture of $21,236 was recorded
within gain on settlement of debts in the consolidated statements
of operations and comprehensive income. As of January 31, 2018, the
carrying value of the convertible debenture is $nil (January 31,
2017 - $275,011) which is net of debt discounts related to
conversion feature, financing costs and warrants of $nil, $nil and
$nil, respectively (January 31, 2017 - $94,709, $6,126 and $6,477,
respectively). As of January 31, 2018, interest accrued on the
convertible debenture is $nil (January 31, 2017 - $10,307) and the
fair value of the conversion option derivative liability is $nil
(January 31, 2017 - $312,541).</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreakab0357b2-2553-4f48-b3e0-f974973f4051" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
F-11</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>PIVOT
PHARMACEUTICALS INC.</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Notes to the
Consolidated Financial Statements</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Year ended
January 31, 2017</p>
<p style="MARGIN: 0px">(Expressed in U.S. dollars)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>7. Derivative
Liability</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">Derivative
liability consists of convertible debenture with variable
conversion price (Note 6). On September 18, 2017, the convertible
debenture was converted into shares of common stock (Note 6). The
fair value of derivative liability as at January 31, 2018 and
January 31, 2017 is as follows:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>January 31,</b></p>
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>January 31,</b></p>
<p style="MARGIN: 0px" align="center"><b>2017</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">September 2016 convertible debenture</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">312,541</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">312,541</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">The fair value
of derivative financial liability was determined using the binomial
option pricing model, using the following assumptions:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Expected</b></p>
<p style="MARGIN: 0px" align="center"><b>Volatility</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Risk-free</b></p>
<p style="MARGIN: 0px" align="center"><b>Interest Rate</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Expected</b></p>
<p style="MARGIN: 0px" align="center"><b>Dividend Yield</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Expected Life</b></p>
<p style="MARGIN: 0px" align="center"><b>(in years)</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">As at issuance date:</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td style="BORDER-BOTTOM: 1px solid" valign="top">
<p style="MARGIN: 0px 0px 0px 15px">September 2016 convertible
debenture</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">296</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">0.45</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">0</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">0.50</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>8. Promissory Note</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>January 31,</b></p>
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>January 31,</b></p>
<p style="MARGIN: 0px" align="center"><b>2017</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td style="BORDER-BOTTOM: 1px solid" valign="top">
<p style="MARGIN: 0px">Principal (Note 8(a))</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="10%" align="right">200,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="10%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%">(a)</td>
<td valign="top">Promissory Note – Former Chief Executive Officer
(Note 3)</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td valign="top">Promissory note bears interest at 8% per annum.
Principal and accrued interest are due on the earlier of: 1) 30
days after the completion of a financing of at least $2,000,000 and
(ii) September 10, 2027, provided that if repayment occurs prior to
the second anniversary date, all interest will be waived. On
February 28, 2018, the Company issued senior secured convertible
debentures for gross proceeds of $5,000,000 Canadian dollars (Note
15). Accordingly, accrued interest being waived, principal was due
and repaid on March 30, 2018. In accordance with ASC 470-10-45-2,
the Company has classified the note payable as a current
liability.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(b)</td>
<td valign="top">Promissory Note – Third Party</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"></td>
<td valign="top">On September 27, 2017, the Company issued a
promissory note in the amount of $400,000, bearing interest at 12%
per annum and maturing on December 31, 2018, which no proceeds have
been received by the Company as at January 31, 2018. As part of the
promissory note, 100,000 shares of our common stock were issued
(Note 9(d)).</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreake70977c0-39a8-4973-95b7-f0232c9fe560" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
F-12</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>PIVOT
PHARMACEUTICALS INC.</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Notes to the
Consolidated Financial Statements</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Year ended
January 31, 2017</p>
<p style="MARGIN: 0px">(Expressed in U.S. dollars)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>9. Common Stock</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="justify">During the year ended
January 31, 2018:</p>
</td>
</tr>
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(a)</td>
<td valign="top">On July 19, 2017, 200,000 shares of common stock
were issued for services rendered.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(b)</td>
<td valign="top">On September 11, 2017, 3,800,000 shares of common
stock were acquired and cancelled pursuant to the share exchange
agreement (Note 3).</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(c)</td>
<td valign="top">On September 12, 2017, 2,500,000 shares of common
stock were issued pursuant to the Altum licensing agreement (Note
4(a)).</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(d)</td>
<td valign="top">On September 18, 2017, 4,623,825 shares of common
stock were issued upon conversion of convertible debenture (Note
6).</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(e)</td>
<td valign="top">On October 26, 2017, 100,000 shares of common
stock were issued pursuant to a promissory note issued (Note
8(b)).</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(f)</td>
<td valign="top">In October 2017, the Company received proceeds
totaling $223,000 pursuant to private placements for the issuance
of 2,230,000 shares of common stock at a price of $0.10 per share.
330,000 shares of common stock were issued on October 30 and
1,900,000 shares of common stock were issued on November 2, 2017.
On November 2, 2017, 200,000 shares of common stock related to
share issue costs on this private placement were issued.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(h)</td>
<td valign="top">On October 31, 2017, the Company settled $35,153
of accounts payable through the issuance of 92,384 shares of common
stock (Note 12(d)), which were issued on November 2, 2017.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(i)</td>
<td valign="top">On November 7, 2017, 50,000 shares of common stock
were issued for services rendered.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(j)</td>
<td valign="top">Effective December 15, 2017, the Company closed a
private placement for an aggregate of 505,000 units, consisting of
one common share and one half of one share purchase warrant, at
price of $0.20 per unit for gross proceeds of $101,000. On November
21, 2017, 380,000 shares of common stock and 190,000 share purchase
warrants were issued. On December 18, 2017, 125,000 shares of
common stock and 62,500 share purchase warrants were issued. Finder’
s fee consisted of a cash payment of $5,050 and issuance of 25,250
units, consisting of one common share and one half of one share
purchase warrant. On December 18, 2017, 25,250 shares of common
stock and 12,625 share purchase warrants related to the finder’s
fee were issued.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" colspan="2">During the year ended January 31,
2017:</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(k)</td>
<td valign="top">On February 10, 2016, the Company issued 100,000
shares of common stock to service providers for services provided
valued at $68,000. The value of the common stock was based on the
market price of the stock on the date of issuance.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(l)</td>
<td valign="top">On February 29, 2016, March 31, 2016, May 2, 2016,
May 31, 2016, June 28, 2016, August 2, 2016 and August 30, 2016,
the Company issued 25,000 shares of common stock on each of these
dates to the Company’s CEO as monthly compensation valued at
$15,000, $13,750, $7,500, $6,000, $4,875, $3,757 and $3,250,
respectively. The value of the common stock was based on the market
price of the stock on the date of issuance.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(m)</td>
<td valign="top">In June 2016, 600,000 shares of common stock were
issued to service providers and valued at $144,500 based on the
market price of the stock on the dates of issuances.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(n)</td>
<td valign="top">On July 31, 2016 and January 31, 2017, 25,000
shares of common stock, valued at $3,750 and $2,708, respectively,
previously held in escrow were released to a member of the Company’
s Scientific Advisory Board (“SAB member”). The value of the common
stock was based on the market price of the stock on the date of
issuance.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreak1c56f852-067f-48bc-a203-d47334096e53" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
F-13</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>PIVOT
PHARMACEUTICALS INC.</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Notes to the
Consolidated Financial Statements</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Year ended
January 31, 2017</p>
<p style="MARGIN: 0px">(Expressed in U.S. dollars)</p>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>10. Share Purchase
Warrants</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">The following
table summarizes the continuity of share purchase warrants:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Number of</b></p>
<p style="MARGIN: 0px" align="center"><b>Warrants</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Weighted Average</b></p>
<p style="MARGIN: 0px" align="center"><b>Exercise</b></p>
<p style="MARGIN: 0px" align="center"><b>Price</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Balance, January 31, 2017</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
434,622</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.10</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Granted (Note 9(j))</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
265,125</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.35</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Expired</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">(434,622</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">0.10</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Balance, January 31, 2018</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">265,125</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" align="right">0.35</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px">As at January 31, 2018, the
following share purchase warrants were outstanding:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" colspan="2">
<p style="MARGIN: 0px" align="center"><b>Number of Warrants</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Exercise</b> <b>Price</b>
<b>$</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="center">
<p style="MARGIN: 0px"><b>Expiry Date</b></p>
</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>&nbsp;</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td width="9%">
<p style="MARGIN: 0px" align="right">190,000</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.35</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td width="9%">
<p style="MARGIN: 0px" align="center">May 20, 2019</p>
</td>
<td width="1%">&nbsp;</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="right">75,125</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">0.35</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="center">June 14 ,2019</p>
</td>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>11. Stock Options</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">Effective
December 30, 2015, the Company adopted a stock option plan. Under
this plan, the Company may grant options to its directors,
officers, employees and consultants up to an amount as determined
by the Company and will be no more than a percentage of its
outstanding common stock as may be required by the stock exchange
the Company is listed with. The exercise price of the stock options
will be determined by the Company and will be no less than any
minimum exercise price as may be required by the stock exchange the
Company is listed with.</p>
<p style="MARGIN: 0px 0px 0px 45px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px">The following table summarizes
the continuity of the Company’s stock options:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Number of</b></p>
<p style="MARGIN: 0px" align="center"><b>Options</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center"><b>Weighted</b>
<p style="MARGIN: 0px"><b>Average</b></p>
<p style="MARGIN: 0px"><b>Exercise Price</b></p>
<b>(US$)</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Weighted Average Remaining
Contractual Life (years)</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Aggregate</b></p>
<p style="MARGIN: 0px" align="center"><b>Intrinsic</b></p>
<p style="MARGIN: 0px" align="center"><b>Value</b></p>
<p style="MARGIN: 0px" align="center"><b>(US$)</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Outstanding, January 31, 2016</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
6,200,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.10</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">3.9</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
32,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Granted</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
11,320,833</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.48</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">4.4</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
36,599</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Forfeited</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">(2,000,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">(0.10</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Outstanding, January 31, 2017</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
15,520,833</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.38</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">4.2</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
68,599</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Granted</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
100,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.39</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">4.79</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
163,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Forfeited</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">(2,000,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">(0.70</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Outstanding, January 31, 2018</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">13,620,833</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">0.34</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">3.26</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">22,917,756</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreakf497557f-f1c6-4085-a44c-4342d3e1258f" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
F-14</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>PIVOT
PHARMACEUTICALS INC.</b></p>
<p style="MARGIN: 0px" align="left">Notes to the Consolidated
Financial Statements</p>
<p style="MARGIN: 0px" align="left">Year ended January 31, 2017</p>
<p style="MARGIN: 0px" align="left">(Expressed in U.S. dollars)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>11. Stock Options
(continued)</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px">The fair value of stock-based
compensation expense was estimated using the Black-Scholes option
pricing model and the following assumptions:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Expected</b></p>
<p style="MARGIN: 0px" align="center"><b>Volatility</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Risk-free</b></p>
<p style="MARGIN: 0px" align="center"><b>Interest Rate</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Expected</b></p>
<p style="MARGIN: 0px" align="center"><b>Dividend Yield</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Expected Life</b></p>
<p style="MARGIN: 0px" align="center"><b>(in years)</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">200,000 options expiring on November 30,
2020</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">415</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">1.48</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">3.8</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">5,250,000 options expiring on February 22,
2021</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">388</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">1.48</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">4.3</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">29,000 options expiring on May 2, 2021</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">375</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">1.73</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">3.5</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">4,000,000 options expiring on December 14,
2021</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">426</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">2.10</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">5.0</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">41,833 options expiring on January 23,
2021</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">428</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">1.94</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0</td>
<td valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">5.0</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">100,000 options expiring on November 14,
2022</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">382</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">1.76</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">0</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">4.8</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px">Additional information
regarding stock options as of January 31, 2018, is as follows:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" colspan="2">
<p style="MARGIN: 0px" align="center"><b>Options
Outstanding</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Options
Exercisable</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Exercise</b> <b>Price</b>
<b>$</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="center">
<p style="MARGIN: 0px" align="center"><b>Expiry Date</b></p>
</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>&nbsp;</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td width="9%">
<p style="MARGIN: 0px" align="right">200,000</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
200,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.25</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td width="9%">
<p style="MARGIN: 0px" align="center">November 30, 2020</p>
</td>
<td width="1%">&nbsp;</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="right">4,000,000</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">4,000,000</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">0.10</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="center">December 14, 2020</p>
</td>
<td>&nbsp;</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="right">5,250,000</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">5,250,000</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">0.70</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="center">February 22, 2021</p>
</td>
<td>&nbsp;</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="right">29,000</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">29,000</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">0.34</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="center">May 2, 2021</p>
</td>
<td>&nbsp;</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="right">4,000,000</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">4,000,000</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">0.10</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="center">December 14, 2021</p>
</td>
<td>&nbsp;</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="right">41,833</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">41,833</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">0.05</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="center">January 23, 2022</p>
</td>
<td>&nbsp;</td>
</tr>
<tr bgcolor="#CCEEFF">
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="right">100,000</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">25,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">0.39</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="center">November 14, 2022</p>
</td>
<td>&nbsp;</td>
</tr>
<tr bgcolor="#FFFFFF">
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="right">13,620,833</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">13,545,833</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">$112,147 of
stock-based compensation have yet to be recognized and will be
recognized in future periods.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>12. Supplemental Cash
Flow Disclosures</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>January 31,</b></p>
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>January 31,</b></p>
<p style="MARGIN: 0px" align="center"><b>2017</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Supplemental disclosures:</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Interest paid</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="10%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="10%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Income tax paid</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">–</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">–</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Non-cash investing and financing
activities:</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Capital contribution through
forgiveness of debt</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">552,888</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">–</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Common stock issued for finders’
 fee</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">39,673</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">–</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Common stock issued for
settlement of accounts payable</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">35,153</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">–</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Common stock issued for
settlement of convertible debenture</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">601,097</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">–</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Common stock issued for
intangible asset</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">262,500</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">–</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Debt discounts on convertible
debt</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">–</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">174,364</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Promissory note issued for
settlement of accrued salaries</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">200,000</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">–</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td style="BORDER-BOTTOM: 1px solid" valign="top">
<p style="MARGIN: 0px 0px 0px 15px">Common stock received and
constructively retired in disposition of assets</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">380,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreak74245184-1d84-4e0f-b9ed-81908cf1ea86" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
F-15</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>PIVOT
PHARMACEUTICALS INC.</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Notes to the
Consolidated Financial Statements</p>
<p style="MARGIN: 0px">Year ended January 31, 2017</p>
<p style="MARGIN: 0px">(Expressed in U.S. dollars)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>13. Related Party
Transactions</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%">(a)</td>
<td valign="top">As at January 31, 2018, the Company owed $4,767
(2017 - $4,154) to a director of the Company, which is unsecured,
non-interest bearing, and due on demand.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(b)</td>
<td valign="top">As at January 31, 2018, the Company owed $nil
(2017 – $18,421) to the Company’s past Chief Executive
Officer.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(c)</td>
<td valign="top">On September 12, 2017, the Company entered into a
licensing agreement with Altum, a party related by way of common
director and officers, whereby the Company acquired worldwide
rights to the BiPhasix™ transdermal drug delivery technology for
the development and commercialization of Cannabinoids, Cannabidiol
and Tetrahydrocannabinol products (Note 4(a)). As at January 31,
2018, the Company owed Altum $5,337 (2017 - $nil) for expenses paid
on behalf of the Company, which was repaid subsequent to year
end.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">(d)</td>
<td valign="top">
<p style="MARGIN: 0px" align="justify">During the year ended
January 31, 2018, a capital contribution amounting to $552,888 was
made by two officers who forgave accrued management fees. In
addition, $35,153 of accounts payable due to a company controlled
by the Company’s Chief Financial Officer were settled for 92,384
shares of common stock.</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>14. Income Taxes</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">The Company has
approximately $7.7 million of non-capital losses carried forward to
offset taxable income in future years which expire beginning in
fiscal 2029. The income tax benefit differs from the amount
computed by applying the Canadian federal and provincial statutory
rates to net loss before income taxes for the years ended January
31, 2018 and 2017, respectively, as a result of the following:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2017</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Net loss before taxes</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
121,182</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
6,329,029</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Statutory rate</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">26.0</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">%</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">26.0</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Expected tax recovery</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
31,507</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
1,645,548</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Lower effective tax rate on
losses in U.S. jurisdiction</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(1,458</td>
<td valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(2,538</td>
<td valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Permanent differences and
other</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">5,950</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
(1,380,771</td>
<td valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Expenses deductible for tax
purposes</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">28</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">35</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Current period losses not
recognized</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">(36,027</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">(262,274</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Income tax provision</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">The significant
components of deferred income tax assets and liabilities as at
January 31, 2018 and 2017, after applying enacted corporate income
tax rates, are as follows:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>2017</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Share issue costs</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">7,047</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">–</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Non-capital losses carried
forward</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
2,004,369</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
2,351,702</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Valuation allowance</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">(2,011,416</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">(2,351,702</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">)</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="justify">Net deferred tax asset</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">–</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreakfa0738cc-9b96-4bcb-ab12-39542549479e" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
F-16</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td>&nbsp;</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>PIVOT
PHARMACEUTICALS INC.</b></p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Notes to the
Consolidated Financial Statements</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">Year ended
January 31, 2017</p>
<p style="MARGIN: 0px">(Expressed in U.S. dollars)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>14. Income Taxes
(continued)</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">The following
table lists the fiscal year in which the loss was incurred and the
expiration date of the operating loss:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="85%" align="center" border=
"0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px" align="left"><b>Expiry Date</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><b>&nbsp;</b></p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Non-Capital</b></p>
<p style="MARGIN: 0px" align="center"><b>Loss</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" colspan="2" align=
"right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">2029</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
353,468</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">2030</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
63,430</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">2031</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
113,439</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">2032</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
535,169</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">2033</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">-</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">2034</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
558,959</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">2035</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
1,185,382</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">2036</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
3,772,475</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">2037</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
1,030,791</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">2038</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">95,570</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
width="9%" align="right">7,708,683</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>15. Subsequent
Events</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">Effective
February 28, 2018, the Company issued promissory notes for up to
CDN $1,000,000 which accrue interest at 10% per annum and mature on
December 29, 2022. CDN$557,000 was advanced to the Company, which
was repaid with proceeds from the issuance of senior secured
convertible debentures on February 28, 2018.</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">Effective
February 28, 2018, the Company issued senior secured convertible
debentures with a conversion price of $1.74 per common share for
aggregate gross proceeds of CDN$5,000,000 (the "Offering"). The
convertible debentures will bear interest at the rate of 10% per
annum, payable quarterly, and will mature 12 months following the
date of their issuance. Beginning on the date that is four months
and one day following the issuance of the convertible debentures,
the Company may force the conversion of the principal amount of the
then outstanding convertible debentures at the conversion price on
not less than 30 days’ notice should the daily volume weighted
average trading price of the shares of common stock be greater than
$2.50 for any 20 consecutive trading days on the Canadian Stock
Exchange, or such other exchange our common shares are principally
traded.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">On February 28,
2018, the Company completed the acquisition of ERS Holdings, LLC (
“ERS”) pursuant to an Exchange Agreement dated as of February 10,
2018 among the Company, ERS and the members of ERS. As
consideration for the purchase, the Company paid $333,333 in cash
on closing, issued 5,000,000 shares of common stock and will pay an
additional $333,333 six and twelve (12) months after closing.
Financial consideration include royalties on future annual net
sales.</p>
<p style="MARGIN: 0px 0px 0px 45px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">On March 2,
2018, the Company completed the acquisition of Thrudermic, LLC (
“Thrudermic”) and worldwide rights to Thrudermic’s patented
Transdermal Nanotechnology for the development and
commercialization of transdermal cannabinoids pursuant to an
Exchange Agreement dated as of March 2, 2018 among the Company, Dr.
Joseph Borovsky, Dr. Leonid Lurya and Thrudermic. As consideration
for the purchase, the Company paid $1 in cash on closing and issued
500,000 shares of our common stock.</p>
<p style="MARGIN: 0px 0px 0px 45px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">On March 12,
2018, the Company granted 200,000 options to purchase common stock
to a third party with exercise price of $1.76 Canadian dollars per
share, expiry on March 11, 2023 and equal monthy vesting over 12
months.</p>
<p style="MARGIN: 0px 0px 0px 45px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px" align="justify">On March 14,
2018 and April 4, 2018, the Company issued 75,000 and 62,500 shares
of common stock, respectively, to third parties for services
rendered. On March 31, 2018, the Company issued 44,087 shares of
common stock pursuant to employment agreements entered into upon
the acquisitions of ERS and Thrudermic.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreak8a6fcac2-8893-44c0-bb83-4aaa13d01467" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
F-17</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><a name=
"Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure">
Item 9. Changes in and Disagreements With Accountants on Accounting
and Financial Disclosure</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">There were no disagreements
related to accounting principles or practices, financial statement
disclosure, internal controls or auditing scope or procedure during
the two fiscal years and interim periods, including the interim
period up through the date the relationship ended.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><a name=
"Item 9A. Controls and Procedures">Item 9A. Controls and
Procedures</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Management’s Report on
Disclosure Controls and Procedures</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">As required by
Rule 13a-15 under the Exchange Act, our management evaluated the
effectiveness of the design and operation of our disclosure
controls and procedures as of January 31, 2018 and determined that
they were not effective.</p>
<p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Disclosure controls and
procedures refer to controls and other procedures designed to
ensure that information required to be disclosed in the reports we
file or submit under the Securities Exchange Act is recorded,
processed, summarized and reported within the time periods
specified in the rules and forms of the SEC and that such
information is accumulated and communicated to our management,
including our president (our principal executive officer) and our
chief financial officer (our principal financial officer and
principal accounting officer), as appropriate, to allow timely
decisions regarding required disclosure. In designing and
evaluating our disclosure controls and procedures, management
recognizes that any controls and procedures, no matter how well
designed and operated, can provide only reasonable assurance of
achieving the desired control objectives, and management is
required to apply its judgment in evaluating and implementing
possible controls and procedures.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Management’s Annual
Report on Internal Control over Financial Reporting</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our management is
responsible for establishing and maintaining adequate internal
control over financial reporting. Under the supervision and with
the participation of our management, including our president (our
principal executive officer) and our chief financial officer (our
principal financial officer and principal accounting officer), we
conducted an evaluation of the effectiveness of our internal
control over financial reporting as of January 31, 2018 using the
criteria established in <i>Internal Control—Integrated
Framework</i> issued by the Committee of Sponsoring Organizations
of the Treadway Commission (COSO).</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">A material weakness is a
deficiency, or combination of deficiencies, in internal control
over financial reporting, such that there is a reasonable
possibility that a material misstatement of our company’s annual or
interim financial statements will not be prevented or detected on a
timely basis. In its assessment of the effectiveness of internal
control over financial reporting as of January 31, 2018, our
company determined that there were control deficiencies that
constituted material weaknesses, as described below:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><em>1.</em></td>
<td valign="top"><i>We did not maintain appropriate financial
reporting controls</i> – As of January 31, 2018, our company has
not maintained sufficient internal controls over financial
reporting for the financial reporting process. As at January 31,
2018, our company did not have sufficient financial reporting
controls with respect to the segregation of incompatible duties
related to the ability to post adjusting journal entries and access
to our company’s assets.</td>
</tr>
</table>
&nbsp;
<p style="MARGIN: 0px" align="justify">Accordingly, our company
concluded that these control deficiencies resulted in a reasonable
possibility that a material misstatement of the annual or interim
financial statements will not be prevented or detected on a timely
basis by the company’s internal controls.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">As a result of the material
weaknesses described above, management has concluded that our
company’s internal control over financial reporting was not
effective as of January 31, 2018 based on criteria established in
<i>Internal Control—Integrated Framework</i> issued by COSO.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak250e89d4-a4f8-4913-adf3-bf814a3b6c4b" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
39</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Sadler, Gibb &amp;
Associates, LLC, our independent registered public auditors, was
not required to and has not issued an attestation report concerning
the effectiveness of our internal control over financial reporting
as of January 31, 2018 pursuant to temporary rules of the
Securities and Exchange Commission that permit our company to
provide only management’s report in this annual report.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Changes in Internal
Controls</i></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">During the period ended
January 31, 2018, there were no changes in our internal control
over financial reporting that materially affected, or are
reasonably likely to materially affect, our internal control over
financial reporting.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><a name="Item 9B. Other Information">Item
9B. Other Information</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On February 5, 2015, we
accepted the resignation of Dr. Ahmad Doroudian as our President
and Chief Executive Officer of our company. Dr. Ahmad Doroudian
remains a director and serves as Chairman of the Board. In
addition, Dr. Hamid Doroudian resigned as a director of our
company. The resignations of Dr. Ahmad Doroudian and Dr. Hamid
Doroudian were not the result of any disagreements with our company
regarding our operations, policies, practices or otherwise.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Also on February 5, 2015,
Dr. Barbara-Jean Bormann-Kennedy (BJ Bormann) and Dr. Wolfgang Renz
were appointed directors of our company. Concurrently with Dr.
Ahmad Doroudian’s resignation, we appointed Dr. Bormann as Chief
Executive Officer of our company.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On November 16, 2015, we
accepted the resignation of Dr. BJ Bormann as director. We also
accepted the resignation of Dr. Bormann as our Chief Executive
Officer effective October 16, 2015. Dr. Bormann’s resignation was
not the result of any disagreements with our company regarding our
operations, policies, practices or otherwise. Dr. Ahmad Doroudian,
our director and Chairman of the Board, was appointed as our
interim Chief Executive Officer.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On November 20, 2015, we
appointed Dr. Pravin Chaturvedi as our new Chief Executive Officer
and Director. Also on the same date, we accepted the resignation of
Dr. Ahmad Doroudian as interim Chief Executive Officer. Dr.
Doroudian remained as Chairman of the board. On February 1, 2016,
Dr. Doroudian became our Chief Business Officer.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On November 18, 2016, we
accepted the resignation of Dr. Ahmad Doroudian as a member of our
Audit Committee. Concurrently, we appointed Dr. Wolfgang Renz to
the Audit Committee. On November 24, 2017, Dr. Ahmad Doroudian was
appointed to the Audit Committee.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On September 11, 2017, we
accepted the resignation of Dr. Pravin Chaturvedi as our Chief
Executive Officer and Director. On the same date, we appointed Dr.
Patrick Frankham as our new Chief Executive Officer.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreakb58d4d69-55e7-4b23-882c-3d6dafb2bba9" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
40</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in" align="center"><b><a name=
"PART III">PART III</a></b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><a name=
"Item 10. Directors, Executive Officers and Corporate Governance">Item
10. Directors, Executive Officers and Corporate
Governance</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">All directors of our company
hold office until the next annual meeting of the security holders
or until their successors have been elected and qualified. The
officers of our company are appointed by our board of directors and
hold office until their death, resignation or removal from office.
Our directors and executive officers, their ages, positions held,
and duration as such, are as follows:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"21%">
<p style="MARGIN: 0px"><b>Name</b></p>
</td>
<td width="2%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px" align="left"><b>Position Held</b> <b>with
the Company</b></p>
</td>
<td width="2%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"8%">
<p style="MARGIN: 0px" align="center"><b>Age</b></p>
</td>
<td width="2%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"20%">
<p style="MARGIN: 0px" align="center"><b>Date First Elected</b></p>
<p style="MARGIN: 0px" align="center"><b>or Appointed</b></p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Dr. Ahmad Doroudian</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="left">Chairman, Secretary, Chief
Business Officer and Director</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">57</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">September 17, 2007</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Dr. Patrick Frankham</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">Chief Executive Officer and Director</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">46</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">November 20, 2015</p>
</td>
</tr>
<tr height="15" bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Moira Ong</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">Chief Financial Officer</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">43</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">December 26, 2010</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Dr. Wolfgang Renz</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">Director</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">48</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">February 5, 2015</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Business
Experience</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The following is a brief
account of the education and business experience during at least
the past five years of each director, executive officer and key
employee of our company, indicating the person’s principal
occupation during that period, and the name and principal business
of the organization in which such occupation and employment were
carried out.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Dr. Ahmad Doroudian –
Chairman, Secretary, Chief Business Officer and
Director</i></b></p>
<p style="MARGIN: 0px" align="justify">Dr. Ahmad Doroudian was as
our appointed president, Chief Executive Officer and Director on
September 17, 2007 and as Chief Executive Officer and secretary on
March 30, 2011. He resigned as President, Chief Executive Officer
and Secretary on August 30, 2011 and was re-appointed as President,
Chief Executive Officer and Secretary on July 24, 2014. Dr.
Doroudian subsequently resigned as President and Chief Executive
Officer on February 5, 2015 and was appointed as Chairman on that
date. Currently, Dr. Ahmad Doroudian acts as our company’s
Chairman, Secretary, Chief Business Officer and Director.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Prior to joining us, Dr.
Doroudian was involved in early stage financing and management of
private and publicly listed companies. From 1997 to 2004, he acted
as the chief executive officer, chairman, vice chairman and
director of PanGeo Pharma, Inc. (now PendoPharm, a division of
Pharmascience Inc.), a TSX-listed company founded by Dr. Doroudian
which received over $100 million dollars in financing. From 2004
through 2007, Dr. Doroudian also served as the president of, Rayan
Pharma Inc., an exporter of pharmaceuticals to Eastern Europe. From
2006 to 2008, Dr. Doroudian was owner and chief executive officer
of ABF Pharmacy, a group of successful retail pharmacies. Dr.
Doroudian was also the chief executive officer of Merus Labs
International Inc., a specialty pharmaceutical company engaged in
the acquisition and licensing of pharmaceutical products.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px"><b><i>Dr. Patrick Frankham –
Director</i></b></p>
<p style="MARGIN: 0px" align="justify">Dr. Patrick Frankham was
appointed as director of our company on July 24, 2014 and as Chief
Executive Officer on September 11, 2017. Dr. Frankham has over 22
years of experience in the biopharmaceutical and services
industries. Prior to joining Pivot Pharmaceuticals he was Executive
Director, Healthcare Innovation, Boehringer-Ingelheim GmbH. He has
also founded several multinational healthcare startup enterprises
including healthcare information technology, services and
pharmaceuticals companies. His professional experience includes
public and private companies as well as multinational corporations.
He has developed pharmaceutical products in several therapeutic
areas and interacted with global regulatory authorities. Notable
prior organizations where he held increasing leadership roles
include, Phoenix International Life Sciences (MDS Pharma Services),
Endoceutics Inc., AeternaZentaris, BioAxone Biosciences, &amp; ICON
Clinical Research. Dr Frankham obtained his PhD in molecular
endocrinology (Université Laval, Canada), and holds an MBA in
Finance (University of Liverpool, UK). We appointed Dr. Frankham to
our board due to his background in the biopharmaceutical
industry.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Moira Ong – Chief
Financial Officer</i></b></p>
<p style="MARGIN: 0px" align="justify">Moira Ong was appointed as
our Chief Financial Officer on December 26, 2010. Ms. Ong has more
than 20 years of experience in public company accounting and audit
reporting. From 2010 through 2012, Ms. Ong was also the vice
president of finance of Merus Labs International Inc., a specialty
pharmaceutical company engaged in the acquisition and licensing of
pharmaceutical products. From 2005 until 2010, Ms. Ong was senior
manager at a global accounting firm in charge of completion of
financial statements for Canadian publicly listed companies. From
2003 to 2005 she served as financial consultant for a private
financial planning company. Ms. Ong was a manager in the banking
and securities group at a global accounting firm in New York from
2000 to 2003. Ms. Ong obtained her Chartered Professional
Accountant designation in 1999 and her Chartered Financial Analyst
designation in 2003.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreakf3b82555-a2e7-4414-bbde-c09e30339344" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
41</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><i>Dr. Wolfgang Renz -
Director</i></b></p>
<p style="MARGIN: 0px" align="justify">Dr. Wolfgang Renz was
appointed as a director of our company on February 5, 2015. Dr.
Wolfgang Renz is president of international business at Physicians
Interactive. Formerly, he served as corporate vice president of
business model &amp; healthcare innovation at Boehringer Ingelheim,
one of the world’s largest pharmaceutical companies. For over a
decade, he has been involved in developing medicines and technology
to help people lead healthier, more productive lives. At Boehringer
Ingelheim, he led a team of specialists to find, test, and develop
the disruptive technologies that will shape the way health care
will be delivered in the future. In addition, he also serves as
adjunct professor of surgery at McGill University’s Faculty of
Medicine in Montreal, Canada. Dr. Renz holds a medical degree and a
Ph.D. from Freiburg University and is board certified in Germany in
emergency medicine.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Family
Relationships</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">There are no other family
relationships between any of our directors, executive officers and
proposed directors or executive officers.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Conflicts of
Interest</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Dr. Doroudian is a
co-founder and chief executive officer of Altum Pharmaceuticals
Inc., a company engaged in the research, development and
commercialization of novel pharmaceutical products.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Dr. Renz is president of
international business at Physicians Interactive and also serves as
adjunct professor of surgery at McGill University’s Faculty of
Medicine in Montreal, Canada.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">While we do not anticipate
that these activities will compete with our business, Dr. Doroudian
and Dr. Renz may have pre-existing fiduciary duties with one or
more organizations and may not agree to present business
opportunities or research data to us unless other entities have
first declined to accept them or consented to their release.
Accordingly, they may have a conflict of interest in determining to
which entity a particular business opportunity should be
presented.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our directors are not
obligated to commit their time and attention exclusively to our
business and, accordingly, they may encounter a conflict of
interest in allocating their time between our operations and those
of other businesses. Our directors devote their time on an as
needed basis. All of our directors, in the course of their other
business activities, may become aware of investment and business
opportunities which may be appropriate for presentation to us as
well as other entities to which they owe a fiduciary duty. As a
result, they may have conflicts of interest in determining to which
entity a particular business opportunity should be presented. They
may also in the future become affiliated with entities engaged in
business activities similar to those we intend to conduct.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In general, officers and
directors of a corporation are required to present business
opportunities to a corporation if:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">the corporation could financially undertake the
opportunity;</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">the opportunity is within the corporation’s line
of business; and</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">it would be unfair to the corporation and its
stockholders not to bring the opportunity to the attention of the
corporation.</td>
</tr>
</table>
<p style="MARGIN: 0px"><font face="Symbol">&nbsp;</font></p>
<p style="MARGIN: 0px"></p>
<table id="pagebreakbed9fac4-d164-4ef2-8bb3-8d9a1e88d4bc" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
42</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<font face="Symbol">&nbsp;&nbsp;</font>&nbsp;
<p style="MARGIN: 0px" align="justify"><b>Involvement in Certain
Legal Proceedings</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">To the best of our
knowledge, none of our directors or executive officers has, during
the past ten years:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="3%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="3%">1.</td>
<td valign="top">been convicted in a criminal proceeding or been
subject to a pending criminal proceeding (excluding traffic
violations and other minor offences);</td>
</tr>
<tr>
<td valign="top" width="3%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="3%">2.</td>
<td valign="top">had any bankruptcy petition filed by or against
the business or property of the person, or of any partnership,
corporation or business association of which he was a general
partner or executive officer, either at the time of the bankruptcy
filing or within two years prior to that time;</td>
</tr>
<tr>
<td valign="top" width="3%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="3%">3.</td>
<td valign="top">been subject to any order, judgment, or decree,
not subsequently reversed, suspended or vacated, of any court of
competent jurisdiction or federal or state authority, permanently
or temporarily enjoining, barring, suspending or otherwise
limiting, his involvement in any type of business, securities,
futures, commodities, investment, banking, savings and loan, or
insurance activities, or to be associated with persons engaged in
any such activity;</td>
</tr>
<tr>
<td valign="top" width="3%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="3%">4.</td>
<td valign="top">been found by a court of competent jurisdiction in
a civil action or by the SEC or the Commodity Futures Trading
Commission to have violated a federal or state securities or
commodities law, and the judgment has not been reversed, suspended,
or vacated;</td>
</tr>
<tr>
<td valign="top" width="3%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="3%">5.</td>
<td valign="top">been the subject of, or a party to, any federal or
state judicial or administrative order, judgment, decree, or
finding, not subsequently reversed, suspended or vacated (not
including any settlement of a civil proceeding among private
litigants), relating to an alleged violation of any federal or
state securities or commodities law or regulation, any law or
regulation respecting financial institutions or insurance companies
including, but not limited to, a temporary or permanent injunction,
order of disgorgement or restitution, civil money penalty or
temporary or permanent cease-and-desist order, or removal or
prohibition order, or any law or regulation prohibiting mail or
wire fraud or fraud in connection with any business entity; or</td>
</tr>
<tr>
<td valign="top" width="3%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="3%">6.</td>
<td valign="top">been the subject of, or a party to, any sanction
or order, not subsequently reversed, suspended or vacated, of any
self-regulatory organization (as defined in Section 3(a)(26) of the
Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as
defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C.
1(a)(29))), or any equivalent exchange, association, entity or
organization that has disciplinary authority over its members or
persons associated with a member.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Compliance with Section
16(a) of the Securities Exchange Act of 1934</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our common stock is not
registered pursuant to Section 12 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”). Accordingly, our officers,
directors, and principal stockholders are not subject to the
beneficial ownership reporting requirements of Section 16(a) of the
Exchange Act.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Code of Ethics</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Effective April 20, 2011,
our company’s board of directors adopted a code of business conduct
and ethics that applies to, among other persons, members of our
board of directors, our company’s officers including our president,
chief executive officer and chief financial officer, employees,
consultants and advisors. As adopted, our code of business conduct
and ethics sets forth written standards that are designed to deter
wrongdoing and to promote:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="3%">1.</td>
<td valign="top">honest and ethical conduct, including the ethical
handling of actual or apparent conflicts of interest between
personal and professional relationships;</td>
</tr>
<tr>
<td valign="top" width="3%">2.</td>
<td valign="top">full, fair, accurate, timely, and understandable
disclosure in reports and documents that we file with, or submit
to, the Securities and Exchange Commission and in other public
communications made by us;</td>
</tr>
<tr>
<td valign="top" width="3%">3.</td>
<td valign="top">compliance with applicable governmental laws,
rules and regulations;</td>
</tr>
<tr>
<td valign="top" width="3%">4.</td>
<td valign="top">the prompt internal reporting of violations of the
code of business conduct and ethics to an appropriate person or
persons identified in the code of business conduct and ethics;
and</td>
</tr>
<tr>
<td valign="top" width="3%">5.</td>
<td valign="top">accountability for adherence to the code of
business conduct and ethics.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our code of business conduct
and ethics requires, among other things, that all of our company’s
senior officers commit to timely, accurate and consistent
disclosure of information; that they maintain confidential
information; and that they act with honesty and integrity.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In addition, our code of
business conduct and ethics emphasizes that all employees, and
particularly senior officers, have a responsibility for maintaining
financial integrity within our company, consistent with generally
accepted accounting principles, and federal and state securities
laws. Any senior officer who becomes aware of any incidents
involving financial or accounting manipulation or other
irregularities, whether by witnessing the incident or being told of
it, must report it to our company. Any failure to report such
inappropriate or irregular conduct of others is to be treated as a
severe disciplinary matter. It is against our company policy to
retaliate against any individual who reports in good faith the
violation or potential violation of our company’s code of business
conduct and ethics by another.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak78c44afb-894a-4ae3-8ecd-c6a46a82d654" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
43</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our code of business conduct
and ethics was included as an exhibit to our annual report on Form
10-K filed with the SEC on May 11, 2011. We will provide a copy of
the code of business conduct and ethics to any person without
charge, upon request. Requests can be sent to: Pivot
Pharmaceuticals Inc., 1275 West 6th Avenue, Vancouver, British
Columbia V6H 1A6.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Committees of the
Board</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">All proceedings of our board
of directors were conducted by resolutions consented to in writing
by all the directors and filed with the minutes of the proceedings
of the directors. Such resolutions consented to in writing by the
directors entitled to vote on that resolution at a meeting of the
directors are, according to the corporate laws of the state of
Nevada and the bylaws of our company, as valid and effective as if
they had been passed at a meeting of the directors duly called and
held.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our company currently does
not have nominating, compensation committees or committees
performing similar functions nor does our company have a written
nominating, compensation or audit committee charter. Our board of
directors does not believe that it is necessary to have such
committees because it believes that the functions of such
committees can be adequately performed by our directors.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our company does not have
any defined policy or procedure requirements for shareholders to
submit recommendations or nominations for directors. The directors
believe that, given the early stage of our development, a specific
nominating policy would be premature and of little assistance until
our business operations develop to a more advanced level. Our
company does not currently have any specific or minimum criteria
for the election of nominees to the board of directors and we do
not have any specific process or procedure for evaluating such
nominees. Our directors assess all candidates, whether submitted by
management or shareholders, and make recommendations for election
or appointment.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">A shareholder who wishes to
communicate with our board of directors may do so by directing a
written request addressed to our president, at the address
appearing on the first page of this annual report.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Audit Committee and Audit
Committee Financial Expert</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our board of directors has
determined that none of our the members of our audit committee
qualifies as an "audit committee financial expert" as defined in
Item 407(d)(5)(ii) of Regulation S-K. Dr. Wolfgang Renz is
"independent" as the term is used in Item 7(d)(3)(iv) of Schedule
14A under the Securities Exchange Act of 1934, as amended.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our company has a formal
audit committee which was formed in May 2010, but currently does
not have a financial expert. Our audit committee consists of Dr.
Patrick Frankham, Dr. Wolfgang Renz and Dr. Ahmad Doroudian.
Financial information relating to quarterly reports was
disseminated to all board members for review. The audited financial
statements for the years ended January 31, 2018 and 2017 were
provided to each member of the board in which any concerns by the
members were directed to management and the auditors.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We believe that the members
of our board of audit committee and our entire board of directors
are collectively capable of analyzing and evaluating our financial
statements and understanding internal controls and procedures for
financial reporting. We believe that retaining an independent
director who would qualify as an "audit committee financial expert"
would be overly costly and burdensome and is not warranted in our
circumstances given the early stages of our development and the
fact that we have not generated any material revenues to date. In
addition, we currently do not have nominating, compensation or
audit committees or committees performing similar functions nor do
we have a written nominating, compensation or audit committee
charter. Our board of directors does not believe that it is
necessary to have such committees because it believes the functions
of such committees can be adequately performed by our board of
directors.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our company has an audit
committee charter which was adopted and approved by our board of
directors on May 25, 2010.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreakf642e29a-fb86-4ba8-88f4-f0e8344062d5" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
44</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px"><b><a name=
"Item 11. Executive Compensation">Item 11. Executive
Compensation</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The particulars of the
compensation paid to the following persons:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">(a)</td>
<td valign="top">our principal executive officer;</td>
</tr>
<tr>
<td valign="top">(b)</td>
<td valign="top">each of our two most highly compensated executive
officers who were serving as executive officers at the end of the
years ended January 31, 2018 and 2017; and</td>
</tr>
<tr>
<td valign="top">(c)</td>
<td valign="top">up to two additional individuals for whom
disclosure would have been provided under (b) but for the fact that
the individual was not serving as our executive officer at the end
of the years ended January 31, 2018 and 2017,</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify">who we will collectively
refer to as the named executive officers of our company, are set
out in the following summary compensation table, except that no
disclosure is provided for any named executive officer, other than
our principal executive officers, whose total compensation did not
exceed $100,000 for the respective fiscal year:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style=
"WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" colspan="37">
<p style="MARGIN: 0px" align="center"><b>SUMMARY COMPENSATION
TABLE</b></p>
</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<b>Name</b>
<p style="MARGIN: 0px"><b>and Principal</b></p>
<b>Position</b></td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" align=
"center">
<p style="MARGIN: 0px" align="center"><b>Year</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan=
"2" align="center">
<p style="MARGIN: 0px" align="center"><b>Salary ($)</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan=
"2" align="center">
<p style="MARGIN: 0px" align="center"><b>Bonus ($)</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan=
"2" align="center"><b>Stock</b>
<p style="MARGIN: 0px"><b>Awards</b></p>
<b>($)</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan=
"2" align="center"><b>Option</b>
<p style="MARGIN: 0px"><b>Awards</b></p>
<b>($)</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan=
"2" align="center"><b>Non-Equity</b>
<p style="MARGIN: 0px"><b>Incentive</b></p>
<p style="MARGIN: 0px"><b>Plan</b></p>
<p style="MARGIN: 0px"><b>Compensa-tion</b></p>
<b>($)</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan=
"2" align="center"><b>Nonqualified</b>
<p style="MARGIN: 0px"><b>Deferred</b></p>
<p style="MARGIN: 0px"><b>Compensa-tion</b></p>
<p style="MARGIN: 0px"><b>Earnings</b></p>
<b>($)</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan=
"2" align="center"><b>All</b>
<p style="MARGIN: 0px"><b>Other</b></p>
<b>Compens-ation ($)</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" colspan=
"2" align="center">
<p style="MARGIN: 0px" align="center"><b>Total ($)</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="bottom">
<p style="MARGIN: 0px">Dr. Patrick Frankham <sup>(1)</sup></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" align="center">
<p style="MARGIN: 0px">2018</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><i>President, Chief Executive
Officer and Director</i></p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"5%" align="right">
<p style="MARGIN: 0px" align="center">2017</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"5%" align="right">N/A</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"5%" align="right">N/A</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"5%" align="right">N/A</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"5%" align="right">N/A</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"5%" align="right">N/A</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"5%" align="right">N/A</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"5%" align="right">N/A</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" width=
"5%" align="right">N/A</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Dr. Pravin Chaturvedi <sup>(2)</sup></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" align="right">
<p style="MARGIN: 0px" align="center">2018</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" align="right">117,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="center">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" align="right">117,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><i>Past President, Chief
Executive Officer and Director</i></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top">
<p style="MARGIN: 0px" align="center">2017</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" align=
"right">125,000</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" colspan=
"2">
<p style="MARGIN: 0px" align="right">&nbsp;Nil</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" align=
"right">54,132</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" align=
"right">860,705</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" colspan=
"2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" colspan=
"2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" colspan=
"2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" align=
"right">1,039,837</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Moira Ong <sup>(3)</sup></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" align="right">
<p style="MARGIN: 0px" align="center">2018</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><em>Chief Financial</em>
<i>Officer</i></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center">&nbsp;2017</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" colspan="2">
<p style="MARGIN: 0px" align="right">&nbsp;Nil</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px"><sup>(5)</sup></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" align=
"right">430,352</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" colspan="2">
<p style="MARGIN: 0px" align="right">&nbsp;Nil</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom" align=
"right">430,352</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Dr. Ahmad Doroudian <sup>(4)</sup></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px" align="center">2018</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><em>Chairman, Secretary, Chief
Business Officer and Director</em></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" align=
"right">
<p style="MARGIN: 0px" align="center">2017</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" colspan=
"2">
<p style="MARGIN: 0px" align="right">&nbsp;Nil</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><sup>(5)</sup></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" colspan=
"2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" colspan=
"2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" align=
"right">860,705</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" colspan=
"2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" colspan=
"2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" colspan=
"2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top" align=
"right">860,705</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">___________</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">(1)</td>
<td valign="top">Dr. Frankham was appointed as our president, Chief
Executive Officer and Director on September 11, 2017.</td>
</tr>
<tr>
<td valign="top">(2)</td>
<td valign="top">Dr. Chaturvedi was appointed as our president,
Chief Executive Officer and Director on November 20, 2015 and
resigned as Chief Executive Officer and Director on September 11,
2017.</td>
</tr>
<tr>
<td valign="top">(3)</td>
<td valign="top">Ms. Ong was appointed as our Chief Financial
Officer on December 26, 2010.</td>
</tr>
<tr>
<td valign="top">(4)</td>
<td valign="top">Dr. Doroudian was appointed as our President,
Chief Executive Officer and Director on September 17, 2007 and as
Chief Executive Officer and Secretary on March 30, 2011. He
resigned as President, Chief Executive Officer and Secretary on
August 30, 2011 and was re-appointed as president, Chief Executive
Officer and secretary on July 24, 2014. Dr. Doroudian subsequently
resigned as President and Chief Executive Officer on February 5,
2015 and was appointed as Chairman on that date. Currently Dr.
Ahmad Doroudian acts as our company’s Chairman, Secretary, Chief
Business Officer and Director.</td>
</tr>
<tr>
<td valign="top">(5)</td>
<td valign="top">Amounts incurred as salaries for the year ended
January 31, 2017 of $200,000 for Ms. Ong and $200,000 for Dr.
Doroudian were forgiven on July 31, 2017.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Other than as set out below,
there are no arrangements or plans in which we provide pension,
retirement or similar benefits for directors or executive officers.
Our directors and executive officers may receive share options at
the discretion of our board of directors in the future. We do not
have any material bonus or profit sharing plans pursuant to which
cash or non-cash compensation is or may be paid to our directors or
executive officers, except that share options may be granted at the
discretion of our board of directors.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreake743c303-e202-4ad8-a83c-5cbc8df8cce2" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
45</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Stock Option Plan</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our company has stock option
plan which was adopted and approved by our shareholders on December
30, 2015.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Stock Options/SAR
Grants</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">During our fiscal year ended
January 31, 2018, we did not grant any stock options to officers
and directors.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">During our fiscal year ended
January 31, 2017:</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td width="4%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top" width="4%"><font style=
"FONT-FAMILY: Symbol">·</font></td>
<td valign="top">5,000,000 stock options with exercise price of
$0.70 and maturity on February 22, 2021 to officers and directors,
including our past President, Dr. Chaturvedi.</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top"><font style="FONT-FAMILY: Symbol">·</font></td>
<td valign="top">4,000,000 stock options with exercise price of
$0.10 and maturity on December 14, 2021 were granted to two of our
directors.</td>
</tr>
</table>
<font face="Symbol">&nbsp;</font>&nbsp;
<p style="MARGIN: 0px" align="justify"><b>Outstanding Equity Awards
at Fiscal Year End</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The particulars of
unexercised options, stock that has not vested and equity incentive
plan awards for our named executive officers are set out in the
following table:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style=
"WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" colspan="17" align="center">
<p style="MARGIN: 0px" align="center"><b>Options Awards</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" colspan="14" align="center">
<p style="MARGIN: 0px" align="center"><b>Stock Awards</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px" align="left"><b>Name</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="2" align="center"><b>Number of</b>
<p style="MARGIN: 0px"><b>Securities</b></p>
<p style="MARGIN: 0px"><b>Underlying</b></p>
<p style="MARGIN: 0px"><b>Unexercised</b></p>
<p style="MARGIN: 0px"><b>Options</b></p>
<p style="MARGIN: 0px"><b>(#)</b></p>
<b>Exercisable</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="2" align="center"><b>Number of</b>
<p style="MARGIN: 0px"><b>Securities</b></p>
<p style="MARGIN: 0px"><b>Underlying</b></p>
<p style="MARGIN: 0px"><b>Unexercised</b></p>
<p style="MARGIN: 0px"><b>Options</b></p>
<p style="MARGIN: 0px"><b>(#)</b></p>
<b>Unexercisable</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="2" align="center"><b>Equity</b>
<p style="MARGIN: 0px"><b>Incentive</b></p>
<p style="MARGIN: 0px"><b>Plan Awards:</b></p>
<p style="MARGIN: 0px"><b>Number of</b></p>
<p style="MARGIN: 0px"><b>Securities</b></p>
<p style="MARGIN: 0px"><b>Underlying</b></p>
<p style="MARGIN: 0px"><b>Unexercised</b></p>
<p style="MARGIN: 0px"><b>Unearned</b></p>
<p style="MARGIN: 0px"><b>Options</b></p>
<b>(#)</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="2" align="center"><b>Option</b>
<p style="MARGIN: 0px"><b>Exercise</b></p>
<p style="MARGIN: 0px"><b>Price</b></p>
<b>($)</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="center">
<p style="MARGIN: 0px" align="center"><b>Option</b> <b>Expiration
Date</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="2" align="center"><b>Number of</b>
<p style="MARGIN: 0px"><b>Shares or Units of</b></p>
<p style="MARGIN: 0px"><b>Stock That Have Not</b></p>
<p style="MARGIN: 0px"><b>Vested</b></p>
<b>(#)</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="2" align="center"><b>Market Value of Shares or</b>
<p style="MARGIN: 0px"><b>Units of That Have</b></p>
<p style="MARGIN: 0px"><b>Not Vested</b></p>
<b>($)</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="2" align="center"><b>Equity</b>
<p style="MARGIN: 0px"><b>Incentive Plan Awards:</b></p>
<p style="MARGIN: 0px"><b>Number of</b></p>
<p style="MARGIN: 0px"><b>Unearned</b></p>
<p style="MARGIN: 0px"><b>Shares, Units or Other</b></p>
<p style="MARGIN: 0px"><b>Stock Rights That Have Not</b></p>
<p style="MARGIN: 0px"><b>Vested</b></p>
<b>(#)</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
colspan="2" align="center"><b>Equity</b>
<p style="MARGIN: 0px"><b>Incentive</b></p>
<p style="MARGIN: 0px"><b>Plan Awards:</b></p>
<p style="MARGIN: 0px"><b>Market or</b></p>
<p style="MARGIN: 0px"><b>Payout Value</b></p>
<p style="MARGIN: 0px"><b>of Unearned</b></p>
<p style="MARGIN: 0px"><b>Shares, Units or Other</b></p>
<p style="MARGIN: 0px"><b>Rights That</b></p>
<p style="MARGIN: 0px"><b>Have Not</b></p>
<p style="MARGIN: 0px"><b>Vested</b></p>
<b>($)</b></td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">Dr. Patrick Frankham</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="5%" align="right">
2,000,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="5%" align="right">
2,000,000</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="5%" align="right">N/A</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="5%" align="right">0.10</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td width="9%">
<p style="MARGIN: 0px" align="center">December</p>
<p style="MARGIN: 0px" align="center">14, 2020</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="5%" align="right">N/A</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="5%" align="right">N/A</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="5%" align="right">N/A</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="5%" align="right">N/A</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><i>Chief Executive
Officer</i></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">2,000,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">2,000,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">N/A</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">0.10</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid">
<p style="MARGIN: 0px" align="center">December</p>
<p style="MARGIN: 0px" align="center">14, 2021</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">N/A</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">N/A</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">N/A</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">N/A</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">Moira Ong <i>Chief
Financial</i> <i>Officer</i></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">1,000,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">1,000,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">N/A</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">0.70</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid">
<p style="MARGIN: 0px" align="center">February 22, 2021</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">N/A</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">N/A</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">N/A</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">N/A</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">Dr. Ahmad Doroudian <i>Chief
Business Officer</i></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">2,000,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">2,000,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">N/A</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">$</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">0.70</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid">
<p style="MARGIN: 0px" align="center">February 22, 2021</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">N/A</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">N/A</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">N/A</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 1px solid" valign="bottom"
align="right">N/A</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak87bba0ac-fa75-49f6-876c-828320e2e479" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
46</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Option Exercises</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">During our fiscal year ended
January 31, 2018, there were no options exercised by our named
officers.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Compensation of
Directors</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Other than set out below, we
do not have any agreements for compensating our directors for their
services in their capacity as directors, although such directors
are expected in the future to receive stock options to purchase
shares of our common stock as awarded by our board of
directors.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We have determined that Dr.
Wolfgang Renz is an independent director, as that term is used in
Item 7(d)(3)(iv)(B) of Schedule 14A under the <i>Securities
Exchange Act of 1934</i>, as amended, and as defined by Rule
4200(a)(15) of the NASDAQ Marketplace Rules.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Effective November 19, 2015,
we entered into director services agreements with our directors,
Dr. Wolfgang Renz and Dr. Patrick Frankham. Pursuant to the
agreements each director shall provide director services to our
company for a period of 24 months in consideration for 10,000,000
options to purchase our common stock to be granted as follows:
2,000,000 options on each of December 15, 2015, December 15, 2016,
December 15, 2017, December 15, 2018 and December 15, 2019. Each
agreement may be terminated by our company without notice for
cause, or by any party with 30 days prior notice. No options were
granted on December 15, 2017 as such grants would have exceeded the
limitations set out in our Stock Option Plan.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Pension, Retirement or
Similar Benefit Plans</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">There are no arrangements or
plans in which we provide pension, retirement or similar benefits
for directors or executive officers. We have no material bonus or
profit sharing plans pursuant to which cash or non-cash
compensation is or may be paid to our directors or executive
officers, except that stock options may be granted at the
discretion of the board of directors or a committee thereof.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Indebtedness of
Directors, Senior Officers, Executive Officers and Other
Management</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">None of our directors or
executive officers or any associate or affiliate of our company
during the last two fiscal years, is or has been indebted to our
company by way of guarantee, support agreement, letter of credit or
other similar agreement or understanding currently outstanding.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak7d7c1661-9aa2-4d20-b05d-a5bcbc9cda88" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
47</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px"><b><a name=
"Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters">
Item 12. Security Ownership of Certain Beneficial Owners and
Management and Related Stockholder Matters</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The following table sets
forth, as of May 1, 2018, certain information with respect to the
beneficial ownership of our common shares by each shareholder known
by us to be the beneficial owner of more than 5% of our common
shares, as well as by each of our current directors and executive
officers as a group. Each person has sole voting and investment
power with respect to the shares of common stock, except as
otherwise indicated. Beneficial ownership consists of a direct
interest in the shares of common stock, except as otherwise
indicated.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style=
"WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px"><b>Name and Address of Beneficial
Owner</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" colspan="3" align="center">
<p style="MARGIN: 0px" align="center"><b>Amount and Nature
of</b></p>
<p style="MARGIN: 0px" align="center"><b>Beneficial
Ownership</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Percentage of</b></p>
<p style="MARGIN: 0px" align="center"><b>Class
<sup>(1)</sup></b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">Dr. Ahmad Doroudian <sup>(2)</sup>
<p style="MARGIN: 0px">4172 Doncaster Way</p>
Vancouver BC V6S 1V9</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="30%" colspan="2" align=
"right">
<p style="MARGIN: 0px" align="center">23,050,889<sup>(3)</sup>
CommonShares</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">26.18</td>
<td valign="bottom" width="1%">%</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Dr. Patrick Frankham <sup>(6)</sup></p>
<p style="MARGIN: 0px">388 De La Vauvette</p>
<p style="MARGIN: 0px">Rosemere, QC, J7A 4J7</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" colspan="2" align="right">
<p style="MARGIN: 0px" align="center">4,000,000<sup>(7)</sup>
CommonShares</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">4.54</td>
<td valign="bottom">%</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">Moira Ong <sup>(4)</sup>
<p style="MARGIN: 0px">2392 Lawson Avenue</p>
West Vancouver, BC V7V 2E6</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" colspan="2" align="right">
<p style="MARGIN: 0px" align="center">3,092,384<sup>(5)</sup>
CommonShares</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">3.51</td>
<td valign="bottom">%</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Dr. Wolfgang Renz <sup>(8)</sup></p>
<p style="MARGIN: 0px">Am Hochgericht 31 Rheinfelden, Germany
79618</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" colspan="2" align="right">
<p style="MARGIN: 0px" align="center">4,000,000<sup>(9)</sup>
CommonShares</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">4.54</td>
<td valign="bottom">%</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Patrick Rolfes <sup>(10)</sup></p>
<p style="MARGIN: 0px">1161 N. Anaheim Blvd.</p>
<p style="MARGIN: 0px">Anaheim, CA 92801</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" colspan="2" align="right">
<p style="MARGIN: 0px" align="center">779,763<sup>(11)</sup>
CommonShares</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">0.89</td>
<td valign="bottom">%</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Joseph Borovsky <sup>(12)</sup></p>
<p style="MARGIN: 0px">4843 Gate Post Lane</p>
<p style="MARGIN: 0px">Wilmington, NC 28412</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" colspan="2" align="right">
<p style="MARGIN: 0px" align="center">255,023<sup>(13)</sup>
CommonShares</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" align="right">0.29</td>
<td valign="bottom">%</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px"><b><i>Directors and Officers as a
Group<sup>(1)</sup></i></b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" colspan="3">
<p style="MARGIN: 0px" align="center"><b><i>35,178,059</i></b>
<b><i>Common Shares</i></b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" valign="bottom">
<p style="MARGIN: 0px"><i><b>&nbsp;</b></i></p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: 3px double" valign="bottom"
align="right">
<p style="MARGIN: 0px" align="right"><i style=
"MARGIN: 0px"><b>39.95</b></i></p>
</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom">
<i><b>%</b></i></td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">None</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" colspan="2" align="right">
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: black 3px double" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" style="BORDER-BOTTOM: black 3px double" valign=
"bottom" align="right">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px"><b><i>Over 5% Shareholders as a
Group</i></b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" colspan="3">
<p style="MARGIN: 0px" align="center"><b><i>Nil</i></b>
<b><i>Common Shares</i></b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 3px double" colspan="2">
<p style="MARGIN: 0px" align="right"><b style=
"MARGIN: 0px"><i>Nil</i></b></p>
</td>
<td style="PADDING-BOTTOM: 3px" valign="bottom">
<p style="MARGIN: 0px"><b><em>%</em></b></p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">___________</p>
<p style="MARGIN: 0px" align="justify"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="top" width="4%">(1)</td>
<td valign="top">Under Rule 13d-3, a beneficial owner of a security
includes any person who, directly or indirectly, through any
contract, arrangement, understanding, relationship, or otherwise
has or shares: (i) voting power, which includes the power to vote,
or to direct the voting of shares; and (ii) investment power, which
includes the power to dispose or direct the disposition of shares.
Certain shares may be deemed to be beneficially owned by more than
one person (if, for example, persons share the power to vote or the
power to dispose of the shares). In addition, shares are deemed to
be beneficially owned by a person if the person has the right to
acquire the shares (for example, upon exercise of an option) within
60 days of the date as of which the information is provided. In
computing the percentage ownership of any person, the amount of
shares outstanding is deemed to include the amount of shares
beneficially owned by such person (and only such person) by reason
of these acquisition rights. As a result, the percentage of
outstanding shares of any person as shown in this table does not
necessarily reflect the person’s actual ownership or voting power
with respect to the number of shares of common stock actually
outstanding on April 28, 2017. As of April 28, 2017, there were
75,647,114 shares of our company’s common stock issued and
outstanding.</td>
</tr>
<tr>
<td valign="top">(2)</td>
<td valign="top">Dr. Ahmad Doroudian was appointed as our
President, Chief Executive Officer and Director on September 17,
2007 and as Chief Executive Officer and Secretary on March 30,
2011. He resigned as President, Chief Executive Officer and
Secretary on August 30, 2011 and was re-appointed as President,
Chief Executive Officer and Secretary on July 24, 2014. Dr.
Doroudian subsequently resigned as President and Chief Executive
Officer on February 5, 2015 and was appointed as Chairman on that
date. Currently Dr. Ahmad Doroudian acts as our company’s Chairman,
Secretary, Chief Business Officer and Director.</td>
</tr>
<tr>
<td valign="top">(3)</td>
<td valign="top">Includes 17,385,939 shares owned by Dr. Doroudian,
200,000 shares owned by Khadija Zerouali, the spouse of Dr. Ahmad
Doroudian, 200,000 shares owned by Kinwa Pharma International
Company Ltd., a company over which Dr. Ahmad Doroudian and Ms.
Zerouali have shared voting and investment power, 3,264,950 shares
owned by Sassel Investments Inc., a company over which Dr. Ahmad
Doroudian has voting and investment power and 2,000,000 options to
purchase shares at $0.70 for a period of five years from February
23, 2016.</td>
</tr>
<tr>
<td valign="top">(4)</td>
<td valign="top">Ms. Ong was appointed as our Chief Financial
Officer on December 26, 2010.</td>
</tr>
<tr>
<td valign="top">(5)</td>
<td valign="top">Includes 2,092,384 shares owned by Ms. Ong and
1,000,000 options to purchase shares at $0.70 for a period of five
years from February 23, 2016.</td>
</tr>
<tr>
<td valign="top">(6)</td>
<td valign="top">Dr. Patrick Frankham was appointed as Director of
our company on July 24, 2014 and as our Chief Executive Officer on
September 11, 2017.</td>
</tr>
<tr>
<td valign="top">(7)</td>
<td valign="top">Includes 2,000,000 options to purchase shares at
$0.10 for a period of five years from December 15, 2015 and
2,000,000 options to purchase shares at $0.10 for a period of five
years from December 15, 2016.</td>
</tr>
<tr>
<td valign="top">(8)</td>
<td valign="top">Dr. Renz was appointed as a Director of our
company on February 5, 2015.</td>
</tr>
<tr>
<td valign="top">(9)</td>
<td valign="top">Includes 2,000,000 options to purchase shares at
$0.10 for a period of five years from December 15, 2015 and
2,000,000 options to purchase shares at $0.10 for a period of five
years from December 15, 2016.</td>
</tr>
<tr>
<td valign="top">(10)</td>
<td valign="top">Patrick Rolfes was appointed as President of our
fully owned subsidiary, Pivot Naturals, LLC (formerly ERS Holdings,
LLC) on March 1, 2018.</td>
</tr>
<tr>
<td valign="top">(11)</td>
<td valign="top">Includes 779,763 shares owned by Mr. Rolfes.</td>
</tr>
<tr>
<td valign="top">(12)</td>
<td valign="top">Joseph Borovsky was appointed as Vice President,
Product Formulation on March 1, 2018.</td>
</tr>
<tr>
<td valign="top">(13)</td>
<td valign="top">Includes 255,023 shares owned by Mr.
Borovsky.</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreak1123adf3-424b-48e4-9b5e-4703753593ff" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
48</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Changes in
Control</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We are unaware of any
contract or other arrangement or provisions of our Articles or
Bylaws the operation of which may at a subsequent date result in a
change of control of our company. There are not any provisions in
our Articles or Bylaws, the operation of which would delay, defer,
or prevent a change in control of our company.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Securities Authorized for
Issuance Under Equity Compensation Plans</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The following table sets
forth, as of May 1, 2018, securities authorized for issuance under
our equity compensation plan.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style=
"WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid" valign="bottom">
<p style="MARGIN: 0px" align="left"><b>Plan Category</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Number of Securities to be
Issued Upon Exercise of Outstanding Options, Warrants and
Rights</b></p>
<p style="MARGIN: 0px" align="center"><b>(Column A)</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Weighted-average Exercise
Price of Outstanding Options, Warrants and Rights</b></p>
<p style="MARGIN: 0px" align="center"><b>(Column B)</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>Number of Securities
Remaining Available for Future Issuance Under Equity Compensation
Plans (Excluding Securities Reflected in Column A) (Column
C)</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Equity compensation plans approved by
security holders</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
13,885,958</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.34</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">N/A</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Equity compensation plans not approved by
security holders</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">N/A</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">N/A</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">N/A</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Total</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
13,885,958</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">$</td>
<td id="ffcell" valign="bottom" width="9%" align="right">0.34</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">N/A</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><a name=
"Item 13. Certain Relationships and Related Transactions, and Director Independence">
Item 13. Certain Relationships and Related Transactions, and
Director Independence</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Except as disclosed herein,
no director, executive officer, shareholder holding at least 5% of
shares of our common stock, or any family member thereof, had any
material interest, direct or indirect, in any transaction, or
proposed transaction since the year ended January 31, 2018, in
which the amount involved in the transaction exceeded or exceeds
the lesser of $120,000 or one percent of the average of our total
assets at the year-end for the last three completed fiscal
years.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>Director
Independence</b></p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We currently act with three
directors, consisting of Dr. Ahmad Doroudian, Dr. Patrick Frankham
and Dr. Wolfgang Renz. Dr. Wolfgang Renz is an independent
director.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our audit committee consists
of Dr. Wolfgang Renz and Dr. Ahmad Doroudian.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">We do not have a standing
compensation or nominating committee, but our entire board of
directors acts in such capacities.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"></p>
<table id="pagebreaka03acd1c-541d-49be-aec1-6e85336283f2" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
49</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;&nbsp;</p>
<p style="MARGIN: 0px"><b><a name=
"Item 14. Principal Accounting Fees and Services">Item 14.
Principal Accounting Fees and Services</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The aggregate fees billed
for the most recently completed fiscal year ended January 31, 2018
and for the fiscal year ended January 31, 2018 for professional
services rendered by the principal accountant for the audit of our
annual financial statements and review of the financial statements
included in our quarterly reports on Form 10-Q and services that
are normally provided by the accountant in connection with
statutory and regulatory filings or engagements for these fiscal
periods were as follows:</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style=
"WIDTH: 100%; TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" colspan="6" align="center">
<p style="MARGIN: 0px" align="center"><b>Year Ended</b></p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>January 31,</b></p>
<p style="MARGIN: 0px" align="center"><b>2018</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="hdcell" style="BORDER-BOTTOM: black 1px solid" valign=
"bottom" width="9%" colspan="2" align="center">
<p style="MARGIN: 0px" align="center"><b>January 31,</b></p>
<p style="MARGIN: 0px" align="center"><b>2017</b></p>
<p style="MARGIN: 0px" align="center"><b>$</b></p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Audit Fees</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
25,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
24,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">Audit Related Fees</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Tax Fees</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">All Other Fees</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td colspan="2">
<p style="MARGIN: 0px" align="right">Nil</p>
</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px">Total</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
25,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td id="ffcell" valign="bottom" width="9%" align="right">
24,000</td>
<td style="PADDING-BOTTOM: 1px" valign="bottom" width="1%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our board of directors
pre-approves all services provided by our independent auditors. All
of the above services and fees were reviewed and approved by the
board of directors either before or after the respective services
were rendered.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Our board of directors has
considered the nature and amount of fees billed by our independent
auditors and believes that the provision of services for activities
unrelated to the audit is compatible with maintaining our
independent auditors’ independence.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreakc59b2a47-3928-4771-8059-fd42bed5dd03" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
50</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>PART IV</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b><a name=
"Item 15. Exhibits and Financial Statement Schedules">Item 15.
Exhibits and Financial Statement Schedules</a></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">(a)</p>
</td>
<td colspan="3">
<p style="MARGIN: 0px">Financial Statements</p>
</td>
</tr>
<tr height="15">
<td width="4%"></td>
<td width="4%" colspan="2"></td>
<td></td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td></td>
<td valign="top" colspan="2">
<p style="MARGIN: 0px">(1)</p>
</td>
<td>
<p style="MARGIN: 0px">Financial statements for our company are
listed in the index under Item 8 of this document</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td></td>
<td colspan="2"></td>
<td></td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td></td>
<td valign="top" colspan="2">
<p style="MARGIN: 0px">(2)</p>
</td>
<td>
<p style="MARGIN: 0px">All financial statement schedules are
omitted because they are not applicable, not material or the
required information is shown in the financial statements or notes
thereto.</p>
</td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td></td>
<td colspan="2"></td>
<td></td>
</tr>
<tr height="15" bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px">(b)</p>
</td>
<td colspan="3">
<p style="MARGIN: 0px">Exhibits</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="8%">
<p style="MARGIN: 0px" align="left"><b>Exhibit</b></p>
<p style="MARGIN: 0px" align="left"><b>Number</b></p>
</td>
<td width="2%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="bottom">
<p style="MARGIN: 0px"><b>Description</b></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><b>(3)</b></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><b>Articles of Incorporation and
Bylaws</b></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-1.htm">
3.1</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-1.htm">
Articles of Incorporation 649186 B.C. Ltd. (incorporated by
reference from our Registration Statement on Form S-1 filed on
August 7, 2009)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-2.htm">
3.2</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-2.htm">
“Company Act” Memorandum of 649186 B.C. Ltd. Certificate of
Amendment (incorporated by reference from our Registration
Statement on Form S-1 filed on August 7, 2009)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-3.htm">
3.3</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-3.htm">
Certificate of Filing of 649186 B.C. Ltd. (incorporated by
reference from our Registration Statement on Form S-1 filed on
August 7, 2009)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-4.htm">
3.4</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-4.htm">
Certificate of Incorporation of 649186 B.C. Ltd. (incorporated by
reference from our Registration Statement on Form S-1 filed on
August 7, 2009)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-5.htm">
3.5</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-5.htm">
Certificate of Name Change of 649186 B.C. Ltd. to Xerxes Health
Corp. (incorporated by reference from our Registration Statement on
Form S-1 filed on August 7, 2009)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-6.htm">
3.6</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-6.htm">
Transition Application of Xerxes Health Corp. (incorporated by
reference from our Registration Statement on Form S-1 filed on
August 7, 2009)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-7.htm">
3.7</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-7.htm">
Certificate of Name Change of Xerxes Health Corp. to Neurokine
Pharmaceuticals Inc. (incorporated by reference from our
Registration Statement on Form S-1 filed on August 7, 2009)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-8.htm">
3.8</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-8.htm">
Notice of Alteration to Authorized Share Structure (incorporated by
reference from our Registration Statement on Form S-1 filed on
August 7, 2009)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000151116414000332/exhibit31noticeofalteration.htm">
3.9</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000151116414000332/exhibit31noticeofalteration.htm">
Notice of Alteration to Authorized Share Structure (incorporated by
reference to our Current Report on Form 8-K filed on June 4,
2014)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793214005324/neukf_31.htm">
3.10</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793214005324/neukf_31.htm">
Notice of Alteration removing Pre-Existing Company Provisions
(incorporated by reference to our Current Report on Form 8-K filed
on October 9, 2014)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793214005324/neukf_32.htm">
3.11</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793214005324/neukf_32.htm">
Articles (incorporated by reference to our Current Report on Form
8-K filed on October 9, 2014)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215002579/neukf_ex31.htm">
3.12</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215002579/neukf_ex31.htm">
Notice of Alteration changing name to Pivot Pharmaceuticals Inc.
(incorporated by reference to our Current Report on Form 8-K filed
on April 17, 2015)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215003905/pvotf_ex313.htm">
3.13</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215003905/pvotf_ex313.htm">
Certificate of Name Change of Neurokine Pharmaceuticals Inc. to
Pivot Pharmaceuticals Inc. (incorporated by reference to our
Quarterly Report on Form 10-Q filed on June 17, 2015)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><b>(10)</b></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><b>Material Contracts</b></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-2.htm">
10.1</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-2.htm">
Non-Exclusive License Agreement with Globe Laboratories Inc. dated
June 17, 2008 (incorporated by reference to our Registration
Statement on Form S-1/A filed on December 3, 2009)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-8.htm">
10.2</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-8.htm">
Clinical Trial Services Agreement with Virtus Clinical Development
(Pty) Limited dated March 1, 2009 (incorporated by reference to our
Registration Statement on Form S-1/A filed on March 4,
2010)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-9.htm">
10.3</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-9.htm">
Master Service Agreement with Northern Lipids Inc. dated October 2,
2007 (incorporated by reference to our Registration Statement on
Form S-1/A filed on December 3, 2009)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-10.htm">
10.4</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-10.htm">
Assignment of Invention (NK-001) dated January 30, 2008
(incorporated by reference to our Registration Statement on Form
S-1/A filed on December 3, 2009)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-11.htm">
10.5</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-11.htm">
Assignment of Invention (NK-002) dated April 18, 2008 (incorporated
by reference to our Registration Statement on Form S-1/A filed on
December 3, 2009)</a></p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreakeed95dc2-1852-4fd7-9b81-f7fa878b9370" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
51</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr bgcolor="#CCEEFF">
<td valign="top" width="8%">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000106299310002584/exhibit10-2.htm">
10.6</a></p>
</td>
<td width="2%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000106299310002584/exhibit10-2.htm">
Subscription Agreement with Ahmad Doroudian (incorporated by
reference to our Form 8-K filed on August 12, 2010)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000151116413000559/neurokineadoroudiandebtsettl.htm">
10.7</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000151116413000559/neurokineadoroudiandebtsettl.htm">
Debt Settlement Subscription Agreement dated September 26, 2013
with Ahmad Doroudian (incorporated by reference to our Quarterly
Report on Form 10-Q filed on December 16, 2013)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_101.htm">
10.8</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_101.htm">
Director Services Agreement dated February 25, 2015 with
Barbara-Jean Bormann-Kennedy (incorporated by reference to our
Current Report on Form 8-K filed on March 26, 2015)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_103.htm">
10.9</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_103.htm">
Director Services Agreement dated February 25, 2015 with Dr.
Patrick Frankham (incorporated by reference to our Current Report
on Form 8-K filed on March 26, 2015)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_102.htm">
10.10</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_102.htm">
Director Services Agreement dated February 26, 2015 with Dr.
Wolfgang Renz (incorporated by reference to our Current Report on
Form 8-K filed on March 26, 2015)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_104.htm">
10.11</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_104.htm">
Consulting Services Agreement dated February 25, 2015 with Dr.
Giora Davidai (incorporated by reference to our Current Report on
Form 8-K filed on March 26, 2015)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1012.htm">
10.12</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1012.htm">
Director Services Agreement dated November 19, 2015 with Dr.
Patrick Frankham (incorporated by reference to our Quarterly Report
on Form 10-Q filed on December 15, 2015)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1013.htm">
10.13</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1013.htm">
Director Services Agreement dated November 19, 2015 with Dr.
Wolfgang Renz (incorporated by reference to our Quarterly Report on
Form 10-Q filed on December 15, 2015)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1014.htm">
10.14</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1014.htm">
Consulting Services Agreement dated November 19, 2015 with Dr.
Giora Davidai (incorporated by reference to our Quarterly Report on
Form 10-Q filed on December 15, 2015)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215007334/pvotf_ex101.htm">
10.15</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215007334/pvotf_ex101.htm">
Plan of Merger and Acquisition Agreement between our company and
IndUS Pharmaceuticals, Inc., dated November 4, 2015 (incorporated
by reference to our Current Report on Form 8-K filed on November
23, 2015 and our Current Report on Form 8-K/A filed on February 3,
2016)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1016.htm">
10.16</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1016.htm">
Employment Agreement dated November 20, 2015 with Dr. Pravin
Chaturvedi (incorporated by reference to our Quarterly Report on
Form 10-Q filed on December 15, 2015)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793216009996/pvotf_ex1017.htm">
10.17</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793216009996/pvotf_ex1017.htm">
Employment Agreement dated February 1, 2016 with Dr. Ahmad
Doroudian (filed on April 29, 2016 with our Annual Report on Form
10-K)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793216009996/pvotf_ex1018.htm">
10.18</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793216009996/pvotf_ex1018.htm">
Employment Agreement dated February 1, 2016 with Moira Ong (filed
on April 29, 2016 with our Annual Report on Form 10-K)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793216009996/pvotf_ex1019.htm">
10.19</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793216009996/pvotf_ex1019.htm">
Consulting Services Agreement dated February 1, 2016 with Soho
Capital Inc. (filed on April 29, 2016 with our Annual Report on
Form 10-K)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1020.htm">
10.20</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1020.htm">
Convertible debenture agreement dated September 29, 2016 with Avro
Capital Partners Inc. (incorporated by reference to our Quarterly
Report on Form 10-Q filed on September 15, 2017)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793217004439/pvotf_ex1021.htm">
10.21</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793217004439/pvotf_ex1021.htm">
Exchange Agreement between our company, IndUS Pharmaceuticals, Inc.
and Pravin Chaturvedi, dated September 11, 2017 (incorporated by
reference to our Current Report on Form 8-K filed on September 12,
2017)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793217004439/pvotf_ex1022.htm">
10.22</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793217004439/pvotf_ex1022.htm">
Licensing Agreement between our company and Altum Pharmaceuticals
Inc. dated September 12, 2017 (incorporated by reference to our
Current Report on Form 8-K filed on September 12, 2017)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1023.htm">
10.23</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1023.htm">
Debt Forgiveness Agreement dated July 31, 2017 between our company
and Dr. Ahmad Doroudian (filed on September 15, 2017 with our
Quarterly Report on Form 10-Q)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1024.htm">
10.24</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1024.htm">
Debt Forgiveness Agreement dated July 31, 2017 between our company
and Moira Ong (filed on September 15, 2017 with our Quarterly
Report on Form 10-Q)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1025.htm">
10.25</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1025.htm">
Debt Forgiveness Agreement dated July 31, 2017 between our company
and Soho Capital Inc. (filed on September 15, 2017 with our
Quarterly Report on Form 10-Q)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793217006095/pvotf_ex1026.htm">
10.26</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793217006095/pvotf_ex1026.htm">
Debt Settlement Agreement dated September 18, 2017 between our
company and Avro Capital Partners, Inc. (filed on December 15, 2017
with our Quarterly Report on Form 10-Q)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793217006095/pvotf_ex1027.htm">
10.27</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793217006095/pvotf_ex1027.htm">
Collaboration and License Agreement dated September 23, 2017
between our company and SolMic GmbH (filed on December 15, 2017
with our Quarterly Report on Form 10-Q)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793217006095/pvotf_ex1028.htm">
10.28</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793217006095/pvotf_ex1028.htm">
Letter of Intent dated November 7, 2017 between our company and
Thrudermic LLC (filed on December 15, 2017 with our Quarterly
Report on Form 10-Q)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1029.htm">
10.29</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1029.htm">
Share Exchange Agreement between our company, ERS Holdings, LLC and
the members of ERS Holdings, LLC dated February 10, 2018
(incorporated by reference to our Current Report on Form 8-K filed
on March 12, 2018)</a></p>
</td>
</tr>
</table>
&nbsp;
<p style="MARGIN: 0px"></p>
<table id="pagebreak12e99456-3bee-4d30-acad-4e40dace6e44" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
52</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr bgcolor="#CCEEFF">
<td valign="top" width="8%">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1030.htm">
10.30</a></p>
</td>
<td width="2%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1030.htm">
Royalty Agreement between our company and AquaBrew Inc. dated March
1, 2018 (incorporated by reference to our Current Report on Form
8-K filed on March 12, 2018)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1031.htm">
10.31</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1031.htm">
Employment Agreement between our company and Patrick Rolfes dated
March 1, 2018 (incorporated by reference to our Current Report on
Form 8-K filed on March 12, 2018)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1032.htm">
10.32</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1032.htm">
Share Exchange Agreement between our company, Thrudermic, LLC, Dr.
Joseph Borovsky and Dr. Leonid Lurya dated March 2, 3018
(incorporated by reference to our Current Report on Form 8-K filed
on March 12, 2018)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1033.htm">
10.33</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1033.htm">
Employment Agreement between our company and Joseph Borovsky dated
March 1, 2018 (incorporated by reference to our Current Report on
Form 8-K filed on March 12, 2018)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1034.htm">
10.34</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1034.htm">
10% Senior Secured Convertible Debenture (CDN$2,500,000) due March
2, 2019 (CD-1) (incorporated by reference to our Current Report on
Form 8-K filed on March 12, 2018)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1035.htm">
10.35</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1035.htm">
10% Senior Secured Convertible Debenture (CDN$2,500,000) due March
2, 2019 (CD-2) (incorporated by reference to our Current Report on
Form 8-K filed on March 12, 2018)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><b>(31)</b></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><b>Rule 13a-14(d)/15d-14(d)
Certifications</b></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"pvotf_ex311.htm">31.1*</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href="pvotf_ex311.htm">Section 302
Certification under the Sarbanes-Oxley Act of 2002 of Principal
Executive Officer</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"pvotf_ex312.htm">31.2*</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href="pvotf_ex312.htm">Section 302
Certification under the Sarbanes-Oxley Act of 2002 of Principal
Financial Officer</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><b>(32)</b></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><b>Section 1350 Certifications</b></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"pvotf_ex321.htm">32.1*</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href="pvotf_ex321.htm">Section 906
Certification under the Sarbanes-Oxley Act of 2002 of Principal
Executive Officer</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"pvotf_ex322.htm">32.2*</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href="pvotf_ex322.htm">Section 906
Certification under the Sarbanes-Oxley Act of 2002 of Principal
Financial Officer</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><b>99</b></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><b>Additional Exhibits</b></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215003905/pvotf_ex991.htm">
99.1</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215003905/pvotf_ex991.htm">
Audit Committee Charter (filed on June 17, 2015 with our Annual
Report on Form 10-K/A)</a></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215007379/pvotf_def14a.htm">
99.2</a></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><a href=
"http://www.sec.gov/Archives/edgar/data/1464165/000147793215007379/pvotf_def14a.htm">
Stock Option Plan (filed on November 25, 2015 with our Definitive
Proxy Statement on Schedule 14A)</a></p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left"><b>101*</b></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><b>Interactive Data Files</b></p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">101.INS</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">XBRL Instance Document</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">101.SCH</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">XBRL Taxonomy Extension Schema Document</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">101.CAL</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">XBRL Taxonomy Extension Calculation Linkbase
Document</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">101.DEF</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">XBRL Taxonomy Extension Definition Linkbase
Document</p>
</td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">101.LAB</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">XBRL Taxonomy Extension Label Linkbase
Document</p>
</td>
</tr>
<tr bgcolor="#FFFFFF">
<td valign="top">
<p style="MARGIN: 0px" align="left">101.PRE</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">XBRL Taxonomy Extension Presentation
Linkbase Document</p>
</td>
</tr>
</table>
_______
<p style="MARGIN: 0px" align="justify"><i>* Filed herewith.</i></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"></p>
<table id="pagebreakd2f2fb0b-fe90-4dbb-9d73-ce862930c09c" class=
"pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0"
cellpadding="0" width="100%" border="0">
<tr>
<td class="hpbhr">&nbsp;</td>
</tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">
53</td>
</tr>
<tr>
<td>
<div style=
"WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>
&nbsp;</td>
</tr>
<tr>
<td><i><a href="#TOC">Table of Contents</a></i></td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>SIGNATURES</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">In accordance with Section
13 or 15(d) of the Exchange Act, the registrant caused this report
to be signed on its behalf by the undersigned, thereunto duly
authorized.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td width="50%"></td>
<td width="3%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td width="35%"></td>
<td width="12%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="top">
<p style="MARGIN: 0px" align="center"><b>PIVOT</b>
<b>PHARMACEUTICALS INC.</b></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px" align="center">(Registrant)</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">Dated: May 1, 2018</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="top">
<p style="MARGIN: 0px"><i>/s/ Patrick Frankham</i></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><b>Dr. Patrick Frankham</b></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">Chief Executive Officer and Director</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">(Principal Executive Officer)</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">Dated: May 1, 2018</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="top">
<p style="MARGIN: 0px"><i>/s/ Moira Ong</i></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><b>Moira Ong</b></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">Chief Financial Officer</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">(Principal Financial Officer and
Principal</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">Accounting Officer)</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed
below by the following persons on behalf of the registrant and in
the capacities and on the dates indicated.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cellpadding="0" width="100%" border="0">
<tr height="15">
<td width="50%"></td>
<td width="3%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td width="35%"></td>
<td width="12%">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">Dated: May 1, 2018</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="top">
<p style="MARGIN: 0px"><i>/s/ Patrick Frankham</i></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><b>Dr. Patrick Frankham</b></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">Chief Executive Officer and Director</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">(Principal Executive Officer)</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">Dated: May 1, 2018</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="top">
<p style="MARGIN: 0px"><i>/s/ Ahmad Doroudian</i></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><b>Dr. Ahmad Doroudian</b></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td valign="top"></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">Chairman, Secretary and Director</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">Dated: May 1, 2018</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td style="BORDER-BOTTOM: 1px solid" valign="top">
<p style="MARGIN: 0px"><i>/s/ Wolfgang Renz</i></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px"><b>Dr. Wolfgang Renz</b></p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
<tr height="15">
<td valign="top">
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
<td valign="top">
<p style="MARGIN: 0px">Director</p>
</td>
<td>
<p style="MARGIN: 0px">&nbsp;</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 0in"></p>
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN"
cellspacing="0" cols="1" cellpadding="0" width="100%" align=
"center" border="0">
<tr>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center">54</p>
</td>
</tr>
</table>
<p style="MARGIN: 0px">&nbsp;</p>
<!--Document Created by EDGARMaster-->
</body>
</html>

